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INTRODUCTION 
Polycystic ovarian syndrome (PCOS) or stein - leventhal syndrome is one of the 
most common endocrine disorders, affecting 20% of women in reproductive age
[1]
. It is a 
complex multidimensional disorder with presence of polycystic ovaries in a women with 
cluster of symptoms which includes amenorrhoea, oligomenorrhoea, hirsutism, 
anovulation and other signs of androgen excess such as acne and crown pattern 
baldness
[2]
.The exact prevalence of PCOS is not known as the syndrome is not defined 
precisely. The estimated prevalence is 5-10% among the reproductive age women
[3]
.
 
PCO 
receives more attention because of its high prevalence and possibly of its reproductive, 
metabolic and cardiovascular consequences.       
Environmental and genetic factors have a major role in the development of 
PCOS
[2]
.
 
Obesity, exacerbated by poor dietary choices and physical inactivity, worsens 
PCOS in susceptible individuals. The role of other environmental modifiers such as 
infectious agents or toxins is speculative. PCOS may be common in our society owing to 
evolutionary advantages of the syndrome in ancient times, including smaller family sizes, 
reduced exposure to childbirth-related mortality, increased muscle mass and greater 
capacity to store energy
[4]. 
Genetic sequence plays a strong role in the etiology of 
PCOS
[5]. 
That is, it is inherited as a complex genetic trait. It is possible that a gene 
(CYP11A1, CYP17A1) may render the ovary susceptible to insulin stimulation of 
androgen secretion while blocking follicular maturation
 [6]
. 
  PCOS develops due to excessive luteinizing hormones (LH) by the anterior 
pituitary gland with increase in LH/Follicle stimulating hormone (FSH) ratio and through 
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high levels of insulin in blood and insulin resistance
[2]
. The main underlying cause of 
female infertility is PCOS. The most common immediate symptoms are anovulation, 
oligomenorrhea, amenorrhea and ultrasound evidence of polycystic ovaries, excess 
androgenic hormones producing hirsutism, acne, alopecia, seborrhoea and insulin 
resistance. Certain mood disorders such as sadness, nervousness, bipolar disorder and 
consumption disorder can happen more habitually in women having PCOS
 [7]
. 
Though the diagnostic criterion of PCOS were offered by 3 groups, the ultimate 
diagnostic criteria for PCOS was based on revised 2003 Rotterdam’s Criteria, (2 out of 3 
should be positive), a. Oligo ovulation and/or anovulation, b. Excess androgen activity 
(Clinical or biochemical signs of hyperandrogenism), c. Polycystic ovaries on 
ultrasonogram, after excluding other causes like congenital adrenal hyperplasia, cushings 
syndrome, hyperprolactinemia, thyroid disease, acromegaly and androgen secreting 
tumours of the ovary
 [8]
. 
Complications of PCOS include reproductive complications such as increased 
incidence of miscarriage, endometrial cancer, infertility and cardiovascular complications 
such as coronary artery disease, hypertension and metabolic complications of obesity, 
insulin resistance, and type 2 diabetes
[2]
.
 
Identification of patients worry is necessary 
when prioritizing goals and formulating a treatment plan. So the treatment depends on 
patients requirements of either hormonal contraception or ovulation induction. Lifestyle 
modification such as behavioral pattern, diet and exercise stays the first line of 
management. Medications used in the management of PCOS include oral contraceptive 
agents like ethinyl estradiol, medroxyprogesterone to restore menstrual cyclicity, GnRH 
3 
 
agonists; antiandrogens such as spironolactone, finasteride, flutamide, dexamethazone,  
selective oestrogen receptor modulator, clomiphene citrate for ovulation induction;  
hypoglycemic agents  such as metformin, thiazolidinediones, topical eflornithine 
hydrochloride for hirsutism. Surgical management includes electrocautery, laser ovarian 
drilling and multiple biopsy
[9]
. 
Though the insulin sensitizer-metformin in PCOS has improved metabolic 
disorders as a consequence of insulin resistance and the subsequent chronic sequalae, 
such as dyslipidemia, diabetes, hypertension and cardiovascular disease and it is 
associated with gastrointestinal side effects such as nausea, vomiting, diarrhea, lactic 
acidosis rarely 
[10]
. Another drug, thiazolidinediones are associated with weight gain, 
cardiovascular events, fragile fractures and bladder cancer
 [11]
. 
Recently, Myoinositol (MI) - a novel insulin sensitizer has been developed for 
treating PCOS with infertility. MI could be proposed as a substitute to metformin 
treatment because the former can affect insulin target tissues and cells and augument the 
insulin effects without the side effect of metformin. Certain studies have demonstrated 
that, treatment with MI is effective in reducing hormonal, metabolic and oxidative 
abnormalities in PCOS patients by improving insulin resistance
[12]
.The need for doing 
this study of demonstrating the efficacy and safety of myoinositol  was because of its 
limited studies available in India till now pertaining to supplementation of inositol for 
PCOS treatment. 
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AIMS AND OBJECTIVES 
Based on the survey of literature, the effect of MI on PCOS, it was understood that 
limited works were carried out on the anovulatory PCOS and infertility cases. Keeping 
these in mind it was decided to carry out the study to evaluate the effects of MI on PCOS 
The objectives of the present study are 
To evaluate the   effects of MI on ovulation 
To evaluate the hormonal effect of MI on hyperandrogenism   
To evaluate the metabolic effects of MI on blood sugar and lipids. 
To assess the safety of MI on PCOS patients  
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REVIEW LITERATURE 
Definition and type of PCOS 
PCOS is a complex heterogenous disorder characterized by oligo ovulation and/or 
anovulation with increased androgen activity and polycystic ovaries by gynecological 
ultrasound
[9]
. 
Types of PCOS include (a) Mild PCOS accounts for 16% with irregularity of 
cycles, numerous cystic ovaries on USG, a little elevated androgen levels and normal 
level of insulin. (b) Ovulatory PCOS (16%) with normal cycles, polycystic ovaries on 
USG, elevated androgen levels with increased insulin (c) Hyperandrogenism and 
persistent anovulation accounts for 7% with irregular cycles, typical ovaries on 
ultrasound, elevated androgen levels, increased insulin and potential long-term risks (d) 
61% of Severe PCOS with irregular cycles, polycystic ovaries on USG, elevated 
androgen levels, increased insulin and potential long-term risks
[13]
. 
Prevalence 
According to the revised Rotterdams criteria, the prevalence amongst the general 
female population has increased  to 10%
[3]
. 
 
Global prevalence accounts for 2.2% to 26%, 
roughly 1 in 15 women worldwide, 36% of Indian women are suffering from PCOS
[14]
. 
History of PCOS 
The PCOS was previously called Stein-Leventhal Syndrome after the physicians 
who first characterized it in the 1935. Stein and Leventhal surgically explored the obese 
women, who presented with amenorrhea, hirsutism, infertility and bilateral enlarged 
polycystic ovaries. To invent more about the pathology of ovary, Stein and Leventhal 
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performed ovarian biopsy by taking out wedges of ovarian tissue. The Pathological 
examination did not showed much results, but surprisingly women started menstruating 
on a regular basis after 3-5 months. Surprisingly their first patient became pregnant 
within the 1
st
 year of the surgery after a long period of married life. Based on the work of 
these two scientists, a primary defect of the ovary was considered to be responsible for 
this condition and was referred to as Polycystic Ovarian Disease (PCOD).  However 
subsequently, extensive work has thrown light on the fact that PCOD is no longer a 
disorder confined to the ovaries, but involves a complex pathophysiology of the various 
organ systems. Hence, PCOD is now referred to as Polycystic Ovarian Syndrome 
(PCOS)
[15]
. 
Etiology 
  Genetic sequences has the strong implication in the etiology of PCOS
[5]. 
Clustering 
of PCOS in families strongly suggest that mode of inheritance is consistent with 
autosomal dominant pattern
[2]
. It is possible that the gene (CYP11A1, CYP17A1) may 
render the ovary liable to stimulation of insulin by androgen secretion and thereby 
leading to blockage of follicular maturation
[6]
.Though the genes were grouped in to four 
categories such as insulin resistance-related genes, genes that interfering with synthesis 
and  action of androgens, gene that codes for inflammatory cytokines and candidate 
genes, it is the candidate gene which are most likely to be involved in the pathogenesis of 
PCOS
[9]
. 
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Pathophysiology  
In a normal state, there will be pulsatile release of gonadotropin-releasing 
hormone (GnRH) from the  hypothalamus. The pituitary gland responds to GnRH by 
releasing LH and FSH. The FSH and LH stimulate follicle growth. LH enhances ovarian 
theca cells to release androgens (androstenedione) and FSH stimulates cells of granulosa 
to change the androstenedione into estrone and estradiol. Both oestrogen and 
progesterone offer negative feedback to GnRH secreted by hypothalamus and on the 
pituitary. Several follicles begin to grow with each cycle but only one matures. Estradiol 
triggers the acute release of luteinizing hormone (LH). LH surge occurs and the mature 
follicle ruptures
[16]
. 
While in case of PCOS, the follicular growth seems to be normal up to the mid-
antral phase, after that the maturation ceases and follicle undergo atresia. The follicular 
fluid accumulates and follicle got enlarged, the granulosa cell layer degenerates, appears 
like a thin-walled cyst
[17]
.
 
The causative of hyperandrogenism and anovulation in PCOS 
arises from abnormalities in 4 endocrinologically active compartments such as ovaries, 
adrenal glands, periphery -which includes fat and hypothalamo-pituitary compartment.  
Ovarian compartment was the most reliable contributor of androgen
 [9]
.
 
The 
improved ovarian androgen production seen in PCOS was a result of sequence of 
complex biochemical processes which begins with disordered activity of the enzyme 
cytochrome P450, 17α which catalyses 17-hydroxylase and 17/20 lyase activities, [18]  
which is the rate limiting step in androgen biosynthesis
[19]. 
The increased testosterone 
levels in PCOS were considered to be ovarian in origin and the total testosterone were 
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usually between 20-80ng/dl. Treatment with GnRH agonist therapy more effectively 
suppresses serum testosterone and androstenedione levels. Though the hyperfunctioning 
of CYP17 enzyme coexists in ovaries and the adrenals, DHEA-S was raised in above 50 
% of patients.  
In the peripheral compartment, the presence or absence of hirsutism was 
determined by the activity of 5α reductase in the skin . Peripheral aromatization is 
increased with increased body weight. Oestrogen metabolism got decreased. Estrone (E1) 
levels are increased as a result of peripheral aromatization of androstenedione
[9]
. 
In hypothalamic-pitiutary compartment-PCOS develops due to excessive LH by 
anterior pituitary gland as a result of pulse frequency of GnRH with increase in LH/FSH 
ratio and through high levels of insulin in blood and insulin resistance. Persistently 
elevated levels of LH will produce more amount of androstenedione by causing increased 
cytochrome P450 activity. Insulin like Growth Factor (IGF) potentiates the expression of 
LH receptors and stimulates LH induced androgen production and accumulation of 
androgens in the ovary
[2]
.
 
IGF also acts as an amplifier of action of FSH
[20]
.
 
FSH levels 
are not increased because of the combined effect of increased GnRH pulse frequency and 
synergistic negative feedback on persistently elevated estrogen levels and normal 
follicular inhibin
 [9]
. 
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Figure 1. Pathophysiological Characteristics of  PCOS 
 
Figure 2. Pathophysiological Characteristics – Flow Chart  
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Symptoms and diagnostic criteria 
The most common symptoms are menstrual disturbances such as oligomenorrhoea 
or amenorrhoea, and symptoms due to excess androgenic hormones such as hirsutism, 
acne, alopecia, seborrheoa and anovulatory infertility
 [7].
 
The diagnostic criteria for PCOS have been obtained by three groups namely 
A. The National Institutes of Health + National Institution of Child wellbeing and Human 
Disease;based on exclusion of other androgen excess or related disorders include all the 
following 1.Clinical and/or biochemical hyperandrogenism, 2.Menstrual dysfunction  
B. The European Society for Human Reproduction and Embryology/American Society 
for Reproductive Medicine (ESHRE/ASRM); based on exclusion of other androgen 
excess or related disorders includes two of the following 1.Clinical and/or biochemical 
hyperandrogenism, 2.Oligo-ovulation or anovulation, 3. Polycystic ovaries  
C. The Androgen Excess and PCOS Society: based on exclusion of other androgen 
excess or related disorders includes all the following 1.Clinical and/or biochemical hyper-
androgenism, 2. Ovarian dysfunction and/or polycystic ovaries
[21].
 
Recently, the ultimate diagnostic criteria of PCOS is based on the 2003 
Rotterdams Criteria, (2 of 3 of the following should be positive). a.Oligo ovulation and/or 
anovulation, b.clinical and/or biochemical signs of hyperandrogenism, c. Polycystic 
ovaries on ultrasonogram, after excluding other causes like congenital adrenal 
hyperplasia, cushings syndrome, hyperprolactinemia, thyroid disorder, acromegaly and 
androgen secreting  ovarian tumour
[8].
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The menstrual irregularity in PCOS arises from anovulation or oligo ovulation and 
ranges from amenorrhoea to oligomenorrhoea. Clinical hyperandrogenism includes 
hirsutism, male pattern alopecia and acne
[9]
.
 
But the discrepancy in different states is due 
to genetically determined differences in 5-α reductase activity[2]. The sonographic criteria 
for PCOS required the presence of 12 or more follicles in either of the ovary measuring 2 
to 9 mm in diameter and/or increased ovarian volume of more than 10 ml, usually 
peripherally arranged around an enlarged hyper echogenic central stroma 
[9]
. 
 
 
  
 
 
Figure 3.  Ultra Sonographic View of PCOS 
 
 Association of PCOS with other co-morbidities 
Increased incidence of miscarriage, infertility, endometrial cancer and metabolic 
complications are the common risk factors involved in PCOS. It is associated with central 
obesity with increased waist-hip ratio leading to increased risk of diabetes mellitus and 
cardiovascular complications such as coronary artery disease, hypertension
 [22,23]
.
 
Insulin 
resistance results in hyperinsulinemia with development of hyperglycemia and type 2 
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diabetes. Abnormal lipoproteins such as elevated Total Cholesterol(TC), 
Triglycerides(TGL), Low Density Lipoprotein(LDL) and low levels of High Density 
Lipoprotein(HDL) were noted
[9]
.
 
Women with PCOS has increased prevalence of 
depression, anxiety and eating disorders
[7]
. 
Management of PCOS 
Treatment of PCOS includes non-pharmacological and pharmacological 
management 
Non-pharmacologial management 
 It includes lifestyle modification as the first form of therapy. It includes (a) Gentle 
or structured exercise for > 30 min /day (b)Dietary changes such as fat< 30% per 
day.(c)Reduced saturated and trans fat and glycemic levels with increased fibre and     
polyunsaturated fat. Weight reduction is established with an energy deprival of 500-1000 
kilo calories/day (d)Reduction of psycho-social stressor, stoppage of smoking, moderate 
alcohol and caffine use (e) Group interaction or intervention to support and aid 
implementing changes
[2,9]
.
 
 
Pharmacological management 
Oligomenorrhoea/amenorrhoea with anovulation 
(a) Combined Oral contraceptive pill (OCP) – in patients not desirous of 
conception (b) Cyclic progestins (eg, 10mg medroxyprogesterone acetate for 10 to 14 
days every month for 2/3 months) (c) Metformin- to improve ovulation and menstrual 
cyclicity 
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Hirsutism 
(a) Self-administered and professional cosmetic therapy are the first line (laser 
recommended) - Electrolysis and photoepilation therapy. If cosmetic therapy is not 
adequate, pharmacological therapy can be considered (b)Topical  Eflornithine cream, 
(c)Primary therapy is the OCP (d)Anti-androgen monotherapy (eg, spironolactone or 
cyproterone acetate) -should not be used without adequate contraception (e) Finasteride 
or flutamide (f)Combination therapy - if  6 months of OCP is ineffective, add anti-
androgen to OCP 
Infertility 
 Infertility therapies may include clomiphene citrate, metformin, gonadotrophins, 
surgery (laproscopic ovarian drilling) and in-vitro fertilisation
[6,9]
. 
METFORMIN  
Metformin (Biguanide) is an insulin sensitizer widely used for the treatment of 
patients affected by type 2 DM. As many women with PCOS are insulin resistant, 
metformin was used in the treatment of PCOS patients also
[24]
. 
 
STRUCTURE OF METFORMIN                                                   
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Mechanism of action 
Metformin increases the action of AMP-dependent protein kinase. Activated 
AMPK stimulates fatty acid oxidation, glucose uptake and non-oxidative metabolism and 
reduces lipogenesis, glucogenesis. The net result of these actions is increased glycogen 
storage in skeletal muscle, lower rates of hepatic glucose production, increased insulin 
sensitivity and lower blood glucose levels. The drug does not provoke hyperinsulinemia 
and therefore does not cause hypoglycemia
[25]
. In women with PCOS, elevation of 
circulating insulin and (IGF-I) levels results in overproduction of androgens in ovarian 
theca cells. Metformin inhibits production of androgens in the theca cells, in part through 
reducing pituitary secretion of LH, leading to ovulation and regular menstrual cycles
[26]
. 
 
 
 
 
Figure 4.   Mechanism of Action of Metformin 
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Absorption, Distribution & Elimination 
The drug is primarily absorbed from small intestine, not bound to plasma proteins, 
not metabolized and excreted unchanged in urine. Its plasma t1/2 is 2 hours, action 
lasting for 6-8 hours. OCT1 carries the drug in to hepatocytes & myocytes where it is 
pharmacologically active. OCT2 transports it in to renal tubules for excretion
[25]
. 
 
Uses 
(a).First line therapy for type 2 diabetes (b).Efficacious in preventing the new 
onset of type 2 diabetes mellitus in middle aged, obese persons with impaired glucose 
tolerance and fasting hyperglycemia. In combination with insulin secretogogues or 
thiazolidinediones in type 2 diabetes in whom oral monotherapy is inadequate 
(c).Decrease the risk of macrovascular as well as microvascular disease (d).Reduces 
circulating androgens and hirsutism, restores menstrual cyclicity and improves ovulation 
and fertility in infertile women with polycystic ovary, irrespective of glycemic status of 
the women
[27]
.
 
  
Adverse Effects 
The most common adverse effects are anorexia, nausea, vomiting, abdominal 
discomfort and diarrhea which are dose related and tend to occur at the onset of therapy 
and are transient. Absorption of vitamin B12 appears to be reduced on long term 
metformin therapy. Small increase in blood lactate levels (lactic acidosis) can occur 
which is rare (<1 per 10000 patient years)
[27]
. 
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Contraindication 
Metformin is contraindicated in renal disease, hepatic disease, alcoholism or 
conditions predisposing to anoxia (cardio-pulmonary dysfunction) because of increased 
risk of lactic acidosis
[27]
. 
DrugInteraction                                                                                                                                           
Dose adjustments of metformin is needed in patients taking cationic medications such as 
cimetidine, furosemide and nifedipine because it competes with metformin excretion and 
enhances its toxicity
[25]
. 
Dose 
0.5-1 gm twice daily (with the lowest effective dose recommended and titrated 
over days to weeks to minimize side effects)
[25]
.
 
  
CLINICAL OUTCOMES OF METFORMIN 
In a study conducted by Maciel et al in 2004, between 29 lean versus obese PCOS 
patients for a period of 6 months with 500mg of metformin thrice a day (TID), showed 
that Significant reduction in insulin resistance (fasting insulin), androgen levels (total and 
free testosterone, androstenedione) among lean PCOS. In obese PCOS, only 
enhancement of free testosterone levels and all other parameter showed no change
[28]
. 
In a study conducted by Marcondes et al in 2007 in 12 normal weight PCOS 
patients, BMI 21.5 ± 1.65 kg/m2 with metformin 850 mg TID for 4months, it showed nil 
effect of BMI or hirsutism scores, but there were significant improvement of ovulation 
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rate, testosterone and parameters such as  fasting insulin, HOMA-IR  as well as  decrease 
of LH and increase in FSH
[29]
. 
In a study conducted by Moghetti P among 23 PCOS patients with metformin 500 
mg three times a day or placebo for 6 months, it showed  improvement in mean 
frequency of menstruation (P = 0.002) after metformin therapy, due to striking 
amelioration of menstrual abnormalities in about 50% of subjects. Women given 
metformin showed reduced plasma insulin (P<0.01) and increased insulin sensitivity 
(P<0.05). Concurrently, ovarian hyperandrogenism was attenuated, as indicated by 
significant reductions in serum free testosterone (P<0.05) and in the 17-
hydroxyprogesterone response to GnRH-agonist
[30]
. 
In a study conducted by Fleming R in 92 PCOS patients with Placebo or 
metformin 850 mg, twice a day for 14-weeks Showed that  rate of recurrence of ovulation 
assessed by the fraction of luteal period weeks to observation weeks was notably (P value 
< 0.01) superior in the treated subjects (23%) in comparison with the placebo (13%), and 
the time for initial ovulation was notably (P < 0.05) shorter. The fraction of patients who 
failed to ovulate throughout the placebo-treatment was high (P < 0.05), and the mass of 
ovulations are indicated by normal level in both groups. The outcome of metformin on  
maturation of follicle was quick, because of the E2 concentration were greater over the 1
st
 
week of treatment. Notable (P < 0.01) for weight reduction was recorded with the 
metformin group, while the placebo showed increased weight (P < 0.05). A significant 
raise in circulating HDL was noticed only with metformin group.The benefits of 
metabolic risk with metformin was not observed in obese subgroup (BMI > 37). No 
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alteration in fasting glucose or insulin, or insulin response to glucose challenge was 
observed after metformin or placebo
[31]
. 
In a systemic review and meta analysis of metformin on PCOS by Jonathan M 
Lord et.al in 2003, showed that metformin is effective in achieving ovulation in women 
with PCOD, with odds ratios of 3.88 (95% confidence interval 2.25 to 6.69) for 
metformin compared with placebo. An analysis of pregnancy rates shows a significant 
treatment effect for metformin and clomiphene (odds ratio 4.40, 1.96 to 9.85). Metformin 
has an effect in reducing fasting insulin concentrations, blood pressure, and low density 
lipoprotein cholesterol. We found no evidence of any effect on body mass index or waist: 
hip ratio. Metformin was associated with a higher incidence of nausea, vomiting, and 
other gastrointestinal disturbances
[32]
. 
DRAWBACKS OF THE EXISTING MEDICATION 
           Oestrogen + progesterone: May enhance hazard of thrombo embolic episodes and 
metabolic risk, gastro-intestinal disturbances(GIT), tenderness of the breast, reduces 
insulin sensitivity, glucose intolerance, alteration in lipid profiles. 
Anti oestrogen (Clomiphene citrate): 20% of patients showed resistance. 
Associated with higher parity, hot flushes, hyper stimulation of ovary and ocular toxicity. 
It is reasonably effective as monotherapy, Least effective in obese PCOS, Showed 
uneven success rate. 
Biguanide (Metformin): Accompanied by reduction in blood glucose and raise of 
serum homocysteine level. It is less effectual for hirsutism. Associated with GIT distress 
and unpleasant metallic taste. Many drug interactions can occur. 
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Antiandrogens (Spironolactone): Raised blood levels of potassium,  hepatitis, GIT 
discomfort, irregular menstrual  bleeding, abnormality in sexual differentiation of  male 
fetus. 
5-Reductase inhibitors: Should not be targeted on to the iso enzyme-5-
reductase in the pilosebaceous unit. 
The above available medication has certain disadvantages. The adverse events can 
limit the outcome of the above medication.  The mechanisms to enhance ovulation 
together with symptom control is the optimal aim in reproductive medicine. Moreover, 
the drugs must have an excellent safety profile. Hence by keeping these in mind 
myoinositol appears to be a promising therapy
[33]
. 
MYO-INOSITOL(MI) 
Chemistry and source  
Inositol, a hexahydroxycyclo-hexane was isolated from the muscle in 1850 by 
Johanes Joseph Scherer from the Greek word as “sinew, fiber“, a “carbohydrate”, “ester“, 
an “alcohol”, and it comes under the sugar-family[34]. The main component in phytates 
was Inositol that is it exists as crystals of the inositol hexaphosphoric acid(IHP). This 
phytate was discovered  by Hartig in 18
th
 centuary as small spherical particles  from seeds 
of various plants which resembled in size as starch grains of potato
[35]
.
 
These particles 
were richest source of phosphorous, calcium and magnesium but lacks lipids or proteins. 
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 STRUCTURE OF MYOINOSITOL 
                                                   
Inositol is a chemical compound with formula C6H12O6, a sixfold alcohol (polyol) 
of cyclohexane. MI appears to be one of nine stereoisometric of a C6 sugar alcohol that 
belongs to vitamin B-Complex groupI
[36,37]
. Inositol is a carbohydrate, assayed at half the 
sweetness of sucrose.
[38] 
The precursor of inositol triphosphate is MI. The former acts as a 
2
nd
 messenger in controlling certain hormones such as Thyroid Stimulating Hormone, 
Follicle Stimulating Hormone and insulin
[39]
. 
Another study conducted in 1988 stated, MI and D-chiro-inositol(DCI)  are the 
two stereoisomers of inositol
[40]
, which are chemical mediators of insulin, acting through 
different mechanisms. Both DCI and MI have identical structures, but differ in the  
chemistry with one  OH group
[41]
.
 
The second messengers for FSH and glucose uptake 
were produced by MI, while the same for improving the uptake of glucose and synthesis 
of glycogen were provided by DCI
[11,36]
.
 
The synthesis of
 
MI  from glucose-6-phosphate 
(G-6-P) occurs by following  steps. Initially the isomerisation of (G-6-P)  by inositol-3-
phosphate synthase enzyme yields myoinositol 1-phosphate, which undergoes 
dephosphorylation by an inositol-monophosphatase enzyme (IMPase1) to give free 
MI
[36]
.  
MI is an essential nutritive component of cell membrane essential for the growth 
and viability of human cells in the culture
[39]
. The serum concentration of MI in healthy 
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adults remains within a range of 20-70 μmol/L, whereas in new-born infants and fetuses, 
it is several times higher than in adults
[42]
. Most inositol is synthesized in the human 
kidneys, in typical amounts of a few grams per day
[43]
.
 
Certain studies were reported that 
testes, the prostate gland, the epididymis and seminal vesicles contain  enormous quantity 
of MI
[42]
. The seminal fluid in male and ovarian fluid in female is the richest sources of 
inositol. MI is naturally present in plant foods and in high concentration in fruits, beans, 
grains, and nuts
[11,36,44]
.
 
 
Mechanism of action 
       MI is a precursor of DCI. DCI is synthetized by an insulin dependent epimerase that 
converts MI into DCI.  
 
            
FIGURE 5.    Mechanism of Action of Myoinositol 
 
Insulin binds to its receptor forms a complex called Insulin Receptor Substrate 
(IRS). IRS Stimulates the messenger called PI3 kinase. MI helps in both production and 
activation of PI3
(34)
. Activated PI3 kinase activates GLUT4.Glucose is then taken up by 
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GLUT4 through glucose channel for utilizing energy. Then IRS Complex breaks down 
releasing the receptor to go back to its original site
[45]
. 
Uses 
MI has been implicated in insulin signal transduction
[46, 47] 
and found to be 
effective in treatment of insulin resistance, hyperandrogenism, and oligo-amenorrhea in 
PCOS
[35,36]
. MI also improves features of dysmetabolic syndrome in post-menopausal 
women, including (TGL), HDL cholesterol and diastolic blood pressure
[48]
.
 
MI is also 
used in panic disorder,
 
Obsessive Compulsive Disorder, unipolar and bipolar depression, 
acute respiratory distress syndrome in premature infants and lithium induced psoriasis but 
occasionally cause nausea, tiredness, headache, dizziness. Inositol can boost the effects of 
selective serotonin reuptake inhibitors
[49]
. 
Dose, Administration, Duration  
Dose is 200- 4000 mg once a day before breakfast for PCOS. MI is available in 
two types of dosage form one in powder form and another newer pharmaceutical 
preparation -soft gelatin capsule. A study on administration of MI as powder and soft 
gelatin capsules resulted in a different bioavailability. MI in Soft gelatin capsule form 
showed similar pharmacokinetic parameters compared with three times higher doses of 
MI in powder form
[50]
.
 
There were certain clinical studies which showed the relationship 
between augmentation of the insulin tissue sensitivity and DCI or Ml oral 
supplementation for  three months
[51]
. 
 
 
23 
 
CLINICAL OUTCOMES OF MI  
Effect of MI on Infertility/Ovulation and Oozyte quality 
 Many studies stated that MI improves oocyte and embryo quality of PCOS. The 
prevalence of infertility among anovulatory PCOS women varies between 35-94%
[52]
. 
Supplementation of MI on PCOS patients with oligo-ovulation, high testosterone, 
hirsutism cases, improves ovarian function, metabolic and hormonal parameters
[8,48]
. 
Another study on PCOS women with MI and placebo showed that, 69.5% ovulated in MI 
group compared to 21% in placebo. A study on calcium signaling in oocytes in various 
species depicts the inositols putative role in oocyte maturation and the early stages of 
fertilization
[53,54,55] 
and quality of the oocytes
[36]
. The presence of MI in high levels 
indicate the well being of the follicle. In a prospective randomized comparative study 
performed between MI and DCI showed, improvement of the oocyte and embryo quality 
in MI than DCI in PCOS
[56]
. In another study, though MI and/or DCI administration 
improves insulin sensitivity only MI is a quality marker for oocytes evaluation
[57]
. In a 
randomized control open label study conducted on patients undergoing Intra Cytoplasmic 
Sperm Insemination(ICSI) or with prior failed attempts of ICSI showed MI improved 
oocyte quality in PCOS patients compared to folic acid alone
[58]
.
 
Another study showed 
that, insulin lowering medications, particularly different isoforms of inositol, when 
administered to patients undergoing ovulation induction for ICSI represent novel 
therapies for restoring spontaneous ovulation, with a potential positive effect on human 
oocyte meiotic maturation
[59]
. Randomized controlled trials of MI in women with PCOS 
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showed improvement in ovarian function and metabolic and hormonal parameters in 
women with PCOS
[60]
. 
 Many ovulatory cycles in PCOS women are accompanied by elevated Estrone  
(E2) and subnormal Plasma concentrations, indicating a suboptimal follicular maturation 
and ovulation with a collection of high number of germinated vesicles and  oocytes with 
degeneration during ovum pick-up
[59]
. In a 14 weeks study performed to determine the 
efficacy of inositol on ovarian and metabolic factors in PCOS showed increased 
ovulation frequency defined by luteal ratio, with increase in ovulation rate evidenced by 
raise in E2 concentrations in MI group through the 1
st
 week of medication and shorter 
mean time to first ovulation
[61]
. A study on association between MI concentration with 
follicular volume and E2 level, showed that there is better development of the oocytes 
with higher level of MI in ovarian follicular fluid depicting the wellbeing of the follicle 
and the quality of oocyte
[62]
. A study on chronic anovulatory infertility in PCOS 
undergoing assisted reproduction techniques showed number of follicles with a diameter 
of more than fifteen millimeter visible at abdominal scan during stimulation protocol and 
significantly more number of oocytes were retrieved at the pickup in MI group
[48]
. 
             In another prospective comparative study on the efficacy of a treatment with MI 
+ folic acid + melatonin with MI + folic acid alone on PCOS women who underwent In 
Vitro Fertilization(IVF) cycles showed that the beneficial efficacy of MI + folic acid in 
improving fertility rate and the coadministration of melatonin can improve the  quality of 
oocyte  and the outcome of pregnancy in women with history of meager oocyte 
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quality
[36]
.  Hence it was anticipated recently as a preventor of folate resistant neural tube 
defects
[43]
. 
 Melatonin is present in both male and female reproductive system. The increased 
level of melatonin in the ovarian follicular fluid and seminal fluid is responsible for the 
reproductive function. It is an antioxidant and free radical scavanger that protects follicles 
from oxidative stress, rescuing them from atresia, leading to complete follicular 
maturation and ovulation. The human seminal fluid contains melatonin, and it stimulates 
flagellar motility of spermatozoa where spermatozoa express melatonin receptors. Hence 
there exists a direct correlation between melatonin concentrations in follicular fluid and 
oocyte quality
 [63,64]
. 
The concentration of MI and DCI in the follicular fluid of PCOS patients verses 
healthy subjects, showed that follicular fluid from regular cycles of healthy patients 
contains elevated concentrations of MI with low concentrations of DCI while in PCOS 
cases, the ratio of the above molecules were entirely opposite. These reports were in 
favour of the “DCI paradox”, accordingly to which “ovaries of PCOS individuals were 
liable to present an increased MI to DCI epimerization which lead to tissue diminution of 
MI that could finally be accountable for the poor oocyte quality in these patients. Further, 
increasing DCI dosage progressively worsens oocyte quality and ovarian response
[65,66]
. 
A study conducted by Isabella, depicted that rising doses of DCI showed “ovary 
toxicity”, characterized by a harmful impact on oocyte quality, and a progressive decline 
in the ovarian response to FSH
[36]
. 
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PCOS  have irregular menstruation pattern ascribed to persistent anovulation. The 
menstrual irregularities in PCOS usually manifest around the time of menarche
[67]
. Some 
PCOS women have oligomenorrhea or secondary amenorrhea. Scanty menstruation has 
been noticed in 85-90% of PCOS women and 30-40% of amenorrheic patients have 
PCOS. Anovulatory menstrual cycles may lead on to dysfunctional uterine bleeding and 
infertility.  
Several prospective randomized controlled studies have stated that MI capable of 
restoring spontaneous ovarian activity with consequent fertility
[59]
 and improves 
ovulatory function
[59,68,69]
. A Study on PCOS  less than 35years showed, though both 
metformin and MI can be considered as first line treatment for restoring normal 
menstrual cycles, MI treatment seems to be more effective than metformin
[70]
.                                                                                                                                                                                                                                                                                                                                                                                                      
MI and Pregnancy 
              In general, PCOS patients are subfertile because of ovulatory disorders and often 
need ovulation induction drugs, such as clomiphene citrate or FSH, which can increase 
the risk of multiple pregnancy and ovarian hyperstimulation syndrome. In a study 
conducted by papaleo et.al, Myo-inositol is capable of restoring spontaneous ovarian 
activity and consequent fertility in most patients with PCOS and the treatment with MI 
did not cause multiple pregnancy
[69]
. 
A 2-year, prospective, randomized, open-label, placebo-controlled study was 
carried out in pregnant women having family history of type 2 diabetes who were treated 
with MI 2g plus folic acid 200µg twice a day may reduce the incidence of Gestational 
Diabetes Mellitus and the delivery of macrosomic fetuses
[71]
. 
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MI and Insulin resistance 
  Several studies have reported that insulin resistance is common among PCOS 
women, regardless of the body mass index
[60]
. The prevalence of insulin resistance in 
PCOS ranges from 50%–70% and occurs independently of obesity and the effect of 
obesity on insulin resistance is additive to that of PCOS
[72,73]
. MI increases whole body 
insulin sensitivity index
[53]
. A 12weeks study on PCOS showed improved  glucose to 
insulin ratio and Homeostatic Model Assessment (HOMA) index, decreased serum free 
testosterone concentration, Dehydroepiandrosterone-Sulfate(DHEA-S), increased Sex 
hormone-binding globulin(SHBG)
 [53,68,74]
 and reduced LH/ FSH ratio
[74]
. According to the 
study performed for treatment of cutaneous disorders in young PCOS women for 3 
months “the administration of MI is a simple and safe treatment that ameliorates the 
metabolic profile of PCOS patients and reducing hirsutism and acne
[75]
 through its actions 
of decreased testosterone and insulin levels, the participants who supplemented with MI 
experienced a reduction in hirsutism, and improvements in skin appearance. A 12 weeks 
study with MI 2 grams + folic acid 200 mcg showed improved insulin sensitivity and 
androgen levels
[76] 
with loss of  weight
[60]
. In a study conducted for 6-8 weeks on insulin 
resistant PCOS women  showed oral administration of DCI would improve insulin 
sensitivity
[68]
. 
The N-acetyl-cysteine(NAC) - a newer mucolytic remedy performing as insulin 
sensitizer, reflects an successful and harmless approach in the management of PCOS. It 
exerts its favorable outcome together by raising the insulin secretion from the beta cells 
of the pancreas and by enhancing an improved sensitivity to the person. Based on 
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evaluating the efficacy of NAC + Inositol + folic acid on ovulation rate and menstrual 
regularity in PCOS patients with and without insulin resistance states that MI and NAC 
may have supplementary non- insulin related action that allowed profit also in those 
individuals with “-ve” HOMA-index[77]. 
A study conducted for 12 weeks showed administration of MI on obese PCOS 
with micro polycvstic ovaries at USG showed reduction in LH, prolactin, insulin levels 
and LH/FSH ratio, improved insulin sensitivity results and menstrual cyclicity 
restored
[76]
. 
MI on Obesity 
Obesity is common in PCOS women. Nearly 30% to 60% of PCOS women 
presents with obesity
[33]
. Obesity is a common risk factor of developing PCOS and 
metabolic dysfunction like insulin resistance
[2]
. Obesity exacerbates the medical and 
marker of atherosclerosis namely endothelial functional impairment, impaired  pulse 
wave velocity, enlarged carotid intima media wall depth, occurrence of carotid plaque 
and amplified coronary artery calcification observed in PCOS women
[78]
. MI reduces 
plasma TGL, TC
[53,68]
, LDL cholesterol and increased  HDL cholesterol as observed from 
previous studies. As per Women ischemia Evaluation Study(WISE), the greater number 
of cardiovascular events were noted in PCOS. A study performed for 6 months with MI 
plus D-chiro-inositol combined therapy further  improves  the metabolic profile of PCOS 
women by significantly reducing the total cholesterol, LDL, TGL, fasting insulin, fasting 
glucose and HOMA index and increased HDL level, thereby reducing the cardiovascular 
risk
[78]
 and weight loss in MI group by reducing circulating leptin level.
 
In another 
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randomized controlled trial, combining MI and DCI more effectively reduces the 
metabolic risk in overweight PCOS in comparison to MI supplementation alone, after 
three months of treatment
[79]
. In a 6-8 weeks study Systolic and diastolic blood pressure 
has been reduced in MI treated PCOS women
[53,68]
. 
              The success of different artificial reproductive techniques depends on Reactive 
oxygen species (ROS) which are produced within the follicle during the ovulatory 
process, and it is believed that oxidative stress may be a cause of poor quality of oocytes, 
pathogenesis and future complications of PCOS. High levels of oxidants, such as H2O2, 
has been found in fragmented embryos
[80]
. The intermediaries namely the ROS of a 
standard oxygen metabolism were produced quicker than the endogenous antioxidant 
defense systems can neutralize. The inter and/or intra molecular cross-linking, inducing 
protein degradation, clustering, and enzyme inactivation occurs due to oxidation. A study 
on MI administration decreases the oxidative stress in erythrocytes of PCOD individuals. 
Certain previous studies have demonstrated that hyperglycemia increases ROS generation 
from peripheral blood leukocytes. The resulting oxidative stress may contribute to a pro-
inflammatory state which induces IR and hyperandrogenism in women with this disorder 
and also increases the risk of cardiovascular events
[12]. 
Safety of MI 
  As Several previous studies  performed for 1 month suggested that MI is a safe 
and effective drug, the safety profile from MI reported that mild side effects of nausea, 
flatus and mild insomnia occurred at doses of 12 grams/day or higher. The dosage 
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commonly used in clinics, that is 4 g/day of inositol is completely free of side effects
[43]
. 
A study on pharmacokinetics and safety of a single intravenous dose of MI in preterm 
infants suggest that supplementation of inositol is safe and beneficial for preterm infants 
with respiratory distress and there is no evidence for MI drug interaction so far
[81]
. 
A study on pharmacokinetics of inositol stated that phosphates of inositol were 
produced from the initial inositol molecule, with every day dietetic intake of inositol of 1 
gm. On reaching the intestinal cells, inositol gets phosphorylated to IHP and undergoes 
dephosphorylation to (IP1-5), which is responsible for signal transduction. MI was 
proposed  to be absorbed immediately, elated  intracellular and dephosphorylated  to 
lower phosphates and it can reach the tumour tissue soon after administration
[33]
. 
In human trials for chemoprevention of lung cancer, states that agents that affect 
the PI3K/AKT/mTOR pathway act as potential chemotherapeutic agents. Evidence shows 
that metformin and derivatives of MI also inhibits PI3K/AKT/mTOR signaling pathway 
particularly in lung-cancer cell lines. Further the regression of dysplasia correlates with 
decreased PI3K activity in patients who had received MI. The efficacy of inositol is 
further increased by combining with budesonide, dexamethasone, NAC and indole 3 
carbinol. In several studies, oral inositol inhibited lung tumorigensis in mice exposed to 
carcinogen
[82]
. 
There were certain known fact that patients with increased levels of insulin need  
more number of FSH IU while undergoing ovarian stimulation protocols. MI deficient 
ovary would impair the FSH signaling, resulting in an increased risk of ovarian 
hyperstimulation in PCOS patients. The physiological ratio of the two isomers (MI/DCI) 
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as 40:1 appears to be the best approach for the PCOS treatment. In order to ensure the 
proper dose and clinical efficacy without compromising ovarian function, manufacturing 
the product as soft gel capsules, by decreasing the dosage to a 3
rd
 of the original powder- 
based drug has been employed. From the above inventive formulation scientists 
anticipated to obtain a two-fold effect: (1) DCI- acts on liver, aimed at reducing insulin 
levels in blood; (2) MI- specific action on the ovary, to counteract the increased DCI 
levels and reestablishing the FSH sensitivity
[36]
. Development of soft gelatin capsules is 
of growing interest and several studies have reported the ability to perform a uniform, 
faster and enhanced absorption compared to other oral forms
[83,84]
. 
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MATERIALS AND METHODS 
Study centre 
The study was conducted after obtaining institutional ethical clearance from 
institutional ethical committee (IEC), Research cell of Chennai Medical College Hospital 
and Research Centre (Affiliated to the Tamil Nadu Dr.MGR Medical University), 
Irungalur, Tiruchirappalli  
Study Period   
24 weeks (from November 2015 to April 2016). 
Chemicals 
Drugs used in this study were Metformin 500mg twice a day, Myoinositol 2gm twice a 
day  
Inclusion Criteria 
PCOS selected according to Rotterdam’s criteria in the age group of 18-40 years were 
included in this study 
Exclusion Criteria 
Patients on hormonal treatment for infertility in last 6 months, patient with 
increased risk of lactic acidosis, diabetic patients on insulin and insulin sensitizers, 
pregnancy and lactation, liver failure, renal failure, lung diseases, ischaemic heart disease 
and peripheral vascular disease were excluded from the study 
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Methodology 
The present study was a prospective, open labelled, parallel arm, randomized 
control study to evaluate the efficacy and safety of Metformin versus MI in women with 
PCOS during the study period of 24 weeks. Total of 132 patients were screened 
according to Rotterdams criteria, out of which 90 PCOS patients who fulfilled the 
inclusion and exclusion criterias were recruited for this study after obtaining informed 
consent from the patients. The selected study subjects were randomly divided in to three 
groups of 30 each. Subjects in each group was treated as follows and continued without 
any change in the treatment for the entire duration of the study.  
Group     No of subjects                         Subject descriptions 
     1                   30                    Control -PCOS patient who delays specific treatment 
                                                but follows Non-Pharmacological treatment  
     2                   30                    PCOS subjects + Tab. Metformin 500mg twice a day 
     3                   30                    PCOS subjects + Tab. Myoinositol 2gm twice a day  
Clinical Assessment: 
All the subjects were interviewed regarding age, past history, personal history, 
family history, menstrual history, obstetric history, treatment history before starting the 
study. Height, weight, BMI, abdominal circumference, blood pressure and 
ultrasonogram(USG) were assessed for all the patient at baseline and periodically during 
the study period. Patients were advised to follow regular exercise and life style 
modifications during the study period 
 
34 
 
Biochemical analysis: 
About 5ml of blood was collected in the morning hours after a 12-hours fast and a 
30-minutes of rest in the supine position. Blood was added with an appropriate 
anticoagulant before estimation. Blood samples were obtained during the early 
proliferative phase (second through third day). Biochemical parameters such as LH, FSH, 
TSH, Prolactin, Fasting serum insulin, Serum-Total Testosterone & Free Testosterone, 
Dehydroepiandrosterone-sulfate(DHEA-S), Serum Androstenediones, (Metabolic)- TC, 
TGL, LDL and HDL, Fasting blood Sugar (FBS) were  evaluated at baseline, 4
th
 week, 
8
th
  week and 12
th
  week , 16
th
  week, 20
th
  week, 24
th
  week of the study period. 
BLOOD SUGAR  
Blood Sugar-Fasting (FBS)  
The sample of blood was collected after the patient fasts for twelve hours 
/overnight.  
 Blood Sugar - Post-Prandial (PPBS)  
After 12 hours of fasting, a meal containing starch and sugar (approx. 100 gms) 
were given. Blood was collected two, hours after the ingestion of the meal.  
Glucose Oxidase Method:  
Glucose oxidase catalyses the oxidation of glucose to gluconic  acid and  hydrogen 
peroxide. This H2 O2 is broken down to water and oxygen by a peroxidase in the 
presence of an oxygen acceptor which itself  is converted to a  coloured  compound,  the  
amount  of  which  can  be  measured colorimetrically. This method is used in various 
autoanalyzers.  
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FASTING INSULIN   
The principle followed a solid phase two site immunoassay. Make the preferred 
number of layered well in the possessor. Fifty µl of standard sample of insulin, 
specimens, and control are dispensed to the proper wells. Thoroughly mix it for ten sec. 
Hundred µl of Conjugate are dispensed into every well. The contents were assorted 
completely for thirty second. It was placed at room heat for 60 minutes. The microtiter 
plate was washed and emptied five times with wash solution (300 µl each well). Hit the 
microtiter platter onto absorbent material to eliminate all remaining droplets of H2O.100 
µl- Chemiluminescence substrate was dispensed in every well. It was lightly mixed for 
ten sec. The effect was stopped by addition 100 µl Stop liquid to each well. Then mixed 
for ten second till the blue colour got entirely changed to yellow colour. The visual 
density was read at 450 nm with micro plate reader in fifteen minutes.  
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HORMONAL PROFILE 
LUTEINIZING HORMONE (LH) 
The principle of this immunoassay followed a classic 2-step ‘sandwich’ kind of 
assay. Specimen Pretreatment was not needed. The reagents were kept at room warmth 
before use.  The assay of Calibrator, control sample and specimen were made in 
replication. The effective solutions of the anti-h LH-HRP and rinse buffer were prepared. 
The essential amount of micro wells strips was removed. Twenty five microlitre of each 
of the above assay samples were pipetted to concomitantly labeled wells in replica     
100 microlit of test buffer was pipetted into each well (multichannel pipette was 
recommended).Then incubated on a plate shaker (approximately 200 rpm) for 30 minutes 
at room temperature. The wells were washed thrice with 300 µl of diluted wash buffer 
per well and the plate was tapped firmly against absorbent paper to ensure that it was 
dry(washer is recommended).100 µl of the conjugate working solution was pipetted into 
each well. Incubated on a plate shaker (approximately 200 rpm) for 30 minutes at room 
temperature. The wells were washed again in the same manner. Hundred microlitre of 
TMB was pipetted in every well at same time intervals. Then incubated on a plate mixer 
for fifteen min till the calibrator showed dark blue colour for required OD. Fifty µ litre of 
stop solution was pipetted to all well at the similar timed intervals. The plate was read on 
a microwell plate reader at 450 nm within 20 minutes after addition of the stop solution.    
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FOLLICLE STIMULATING HORMONE (FSH) 
 The FSH (Human) CLIA Kit was based on the principle of a solid phase enzyme-
linked immunosorbent assay. The desired number of coated well was secured in the 
holder.The data sheet was made with sample identification.50 µl of FSH standard, 
samples, and controls were dispensed into appropriate wells.100 µl of Enzyme Conjugate 
Reagent was dispensed into each well. Then mixed thoroughly for 30 seconds. Incubated 
at room temperature (18-25°C) for 60 minutes. The incubation mixture was removed by 
flicking plate contents into a waste container. The microtiter wells were rinsed and 
flicked 5 times with washing buffer. The wells were sharply striked onto absorbent paper 
to remove residual water droplets.100 µl Chemiluminescence substrate solution was 
dispensed into each well.Then mixed gently for 5 seconds. The wells were read with a 
chemiluminescence microwell reader 5 minutes later. 
 
THYROID STIMULATING HORMONE (TSH)  
 The TSH (Human) CLIA kit test utilizes a unique monoclonal antibody directed 
against a distinct antigenic determinant on the intact TSH molecule. The preferred 
numeral of layered well was held in the receptacle. 50 microlitre of  normal standard, 
samples, and control were dispensed into suitable wells.100 µlit of Enzyme Conjugate 
were immersed into all well.  Then mix it for thirty seconds.  Incubate at room 
temperature (18-22°C) for about 60 minutes. Rinse and flick the microtiter wells 4 times 
with washing solution and final 1 time with distilled water. The wells were sharply 
striked onto absorbent paper to remove residual water droplets. 100 µl 
Chemiluminescence substrate solution was dispensed into each well.Mixed gently for 5 
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seconds. The wells were read with a chemiluminescence microwell reader after 5 
minutes.  
PROLACTIN  
The  prolactin testing was a chemiluminescence immunoassay , based on the 
sandwich principle. The desired number of Microtiter wells in the frame holder was 
secured.  25 µL of each Standard, Control and samples were dispensed with new 
disposable tips into appropriate wells. Dispense 100 µL Enzyme Conjugate into each 
well. Mixed completely for 10 seconds. Incubated for 30 minutes at room temperature. 
The contents of the wells were shaked briskly. The wells were rinsed 5 times with diluted 
Wash Solution (400 µL per well) and the wells were sharply stiked on absorbent paper to 
remove residual droplets. Then 50 µL of the freshly prepared Substrate Solution was 
added to each well and incubated for 10 minutes at room temperature. Read the RLU 
with a microtiter plate luminometer within 20 minutes after incubation time of substrate.  
 
SERUM TESTOSTERONE  
The principle of the following enzyme immunoassay test followed the typical 
competitive binding schematic.  Specimen Pretreatment not required .The reagents ought 
to be in normal heat prior to usage.  The assay of the calibrator, controls and specimen 
were made in replica. The effective preparation of the testosterone-HRP and rinsing  
solutions were made. The necessary quantum of the micro strips was detached. Then it 
was resealed and any idle strips were returned to the fridge. Fifty μl of every calibrator, 
run and specimen test were pipetted into equally labeled wells in replica. Then Pipette it 
out 100 micro litre of the conjugate solution into the wells. Incubated on a plate 
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rotator(200 rotations) for one hr. The wells were washed thrice with three hundred μ litre 
of watery rinse buffer in well and strike the platter hardly onto permeable paper to make 
sure that it was dried out   Then pipette one fifty μ lit of substrate to each well at specific 
intervals and incubate on a plate rotator for ten -15 minutes at normal temperature .50 
micro litre of stop liquid was pipetted out into all well at the same intervals. Following 
adding up of stop solution, the platter on a micro well  reader was read at 450 nanometer  
in twenty minutes  
ANDROSTENEDIONE  
Since it is necessary to perform the determination in duplicate, two wells for each 
of the six points of the standard curve (S0-S5), two for each sample, one for Blank was 
prepared.   
Regent                    Standard                              Sample                           Blank  
Sample                                                                 25 µL   
Standard S0-S5         25 µL    
Control                      25 µL    
Conjugate                 100 µL                               100 µL   
Incubated at 37°C for 1 hour   
The contents from each well were removed. The wells were washed 3 times with 
300 µL of diluted wash solution. Repeat the washing procedure by draining the water 
completely  
Substrate                   100 µL                                100 µL                        100 µL   
Incubate at room temperature 22-28°C for 15 minutes in the dark.  
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Stop solution              100 µL                               100 µL                         100 µL   
The microplate was gently shaked and the absorbance (E) was read at 450 nm against 
Blank 
DHEA-S 
The DHEA ELISA Kit follows a solid phase enzyme-linked immunosorbent assay 
(ELISA), based on the principle of competitive binding.The desired number of Microtiter 
wells were secured in the holder and dispensed with 20 µL of each of the Standard, 
Control and samples with new disposable tips into appropriate wells.100 µL Enzyme 
Conjugate was dispensed into each well and mixed for 10 seconds. Incubated for sixty 
min at room warmth and vigorously vibrate out the contents in the well. They were rinsed 
3 times with diluted Wash Solution (400 µL per well) and the wells sharply striked on 
absorbent paper to remove residual droplets. 100 µL of Substrate Solution was added to 
each well and incubated for 15 minutes at room temperature. The enzymatic reaction was 
stopped by adding 100 µL of Stop Solution to each well and read the OD at 450±10 nm 
with a microtiter plate reader within 10 minutes after adding the Stop Solution.   
LIPID PROFILE 
Serum Lipid Profile Estimations  
Method          
Estimation of Total Cholesterol and HDL Cholesterol: by CHOD/POD method: 
(Liquistar Cholesterol Kit.)    
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TOTAL CHOLESTEROL (TC) 
Specimen: Serum 
Pipette into Dry test tubes B S T 
Cholesterol Standard (R1) 1 ml 1 ml 1 ml 
Cholesterol Standard (R3) - 0.01 ml - 
Serum - - 0.01 ml 
  
Mixed well and kept in the room temperature for 10 min. The absorbance of standard and 
sample was read against reagent blank at 505 mm on spectrophotometer GS5701V within 
60 minutes. 
 
HDL – CHOLESTEROL 
Specimen – Serum 
Assay 
Step I 
Pipette into centrifuge tube Qty 
Serum 0.2 ml 
Precipitating Reagent (R2) 0.2 ml 
 
Mixed well and kept at room temperature for 10 min. 
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 Measured the absorbance of standard and sample against reagent Blank at 505 nm 
on spectrophotometer GS5701V (Electronic Corporation of India Ltd.) within 60 
minutes. 
Calculations  
 
 The intensity of red colour developed is proportional to cholesterol concentration 
and measured at 505 nm by spectrophotometer GS4701V  
 
TRIGLYCERIDES (TGL)  
 (GPO-PAP) End Point 
 
 
(Liquistat Kit – Bio Lab diagnostics) 
Procedure 
Pipette into 3 Test tubes Blank ml Std ml Test ml 
Distilled water 0.05 - - 
Standard - 0.05 - 
Sample - - 0.05 
Working Reagent 1.00 1.00 1.00 
 Mixed well and incubated at 37°C for 10 minutes 
 Added 2 ml distilled water, for a 3 ml optical curvete and read at 546 nm by 
spectrophotometer (GS5701 V). 
 The final colour was stable for at least 30 mts, away from bright light. 
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Calculations   
 
LOW DENSITY LIPOPROTEIN (LDL) AND VERY LOW DENSITY 
LIPOPROTEIN (VLDL) 
 The estimation of LDL and VLDL cholesterol was done by Friedwald calculation 
method. 
Friedwald Calculations 
 
 
STATISTICAL ANALYSIS 
 
Statistics were analyzed by SPSS statistical package before and after treatment. 
The results were tabulated and values were presented as mean (+ or -) and SD. Students’s 
paired‘t’ test P value of < 0.05 was considered to be statistically significant.  
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RESULTS 
Study population with Age Distribution 
       The mean age of the study population are shown in Table 1 and Table 2. Among the 
three groups, 21 to 30 years of age subjects were involved maximum in the study. The 
mean age of subjects in group 1 was 25.63+2.822. Group 2 was 24.20+3.059 and Group 
3 was 24.43+3.685 respectively.  
Table 1. Observations in Study population with Age distribution  
Age Group 
Distribution (in years) 
No. of subjects 
(n=90) 
Percentage 
(%) 
11-15 01 1.11 
16-20 09 10.00 
21-25 40 44.44 
26-30 39 43.33 
31-35 01 1.11 
 
Table 2. Distribution of Mean Age   
Group Age  
(mean ± S.D) 
Group 1 25.63±2.822 
Group 2 24.20±3.059 
Group 3 24.43±3.685 
Total 24.75±3.189 
 
Figure 6. Distribution of mean age  
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 Study population with Marital Status Distribution 
Marital Status Distribution of the study population is shown in Table 3. Maximum 
number of married women were from group 2 and followed by group 1 and group 3. In 
the unmarried women distribution the maximum patients were from group 1 and group 3 
followed by group 2. 
Table 3. Marital Status distribution  
Age Group 
Married Unmarried 
Total (%) No. of 
Patients 
% 
No. of 
Patients 
% 
Group 1 17 56.66 13  43.33 30 (100) 
Group 2 18 60 12 40 30 (100) 
Group 3 17 56.66 13 43.33 30 (100) 
 
Figure 7. Marital status distribution 
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Effect of MI on Weight in PCOS patients 
                                   Table 4.   MI Effects on weight in PCOS patients 
Groups 
Weight (in Kgs.) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 
61.68± 
8.50 
60.65± 
8.11 
59.16± 
13.04 
60.72± 
8.48 
60.63± 
8.33 
60.27± 
8.49 
60.60± 
8.53 
Group 2 
62.90± 
7.92 
63.57± 
9.75 
61.80± 
7.60 
61.27± 
7.11 
63.86± 
17.25 
60.63± 
6.45 
61.50± 
5.81 
Group 3 
63.12± 
9.40 
62.27± 
9.23 
61.07± 
8.87 
60.02± 
8.58 
59.50± 
8.64 
60.62± 
7.05 
61.25± 
7.39 
 
Table 5. Mean difference of Weight on treatment 
Groups 
Mean difference of Weight (in Kgs.) 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 1.03 2.52 0.96 1.05 1.41 1.08 
Group 2 -0.67 1.1 1.63 -0.96 2.27 1.4 
Group 3 0.85 2.05 3.1 3.62 2.5 1.87 
 
Figure 8. Effect of MI on Weight in PCOS patients 
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Group 3 had maximum reduction of weight after 8,12,16,20 and 24 weeks and 
group 3 had a higher reduction of  3.1 kg at the end of 12 weeks and 3.62 kg  at the end 
of the 16 weeks of treatment higher than all other groups. Group 1 had nominal reduction 
of 1.03 kg and 2.52 kg on weight at the end of 4 and 8 weeks which is higher than all 
other groups.  It is observed that Group 3 achieved moderate control of weight than the 
Group 1 and 2.  
It is observed that  all the three groups were statistically insignificant  with p>0.05. 
 
Effect of MI on BMI levels in PCOS patients 
                      Table 6. MI Effects on BMI levels in PCOS patients 
Groups 
BMI (Kg/m
2
) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
 Group 1 
24.02± 
3.17 
23.60± 
2.93 
23.78± 
2.93 
23.62± 
3.03 
23.58± 
2.89 
23.44± 
2.93 
23.55± 
2.90 
Group 2 
24.61± 
3.17 
23.48± 
3.12 
24.17± 
2.99 
23.96± 
2.82 
23.76± 
2.47 
23.78± 
2.30 
23.82± 
2.05 
Group 3 
24.51± 
3.83 
24.16± 
3.72 
23.69± 
3.45 
23.26± 
3.24 
22.87± 
3.27 
23.31± 
3.55 
23.65± 
4.14 
 
Table 7. Mean difference of BMI levels on treatment 
Groups 
Mean difference of BMI (Kg/m
2
) 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0.42 0.24 0.4 0.44 0.58 0.47 
Group 2 1.13 0.44 0.65 0.85 0.88 0.79 
Group 3 0.35 0.82 1.25 1.64 1.2 0.86 
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            Figure 9. Effect of MI on BMI levels in PCOS patients 
 
 
 
 
 
 
 
Group 3 had maximum reduction of BMI after 8,12,16,20 and 24 weeks treatment and 
group 3 had a higher reduction of 1.64  kg/m
2
 at the end of 16 weeks which is higher than 
all other groups. Group 2 had nominal reduction of 1.13 kg/m
2
 on BMI at 4 weeks 
treatment which is higher than all other groups.  It is observed that Group 3 achieved 
moderate control of BMI than the Group 1 and 2.It is observed that all the three groups 
were statistically insignificant because of p value >0.05. 
Effect of MI on Fasting blood glucose level in PCOS patients 
Table 8. MI Effects on fasting blood glucose in PCOS patients 
 
Groups 
Fasting Blood Glucose (mg/dl) 
 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 83.13± 
8.47 
83.10± 
9.95 
83.04± 
8.96 
83.00± 
7.03 
82.92± 
7.71 
82.86± 
14.61 
82.86± 
8.17 
Group 2 83.47± 
9.71 
83.42± 
9.37 
83.33± 
8.66 
83.27± 
8.79 
83.17± 
9.85 
83.17± 
8.38 
83.17± 
6.02 
Group 3 83.33± 
8.84 
83.27± 
10.12 
83.15± 
8.34 
83.02± 
8.02 
82.91± 
8.70 
82.71± 
10.44 
82.71± 
8.60 
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Table 9.  Fasting blood glucose levels during treatment based on Mean difference  
Groups Mean difference of Fasting Blood Glucose (mg/dI)  
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0.03 0.09 0.13 0.21 0.27 0.27 
Group 2 0.05 0.14 0.20 0.30 0.30 0.30 
Group 3 0.06 0.18 0.31 0.42 0.62 0.62 
 
Figure 10.  Effect of MI on fasting blood glucose levels in PCOS patients 
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Mean reduction in FBS was shown in Table 6. Group 3 shows insignificant 
nominal reduction of FBS by 20 and 24 weeks (0.62 mg %) with statistical value of 
P>0.05 but it is higher than group 1 & 2 for the reduction in FBS. The mean difference in 
reduction of fasting blood glucose after 4, 8, 12, 16, 20 and 24 weeks between the groups 
was not statistically significant. 
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Effect of MI on Post Prandial blood glucose level in PCOS patients 
Table 10. Effect of MI on Postprandial blood glucose level in PCOS patients 
 
Groups 
Postprandial  Blood Glucose(mg/dl) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 
102.13± 
16.17 
102.11± 
14.03 
102.03± 
10.80 
102.00± 
11.52 
101.97± 
12.51 
101.97± 
11.75 
101.97± 
11.74 
Group 2 
94.43± 
16.18 
94.39± 
14.25 
94.35± 
13.71 
94.28± 
25.68 
94.15± 
20.77 
94.15± 
13.78 
94.02± 
11.05 
Group 3 
103.93± 
18.62 
103.73± 
12.34 
103.63± 
12.03 
103.31± 
12.04 
103.01± 
13.18 
103.01.± 
5.17 
103.01± 
4.17 
 
Table 11. Mean difference of  post-prandial blood glucose on treatment 
Groups Mean difference of Postprandial  Blood Glucose(mg/dl) 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0.02 0.1 0.13 0.16 0.16 0.16 
Group 2 0.04 0.08 0.15 0.28 0.28 0.41 
Group 3 0.21 0.30 0.62 0.92 0.92 0.92 
 
Figure 11. Effect of MI on postprandial blood glucose levels in PCOS patients 
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Group 3 subjects had nominal reduction of 0.92 mg % after 16 weeks (P>0.05) followed 
by Group 2 which had a minimal reduction of 0.28 mg % after 16 weeks(P>0.05). But it 
is found that all the three groups were not statistically significant. 
Effect of MI on Fasting Insulin level in PCOS patients 
Table 12.  MI Effects on Fasting Insulin level in PCOS patients  
 
Groups 
Fasting Insulin (mg) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 10.55± 
3.77 
10.55± 
3.77 
10.50± 
3.71 
9.96± 
3.39 
9.987± 
3.41 
9.75± 
3.28 
10.22± 
3.45 
Group 2 10.04± 
4.60 
10.04± 
4.20 
9.78± 
4.18 
9.31± 
3.64 
9.16± 
3.47 
8.96± 
3.26 
9.06± 
3.01 
Group 3 10.31± 
3.64 
10.06± 
3.38 
9.69± 
2.85 
8.59± 
2.33 
8.27± 
2.43 
9.47± 
2.87 
10.15± 
3.39 
 
Table 13. Mean difference of Fasting Insulin on treatment 
Groups Mean difference of Fasting Insulin 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0 0.05 0.59 0.56 0.8 0.33 
Group 2 0.01 0.26 0.73 0.88 1.08 0.98 
Group 3 0.25 0.62 1.72 2.04 0.84 0.16 
 
Figure 12. Effect of MI on Fasting Insulin levels in PCOS patients 
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Maximum reduction of fasting insulin after 4,8,12 and 16 weeks under group 3 
had a mean reduction of 1.72 mg% at the end of 12 weeks and 2.04 mg % after the 16 
weeks of treatment higher than the other two groups. Group 2 had nominal reduction of 
1.08 mg% on fasting insulin after 20 weeks of treatment higher than all other groups.   
            The mean difference in reduction of fasting insulin after 4 weeks between the 
groups was not statistically significant except for Group 3. It is found that Group 3 
achieved average glycaemic control of fasting insulin than the Group 1 &2. 
                 The mean difference in reduction of fasting insulin after 8 weeks between the 
groups was not statistically significant except for Group 2 and Group 3. Myoinositol  
achieved moderate glycaemic control of fasting insulin than the Placebo and Metformin. 
                  The mean difference in reduction of fasting insulin for group 3 after 12 weeks  
and 16 weeks were statistically significant with P<0.05 on comparing with  other groups. 
Group 3 achieved higher glycaemic control of fasting insulin than Group 1 & 2. 
Effect of MI on LH levels in PCOS patients 
Table  14.  MI Effects on LH levels in PCOS patients 
 
Groups 
LH (mIU/mL) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 11.66± 
1.64 
11.37± 
1.58 
11.16± 
1.74 
11.13± 
1.84 
10.97± 
1.99 
10.79± 
2.19 
11.03± 
2.11 
Group 2 12.33± 
1.58 
11.87± 
1.55 
11.11± 
1.46 
10.47± 
1.38 
9.40± 
1.90 
9.21± 
1.26 
8.75± 
1.30 
Group 3 12.03± 
1.42 
11.03± 
1.68 
9.43± 
1.57 
7.99± 
1.66 
7.56± 
1.61 
8.68± 
1.73 
10.00± 
0.25 
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Table 15. Mean difference of LH levels on treatment 
Groups Mean difference of LH  (mIU/mL) 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0.29 0.5 0.53 0.69 0.87 0.63 
Group 2 0.46 1.22 1.86 2.93 3.12 3.58 
Group 3 1 2.6 4.04 4.47 3.35 2.03 
 
  Figure 13. Effect of MI on LH levels in PCOS patients 
 
            
 
 
 
 
Group 2 subjects had moderate reduction of LH after 8,12,16,20 and 24 weeks 
with the corresponding comparison based on p values such as when p is i)  
0.003728000<0.01 ii)0.000015000<0.0001 iii)0.000000035<0.0001 
iv)0.000000000<0.0001 and v) 0.000000001 <0.0001 respectively. Group 2 was 
statistically most significant during 12, 16, 20 and 24 weeks and Group 2 achieved 
moderate control of LH than the Group 1. 
Group 3 subjects had significant reduction of LH after 4,8,12,16,20 and 24 weeks 
with the corresponding comparison based on p values such as when p is i)0.01787<0.05 
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ii)0.0000000156<0.0001  iii)0.0000000000000465<0.0001 iv)0.0000000 
0000252<0.0001 v)0.001057<0.001 and vi)0.000000293<0.0001 respectively . It is 
found that Group 3 achieved more statistical significant (p<0.0001) during 8, 12 and 16 
weeks  with a high control of LH than the Group 1 and Group  2.  
Effect of MI on FSH levels in PCOS patients 
Table  16.  MI Effects on FSH levels in PCOS patients 
 
Groups 
FSH (mIU/mL) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 4.94±0.94 4.83±0.97 4.95±1.04 5.18±1.28 5.08±1.36 4.01±2.13 4.16±1.95 
Group 2 5.30±0.86 5.10±0.83 5.30±0.78 5.13±0.73 5.49±1.30 5.57±1.21 5.47±0.94 
Group 3 4.89±0.69 4.64±0.65 4.66±0.55 4.53±0.71 4.83±0.82 4.77±0.45 5.05±0.85 
 
Table 17. Mean difference of  FSH on treatment 
Groups 
Mean difference of FSH (mIU/mL) 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0.11 -0.01 -0.24 -0.14 0.93 0.78 
Group 2 0.2 0 0.17 -0.19 -0.27 -0.17 
Group 3 0.25 0.23 0.36 0.06 0.12 -0.16 
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Figure 14. Effect of MI on FSH levels in PCOS patients 
  
 
 
 
 
 
 
Group 3 had maximum reduction of FSH after 4,8,12 and 16 weeks treatment and 
group 1 had a higher reduction of 0.93 at the end of 20 weeks than all other groups. The 
mean difference in reduction of FSH after 20 weeks for the group 1 was statistically 
significant than group 2 and 3. It is found that group 1 and group 3 achieved average 
control of FSH than the group 2. 
Group 1 was statistically significant at the end of 20 week (p<0.05) compare to 
other groups.  
Effect of MI on LH /FSH Ratio in PCOS patients 
Table  18. MI Effects on LH /FSH Ratio in PCOS patients 
 
Groups 
LH/ FSH Ratio 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 2.42±0.45 2.41±0.42 2.31±0.41 2.23±0.43 2.26±0.54 2.05±0.66 2.13±0.68 
Group 2 2.37±0.42 2.37±0.42 2.04±0.51 1.99±0.48 1.81±0.50 1.74±0.46 1.64±0.36 
Group 3 2.50±0.40 2.43±0.50 2.05±0.39 1.81±0.47 1.61±0.41 1.84±0.3 2.03±0.33 
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Table 19. Mean difference of LH/FSH Ratio on treatment 
Groups Mean difference of LH/FSH Ratio 
4 week 8 week 12 week 16 week 20 week 24 week 
 Group 1 0.01 0.11 0.19 0.16 0.37 0.29 
Group 2 0 0.33 0.38 0.56 0.63 0.73 
Group 3 0.07 0.45 0.69 0.89 0.66 0.47 
 
Figure 15. Effect of MI on LH/FSH ratio in PCOS patients 
 
             The mean LH/FSH level were lowered by the drugs Group 3 and Group 2 and 
this reduction of LH/FSH level by both drugs after 8,12,16,20 weeks showed statistical 
significance (p<0.05).Maximum reduction of LH/FSH level after 16 weeks was observed 
in group 3. It is observed that group 3 had significant reduction of LH/FSH ratio after 
4,8,12,16 and 20 weeks than Group 2 and Group 1. Group 3 achieved significant control 
of LH/FSH than the Group 1 and 2. 
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Over all  Group 2 was statistically significant at the end of 8 and 12 weeks (p<0.01) and 
statistically most significant during 16,20, 24 weeks (p<0.0001) and Group 3 shows 
statistically  most significance  from 8 weeks onwards (p<0.0001) . It is observed that 
Group 3 had higher control of LH/FSH compared with other groups.    
 
Effect of MI on TSH levels in PCOS patients 
                           Table  20.  MI  Effects on TSH  levels in PCOS patients 
 
Groups 
TSH (mU/L) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 3.29±1.41 3.19±1.41 3.17±1.40 3.14±1.40 3.22±1.42 3.22±1.41 3.24±1.41 
Group 2 3.73±1.36 3.33±0.79 3.43±1.48 3.19±0.77 3.15±0.79 3.20±0.69 3.25±0.66 
Group 3 3.07±0.66 3.07±0.65 3.01±0.63 3.01±0.64 3.03±0.62 2.96±0.59 3.02±0.41 
 
Table 21. Mean difference  of  TSH  on treatment 
Groups 
Mean difference of TSH (mU/L) 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0.1 0.12 0.15 0.07 0.07 0.05 
Group 2 0.4 0.3 0.54 0.58 0.53 0.48 
Group 3 0 0.06 0.06 0.04 0.11 0.05 
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Figure 16. Effect of MI on TSH levels in PCOS patients  
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The TSH levels on 12 week for group 3 was showed statistical significance with  p<0.05 
than all other groups. Group 2  achieved moderate TSH reduction than other two groups. 
 
Effect of MI on Prolactin levels in PCOS patients 
Table  22. MI Effects on Prolactin levels in PCOS patients 
 
Groups 
Prolactin (ng/mL) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 11.77± 
3.32 
11.43± 
3.27 
11.30± 
3.19 
11.33± 
3.31 
11.38± 
3.31 
11.54± 
3.26 
11.58± 
3.24 
Group 2 10.68± 
2.65 
10.58± 
1.79 
10.26± 
2.10 
10.42± 
1.69 
10.29± 
1.90 
10.25± 
1.93 
10.26± 
1.94 
Group 3 13.14± 
3.94 
11.95± 
3.31 
10.85± 
2.86 
9.47± 
2.61 
9.44± 
2.26 
9.69± 
2.54 
10.22± 
1.89 
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Table 23. Mean difference of  Prolactin levels on treatment 
Groups Mean difference of Prolactin (ng/mL) 
4 week 8 week 12 week 16 week 20 week 24 week 
 Group 1 0.34 0.47 0.44 0.39 0.23 0.19 
Group 2 0.10 0.06 0.42 0.26 0.43 0.42 
Group 3 1.19 2.29 3.67 3.7 3.45 2.92 
 
 
Figure 17. Effect of MI on Prolactin levels in PCOS patients 
 
            Group 3 lowered the mean prolactin levels after 4,8,12,16,20 and 24 weeks and 
this reduction of prolactin levels after 8,12,16 and 20 weeks was most statistically 
significant with the corresponding comparison based on p values such as when p is i) 
0.01436<0.01 ii)p=0.000119<0.0001 iii) 0.000135<0.0001 and iv) 0.011293<0.01. It is 
observed that Group 3 achieved higher control of prolactin than the Group 1 and Group 2. 
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Effect of MI on T. Testosterone levels in PCOS patients 
Table  24.  MI Effects on T. Testosterone levels in PCOS patients 
Groups 
T.Testosterone (ng/dL) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0.89±0.38 0.95±0.53 0.88±0.39 0.78±0.36 0.78±0.36 0.78±0.36 0.85±0.37 
Group 2 0.97±0.24 1.24±1.38 0.96±0.24 0.88±0.28 0.88±0.27 0.93±0.22 0.93±0.16 
Group 3 1.09±0.99 1.08±0.99 1.08±0.99 1.08±0.99 1.23±1.12 1.40±1.34 1.77±1.75 
 
Table 25. Mean difference  of  T.Testosterone  on treatment 
Groups 
Mean difference of T.Testosterone (ng/dL) 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 -0.06 0.01 0.11 0.11 0.11 0.04 
Group 2 -0.27 0.01 0.09 0.14 0.04 0.04 
Group 3 0.01 0.01 0.01 -0.14 -0.31 -0.68 
 
Figure 18. Effect of MI on T.Testosterone levels in PCOS patients  
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   The mean difference in reduction of T.Testosterone  after 4 weeks for group 3 
was comparatively better than group 1 and 2. The mean difference in reduction of 
T.Testo at 8 weeks for all the groups were significant. All the three groups are equally 
contributed towards the reduction of  T.Testosterone over the periods and not statistically 
significant. 
Effect of MI on Free Testosterone levels in PCOS patients 
         
Table  26. MI Effects on Free Testosterone levels in PCOS patients 
 
Groups 
Free Testo Sterone (pg/ML) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 10.78± 
5.19 
10.76± 
5.18 
10.70± 
5.18 
10.29± 
4.93 
10.31± 
4.92 
10.21± 
4.99 
10.50± 
5.29 
Group 2 10.91± 
4.11 
10.46± 
4.41 
10.59± 
4.04 
9.27± 
3.18 
9.08± 
3.24 
8.36± 
3.17 
8.71± 
2.56 
Group 3 11.85± 
6.33 
10.87± 
5.53 
10.66± 
5.42 
7.61± 
3.29 
7.26± 
3.10 
8.43± 
3.67 
8.52± 
2.93 
 
Table 27. Mean difference of  Free Testosterone levels on treatment 
Groups Mean difference of Free Testosterone 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0.02 0.08 0.49 0.47 0.57 0.28 
Group 2 0.45 0.32 1.64 1.83 2.55 2.20 
Group 3 0.98 1.19 4.24 4.59 3.42 3.33 
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Figure 19. Effect of MI on Free Testosterone levels in PCOS patients 
 
 
               
 
 
 
            Reduction of Free Testosterone after 4 ,8,12,16,20 and 24 weeks among the 
Group 3 and Group 2 was statistically significant  and was maximum in Group 3 at the 
end of 16 weeks (4.59%) and group 2 at the end of 20 weeks (2.55%). On reducing the 
Free Testosterone the significant improvement is observed in group 3 at the earlier stage 
and also at the end of 4, 8,12,16,20 and 24 weeks. The mean difference in reduction of 
Free Testo Sterone after 4 weeks between the group 3 and group 2 was statistically 
significant except for Group 1. It is found that Group 3 achieved higher control of Free 
Testo Sterone than the Group 1 & 2.  
             The mean difference in reduction of Free Testosterone after 8 weeks for the 
group 3 was statistically significant than the other Groups 1 and 2. Group 3 achieved 
higher control of Free Testosterone than the Group 1 & 2.  
The mean difference in reduction of Free Testosterone for group 2 after 20 weeks 
was statistically more significant with p<0.01 and also on 24 weeks with  p<0.05.  
          The mean difference in reduction of Free Testosterone  for group 3 after 12 week 
showed  statistical significance with p value of 0.01 and 16 weeks  was statistically most 
significant (p<0.001). Group 3 achieved higher control of Free Testosterone  and   
treatment with Group 3 was better than the Group 1 and Group2.  
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Effect of MI on S. Androstenedione levels in PCOS patients 
Table  28.  MI Effects on S.Androstenedione levels in PCOS patients 
 
Groups 
S.Androstenedione 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 2.41±0.70 2.41±0.70 2.41±0.70 2.32±0.69 2.32±0.69 2.32±0.69 2.41±0.70 
Group 2 2.57±0.89 2.57±0.88 2.54±0.88 2.41±0.83 2.43±0.84 2.32±0.77 2.20±0.86 
Group 3 2.41±0.83 2.40±0.88 2.40±0.83 2.40±0.82 2.46±0.95 2.29±0.65 1.94±0.66 
 
 
Table 29. Mean difference of S. Androstenedione on treatment  
Groups 
Mean difference of S.Androstenedione 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0.00 0.00 0.09 0.09 0.09 0.00 
Group 2 0.00 0.03 0.16 0.14 0.25 0.37 
Group 3 0.01 0.01 0.01 0.05 0.12 0.47 
 
Figure 20. Effect of MI on S. Androstenedione levels in PCOS patients 
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The mean difference in reduction of  S. Androstenedione after 8,12,16,20 weeks for 
group 2 was better than group 1 and 3. The mean difference in reduction of S. 
Androstenedione at 4 weeks for   group 3 was significant.  Group 2 followed by Group 3 
achieved moderate  reduction of  S. Androstenedione over the periods.  
 
Effect of MI on DHEA-S  levels on PCOS patients 
               Table  30. MI Effects on DHEA-S  levels on PCOS patients 
 
Groups 
DHEAS (mg/DL) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 
259.95± 
45.02 
259.77± 
45.22 
252.47± 
54.95 
245.94± 
63.03 
255.90± 
44.87 
255.33± 
44.97 
258.37± 
44.10 
Group 2 
293.21± 
62.04 
292.46± 
59.63 
289± 
61.14 
278.90± 
55.85 
276.90± 
56.97 
273.81± 
65.95 
284.11± 
61.59 
Group 3 
287.78± 
85.28 
278.40± 
86.46 
277.60± 
80.09 
257.51± 
73.40 
264.61± 
77.20 
260.75± 
15.29 
267.25± 
11.12 
 
Table 31. Mean difference of  DHEA-S levels on treatment 
Groups Mean difference of DHEAS (mg/DL) 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 0.18 7.48 14.01 4.05 4.62 1.58 
Group 2 0.75 4.21 14.31 16.31 19.4 9.1 
Group 3 9.38 10.18 30.27 23.17 27.03 20.53 
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Figure 21. Effect of MI on DHEA-S levels in PCOS patients 
 
 
 
 
          
             
 
 
 
The mean difference in reduction of DHEA-S  for group 2 after 16 and 20 weeks  
was statistically significant  with the p value of 0.030895 and  0.016644 which is less 
than the chosen significance level (p<0.05). Group 2 achieved moderate control of 
DHEA-S.  
             The mean difference in reduction of DHEA-S  for group 3 after 12, 16,20 and 24 
weeks  was statistically significant  with the corresponding  values  of  p  i) 0.03446<0.05 
ii) 0.045497<0.05  iii)  0.011193<0.01 and  iv) 0.02332<0.05. It is found that Group 3 
was most significant by 20 week (p<0.01). Group 3 achieved higher control of DHEA-S 
and treatment with Group 3 was better than the Group 1 and 2.  
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Effect of MI on Total Cholesterol in PCOS patients 
Table 32. MI Effects on Total Cholesterol in PCOS patients 
 
Groups 
Total Cholesterol  (mg/dL) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 
182.93± 
23.00 
179.92± 
23.21 
180.37± 
23.00 
181.24± 
21.99 
181.31± 
21.92 
181.28± 
23.18 
182.24± 
23.02 
Group 2 
166.01± 
26.54 
160.79± 
19.32 
164.83± 
25.60 
166.95± 
25.77 
166.65± 
24.00 
169.91± 
26.65 
176.50± 
28.99 
Group 3 
189.11± 
26.60 
186.15± 
25.92 
185.02± 
24.94 
182.85± 
23.62 
186.18± 
25.47 
173.7± 
19.28 
183.4± 
7.13 
 
Table 33. Mean difference of Total cholesterol on treatment 
Groups Mean difference of Total Cholesterol (mg/dL) 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 3.02 2.56 1.70 1.62 1.66 0.69 
Group 2 5.22 1.18 -0.94 -0.64 -3.90 -10.49 
Group 3 2.96 4.09 6.26 2.93 15.42 5.72 
 
Figure 22. Effect of MI on Total Cholesterol levels in PCOS patients  
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Group 3 controlled  the mean total cholesterol  levels after ,8,12,16,20 and 24 weeks   and 
it was statistically significant by 20 weeks (p<0.05). It is observed that Group 3 achieved 
higher control of  TC than the Group 1 and Group 2. 
 
Effect of MI on Triglycerides in PCOS patients 
                        Table  34. MI Effects on Triglycerides in PCOS patients 
 
Groups 
Triglyceride (mg/dL) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 106.43± 
19.66 
104.41± 
19.73 
104.11± 
19.48 
105.35± 
19.67 
105.21± 
20.13 
105.13± 
20.28 
106.14± 
19.54 
Group 2 100.08± 
14.60 
97.82± 
12.15 
97.69± 
12.12 
99.11± 
13.03 
95.44± 
10.10 
99.04± 
13.88 
99.04± 
16.20 
Group 3 107.73± 
21.51 
101.73± 
23.69 
104.07± 
20.82 
101.97± 
20.63 
102.72± 
20.96 
92.25± 
5.70 
94.50± 
6.06 
 
Table 35. Mean difference of Triglycerides on treatment 
Groups Mean differences of Triglyceride (mg/dL) 
4 week 8 week 12 week 16 week 20 week 24 week 
 Group 1 2.02 2.32 1.08 1.22 1.3 0.29 
Group 2 2.26 2.39 0.97 4.64 1.04 1.04 
Group 3 6 3.66 5.76 5.01 15.4 13.23 
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    Figure 23. Effect of MI on Triglyceride levels in PCOS patients 
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Group 3 significantly reduces Triglycerides  levels after 4,8,12,16,20 and 24 
weeks of treatment and  maximum reduction was shown at 20 weeks (15.48%) and this 
reduction of  triglycerides levels after 20 weeks and 24 weeks was statistically significant 
with the corresponding values of (p=0.001608<0.01) and (p=0.025888<0.05). It is 
observed that Group 3 achieved significant control of  triglycerides than the Group 1 and 
2. 
Effect of MI on LDL Cholesterol levels in PCOS patients 
               Table  36. MI Effects on LDL Cholesterol levels in PCOS patients 
Groups 
LDL  Cholesterol (mg/dL) 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 
127.20± 
20.27 
125.49± 
20.29 
125.73± 
20.10 
126.47± 
19.53 
126.47± 
19.39 
126.33± 
19.86 
126.86± 
20.21 
Group 2 
113.93± 
24.34 
109.83± 
18.44 
113.34± 
22.94 
114.21± 
23.19 
114.41± 
23.73 
116.88± 
23.88 
116.88± 
25.44 
Group 3 
132.53± 
5.68 
129.47± 
23.16 
127.58± 
22.13 
125.08± 
20.84 
127.44± 
23.52 
119.75± 
17.48 
130.00± 
8.12 
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Table 37. Mean difference of LDL Cholesterol levels on treatment 
Groups 
Mean Difference of LDL Cholesterol(mg/dL) 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 1.71 1.47 0.73 0.73 0.87 0.34 
Group 2 4.1 0.59 -0.28 -0.48 -2.95 -2.95 
Group 3 3.06 4.95 7.45 5.09 12.78 2.53 
 
Figure 24. Effect of MI on LDL Cholesterol levels in PCOS patients  
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Reduction of LDL Cholesterol after 8,12,16,20 and 24 weeks for Group 3 was 
good  and reduction for Group 1 was average and  the maximum reduction was shown in 
Group 3 at 20 weeks (12.78%) . The improvement in the reduction of LDL Cholesterol  
was shown in the group 3 at the earlier stage such as 8,12,16,20 and 24 weeks. 
        
      The mean difference in reduction of LDL Cholesterol after 12 weeks  for group 3  
was comparatively better than group 1 and group 2. It is found that Group 3  achieved 
higher  control of LDL Cholesterol  than the Group 1 and Group 2.  
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The mean difference in reduction of LDL Cholesterol after 16 weeks for the group 3 was 
better than other groups. Group 3 achieved higher control of LDL than the Group 1 and 2.  
It is found that all the three groups were statistically insignificant due to p>0.05. 
Effect of MI on HDL Cholesterol levels in PCOS patients 
Table  38.  MI Effects on HDL Cholesterol levels in PCOS patients 
 
Groups 
HDL Cholesterol 
0 week 4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 34.44± 
4.91 
33.55± 
4.18 
33.81± 
4.33 
33.70± 
4.55 
33.80± 
3.98 
33.92± 
4.35 
34.15± 
4.46 
Group 2 31.40± 
2.64 
31.73± 
2.71 
32.40± 
2.69 
33.40± 
2.64 
33.63± 
2.56 
33.85± 
2.79 
33.824± 
2.48 
Group 3 35.04± 
5.68 
35.67± 
5.69 
36.63± 
5.56 
37.38± 
5.46 
38.21± 
6.41 
35.50± 
2.78 
35.50± 
3.28 
 
 
Table 39. Mean difference of  HDL Cholesterol levels on treatment 
 
Groups 
Mean difference of HDL Cholesterol 
4 week 8 week 12 week 16 week 20 week 24 week 
Group 1 -0.89 -0.63 -0.74 -0.64 -0.52 -0.29 
Group 2 0.33 1.00 2.00 2.23 2.45 2.42 
Group 3 0.63 1.59 2.34 3.17 0.46 0.46 
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Figure 25. Effect of MI on HDL Cholesterol levels in PCOS patients 
  
 
 
 
 
 
 
 
 
 
         Group 2 subjects had statistically significant from 12 week onwards and this 
increase of HDL levels after 12, 16, 20 and 24 weeks were statistically more significant 
with the corresponding p values of i) 0.005502<0.01 ii) 0.00182<0.01) iii) 
0.001523<0.001 and iv) 0.004157<0.01 and group 3 had a significant improvement of 
3.17% at 16 weeks treatment higher than the other groups 1 and 2. It is observed that 
Group 3 achieved marked increase of HDL than the Group 1 and Group 2. 
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Table 40.  Response of Group 1 with their p values for various clinical parameters 
Parameters 
/ Weeks  
4
th
 Week  8
th
 Week 12
th
 Week 16
th
 Week 20
th
 Week 24
th
 Week 
F.Testo 0.992221 0.953387 0.715826 0.726729 0.671659 0.841435 
DHEAS 0.987707 0.945042 0.732743 0.732743 0.697443 0.893894 
LH 0.499624 0.266666 0.256650 0.153671 0.091896 0.219810 
LH/FSH 0.989457 0.372393 0.118064 0.240141 0.017413 0.070779 
PRO 0.695479 0.590101 0.617507 0.655497 0.790953 0.829273 
TC 0.615061 0.667457 0.771491 0.78086 0.78218 0.907766 
TGL 0.698012 0.652918 0.835589 0.815704 0.805593 0.955259 
LDL 0.748316 0.782517 0.888401 0.888021 0.869431 0.949702 
HDL 0.456842 0.606094 0.551975 0.587639 0.666968 0.810471 
WT 0.639503 0.387901 0.668356 0.638442 0.529727 0.631920 
BMI 0.607807 0.765766 0.633776 0.588604 0.474442 0.563788 
BP 0.869128 0.847933 0.823880 0.872273 0.838781 0.773700 
FBS 0.530037 0.226233 0.186795 0.214962 0.882341 0.350785 
PPBS 0.808728 0.699787 0.985639 0.474514 0.538052 0.632111 
F.I 1.000000 0.962219 0.530769 0.552566 0.389316 0.734473 
FSH 0.662285 0.969422 0.431206 0.665763 0.038340 0.063492 
TSH 0.761180 0.688196 0.857455 0.859915 0.895321 0.761180 
T.Testo 0.641182 0.927652 0.263128 0.246134 0.258703 0.696024 
Serum 
Andro 
0.998552 0.994218 0.624289 0.607775 0.625778 0.997110 
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Figure 26. Response of Group 1 with their p values for various clinical parameters 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
0.55
0.6
0.65
0.7
0.75
0.8
0.85
0.9
0.95
1
F.Testo DHEAS LH LH/FSH PRO TC TGL LDL FSH BMI
p
 v
a
lu
e
Clinical Parameters
Response of Group 1 with their p values for various clinical parameters 
Week 12 Week 16 Week 20 Week 24
p
 v
a
lu
e
 =
0
.0
1
7
4
3
<
 0
.0
5
p
 v
a
lu
e
 =
0
.0
3
8
3
4
<
 0
.0
5
 
          The result of p value after two tailed t-tests for the clinical parameters LH/FSH 
ratio and FSH are found to be significant with p values(=0.01743 and =0.03834)which is 
less than 0.05. So, the response of Group 1 shows profound effect on reduction of 
LH/FSH ratio and FSH values. 
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Table 41.Response of Group 2 with their p values for various parameters  
Parameters 
/ Weeks 
4
th
 Week 8
th
 Week 12
th
 Week 16
th
 Week 20
th
 Week 24
th
 Week 
F.Testo 0.691412 0.76685 0.095086 0.064771 0.012309 0.033106 
DHEAS 0.963057 0.79558 0.122366 0.030895 0.016644 0.183391 
LH 0.264354000 0.003728000 0.000015000 0.000000035 0.000000000 0.000000001 
LH/FSH 0.962706 0.009073 0.002371 0.000021600 0.000001920 0.000000400 
PRO 0.65917 0.93258 0.864548 0.960632 0.921856 0.940318 
TC 0.38783 0.861628 0.889956 0.922467 0.582452 0.228513 
TGL 0.524396 0.499883 0.789827 0.165288 0.787071 0.57777 
LDL 0.475066 0.925478 0.965496 0.940116 0.655423 0.239952 
HDL 0.636817 0.158539 0.005502 0.00182 0.001523 0.004157 
WT 0.776091 0.591542 0.591542 0.412027 0.246733 0.495219 
BMI 0.869218 0.588835 0.412651 0.256057 0.271544 0.300999 
BP 0.178396 0.519626 0.097286 0.205549 0.231268 0.225565 
FBS 0.700975 0.484494 0.144141 0.321593 0.074449 0.115505 
PPBS 0.403964 0.373511 0.638242 0.361414 0.109978 0.065439 
F.I 0.993132 0.822581 0.503286 0.416134 0.313996 0.393144 
FSH 0.353747 1 0.402621 0.521104 0.362678 0.559258 
TSH 0.178019 0.436886 0.070251 0.056141 0.075678 0.120495 
T.Testo 0.303379 0.87407 0.194921 0.209327 0.576482 0.513282 
Serum 
Andro 
0.994318 0.91705 0.497322 0.545187 0.273956 0.182143 
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Figure 27. Response of Group 2 with their p values for various clinical parameters 
 
The result of p value after two tailed t-tests for the clinical parameters F.Testo,                                                                                                                                                                                                                                                                                                                                                                                                             
DHEAS, LH, LH/FSH and HDL are found to be significant with p values 
(=0.012309,=0.016644,=0,=0.0000192 and =0.05) which are all less than 0.05. So, the 
response of Group 2 shows pronouncing effect on F.Testo, DHEAS, LH, LH/FSH ratio, 
and HDL values. 
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Table 42.  Response of Drug 3 with their p values for various clinical parameters 
Parameters/ 
 Weeks 
4
th
 Week 8
th
 Week 12
th
 Week 16
th
 Week 20
th
 Week 24
th
 Week 
F.Testo 0.535254 0.449837 0.002546 0.001583 0.077263 0.158255 
DHEAS 0.67899 0.356797 0.03446 0.045497 0.011193 0.02332 
LH 0.01787 
0.0000000
156 
0.0000000
000000465 
0.0000000
0000252 
0.001057 
0.0000002
93 
LH/FSH 0.556073 0.0000573 
0.0000001
31 
0.0000000
0282 
0.00094 0.083772 
PRO 0.219497 0.01436 0.000119 0.000135 0.011293 0.068303 
TC 0.663699 0.540874 0.338987 0.693362 0.053138 0.355175 
TGL 0.316879 0.513371 0.302429 0.420376 0.001608 0.025888 
LDL 0.621456 0.415311 0.209659 0.46272 0.13015 0.703133 
HDL 0.677932 0.286788 0.115401 0.083178 0.762034 0.812024 
WT 0.728857 0.39649 1.671553 0.171306 0.446686 0.705938 
BMI 0.730426 0.395014 0.18609 0.11654 0.448112 0.748683 
BP 0.258199 0.920065 0.453158 0.475638 0.711113 0.826872 
FBS 0.320624 0.3192 0.158457 0.151677 0.704724 0.059300 
PPBS 0.58164 0.699123 0.541109 0.767224 0.060207 0.39047 
F.I 0.785509 0.473717 0.036675 0.022235 0.523877 0.941334 
FSH 0.984572 0.721108 0.729234 0.837296 0.678972 0.347046 
TSH 0.154717 0.163003 0.054325 0.783885 0.382364 0.77298 
T.Testo 0.979574 0.97549 0.973461 0.639755 0.580906 0.552175 
Serum 
Andro 
0.308918 0.982672 0.996268 0.843839 0.696086 0.320649 
 
 
  
 
 
 
Figure 28. Response of Group 3 with their p values for various clinical parameters 
 
                The result of p value after two tailed t-tests for the clinical parameters F.Testo, 
DHEAS, LH, LH/FSH, PRO, TC, TGL, FI and TSH are found to be statistically 
significant with p values(=0.00255, =0.03446, =0.01787, =0.0000573, =0.01436, 
=0.05314, =0.00108,  =0.03668 and =0.05433) which are all less than 0.05. So, the 
response of Group 3 shows most positive response in almost all the clinical parameters 
such as F.Testo, DHEAS, LH, LH/FSH, PRO, TC, TGL, FI and TSH. Hence the 
Alternate Hypothesis is proved. 
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Table 43. Response of Drugs for various clinical parameters over a period of 24 
weeks 
Parameters 
/ Drugs 
Drug 1 Drug 2 Drug 3 
NH AH NH AH NH AH 
F. Testo    
 
20
th
 week 
 
 
12
th
 week 
DHEAS    
 
16
th
 week 
 
 
12
th
 week 
LH    
 
8
th
 week 
 
 
4
th
 week 
LH/FSH  
 
20
th
 week 
 
 
8
th
 week 
 
 
8
th
 week 
PRO      
 
8
th
 week 
TC      
 
24
th
 week 
TGL      
 
20
th
 week 
LDL       
HDL    
 
12
th
 week 
  
WT       
BMI       
BP       
FBS       
PPBS       
F.I      
 
12
th
 week 
FSH  
 
20
th
 week 
    
TSH 
      
12
th
 week 
T.Testo       
Sevum 
Andvo 
      
  
 
  
 
 
 
Figure 29. Groups and its reactive clinical parameters that passes two tailed t-test with 95% significance level 
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From the Figure 29, it is being inferred that, For Group 3 more number of clinical 
parameters shows significance response for different age group of populations. The p 
values for the clinical parameters F.Testo, DHEAS, LH, LH/FSH, PRO, TC, TGL, FBS, 
PPBS, F.I, TSH are statistically significant (p<0.05) for Group 3  than Group 1 and 
Group 2. 
    Figure 30.Subjects and their outcomes after treatment with three different groups           
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Positive results in treatment were seen for 26 out of 30 patients in Group 3 and 
maximum positive outcome of 87% was achieved only by Group 3 and Group 2 achieved 
next level of positive outcome for 18 out of 30 patients with 60% and Group 1 provided 
positive outcome only for 4 out of 30 patients which is 13.3% only. 
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DISCUSSION 
Polycystic ovarian syndrome is a complex heterogeneous clinical condition 
characterized by hyperandrogenism with chronic oligo/anovulation. The factors 
influencing PCOS include genetic predisposition, high levels of insulin in blood, obesity, 
excessive production of masculine hormones, abnormality in hypothalamic-pituitary-
gonadal axis, environmental pollutants, food adulterants and chronic inflammation
[85]
. 
In our study to evaluate the efficacy of MI on 30 PCOS patients compared to 
placebo (30 patients) and metformin (30 patients) for a period of 24 weeks, at the end of 
the study period MI treated group results in major reduction in Fasting insulin. Previously 
similar studies were done by Genazzani et.al and Unfer V et.al, Martino M zacche et.al 
[60,76]
. 
Our study showed significant reduction in LH from 4
th
 week onwards and 
reduction in LH/FSH ratio from 8
th
 week onwards in MI  group. This was related to the 
prior studies done by Genazzani et.al, Martino M zacchi.et.al, Antonio simone lagana et 
al
 [76]
. 
Our study also showed significant reduction in prolactin from 8
th
 week onwards in 
MI treated group compared to placebo and metformin  group. Previously similar studies 
were done by Genazzani et al
[76]
. 
Our study showed significant reduction in free testosterone  from 12
th
 week 
onwards in MI treated group and the same reduction was from 20
th
 week only in 
metformin treated group.This was related the previous studies done by costantino.et.al, 
Nestler.J E et al., Martino M zacchi et al
[6,8]
. 
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Our study showed significant reduction in DHEA-S from 12
th
 week onwards in MI 
treated group and the same reduction was from 16
th
 week only in metformin treated 
group.  Prior related studies were done by Costantino et al
[8]
. 
Our study showed significant reduction in TC and TGL from 20
th
 week onwards in 
MI treated group and the similar significance was not found in metformin treated group. 
This was similar to the previous studies done by Costantino et al and Nestler JE et al
 [6,8]
. 
Our study showed significant reduction in TSH by 12
th
 week in MI treated group 
and the similar significance was not found in placebo and metformin treated group. There 
were no previous studies indicating the similar significance. 
Our study does not show any significance with respect to the following parameters 
such as FBS, PPBS, FSH, hormonal parameters such as total testosterone, 
androstenedione, lipid profile such as LDL and HDL cholesterol. 
Regularization of menstrual cycle 
In our study 11 out of 13 unmarried women got their cycles regularized after 
treatment with MI followed by 7 out of 12 women in metformin group and 2 out of 13 in 
placebo. These were similar to the previous studies done by Genazzani et al
[76]
, who 
stated that normal menstrual cycles restored with MI were maximum compared to 
placebo. 
Pregnancy Rate 
In our study MI group, 15 out of 17 married infertile PCOS women got conceived 
followed by 11 out of 18 in metformin group and 2 out of 17 in placebo. These were 
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similar to the previous studies done by Gerli et al, who stated that MI has significantly 
increased the frequency of ovulation and pregnancy rate compared to placebo
[61]
. 
Ovulation Rate 
In the present study, in the MI group, total of 26 patients(87%) out of 30 ovulated 
showing positive results compared to metformin group showing 18 out of 30 
patients(60%) showing positive results and placebo group with 4 out of 30 patients 
(13.3%)with positive results. These were similar to the previous studies done by 
costantino.et.al, who stated that ovulation restored with MI was maximum compared to 
placebo
[8]
. 
In a study done by Raffone et al comparing the effect of metformin and MI in 120 
PCOS patients, out of 60 women 50% restored spontaneous ovulation and spontaneous 
pregnancy in 11 women and seven drop out because of side effects on treatment with 
metformin. In MI treated group, out of 60 women 65% restored spontaneous ovulation 
and spontaneous pregnancy in 18 women. It was suggested that MI treatment seems to be 
more effective than metformin as first line treatment for restoring normal menstrual 
cycles in patients with PCOS 
[70]
. 
 In this study, the results revealed that MI was found to be better than metformin 
and placebo in improving the hormonal and metabolic profile with subsequent frequency 
of ovulation and pregnancy outcomes. 
In our study, 5 out of 90 PCOS women showed mild hair growth (hirsutism) on 
the upper lip which according to Ferriman -gallway visual scale 
[86]
 comes under the 
score of <8 which was regarded as normal. 
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Adverse Drug Reaction  
In our study 4 out of 30 patients treated with metformin showed mild GIT 
distutbances but there were no drop out. MI treated group did not show any adverse 
events. These were similar to the previous studies done by Carlomagno et al who stated 
that dosage of 4gm/day commonly used in clinics is completely free of side effects. 
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CONCLUSION 
As PCOS is an emerging disorder during adolescence, early intervention is 
necessary to improve the reproductive health of adolescents and to prevent future 
complications. It is concluded from the present study that MI (non-hormonal drug) was 
effective in the treatment of PCOS in terms of regularization of menstrual cycle, 
induction of ovulation and improving the success rate of pregnancy in infertility cases. It 
was a safe and effective drug in terms of very minimal or absence of side effects 
compared to placebo and metformin. The observations made from this study justify the 
use of MI for the treatment of PCOD. Hence it could be included in the treatment 
protocol of infertility in the near future. Further research with the ideas of finding out the 
exact mechanisms including genetic expression for multiple illnesses of the PCOS is 
required.  
 
LIMITATIONS OF THE STUDY 
The present work was limited to the patients in age group of 18-40 years 
Genetic expression in PCOS patients was not carried out in this study.  
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1 27 M 0 160 65 25.4 120/80 87 88 110 0.80     13 0.15 12 4.2 2.86 3.14 18.3 0.9 25 2.26 270 190 100.2 120 30 PCO+
2 30 M 0 164 66 24.5 130/80 87 80 98 0.82     5.2 0.07 10.2 4.6 2.22 3.2 18.2 1 20.14 1.5 214 180 120 140 35 PCO+
3 25 M 0 158 62 24.8 100/70 87 79 67 1.18     8.6 0.11 10.6 5.4 1.96 3.8 10.3 1.18 10.7 2.1 212 197 94 140 35 PCO+
4 24 M 0 160 62.3 24.3 100/80 86 67 91 0.74     9.8 0.15 10.8 5.6 1.93 2.3 10 1.18 8.2 2.5 426 197 93.4 124 54.9 PCO+
5 24 M 0 148 53 24.2 130/80 86 90 123 0.73     9.6 0.10 12.3 6.2 1.98 3 9.6 0.9 9.4 2.4 240 180 90 120 35 PCO+
6 29 M 0 165 50 18.4 130/80 74 90 72 1.25     10 0.11 12.6 6.4 1.97 3 10.9 0.8 11.8 0.43 263 180 90 120 34 PCO+
7 26 M 0 168 74 26.2 110/70 90 92 117 0.79     9 0.10 10.7 4.2 2.55 3.4 13 2.3 19 2.26 288 180 100 140 35 PCO+
8 28 M 0 170 66 22.8 110/70 84 78 103 0.76     9.2 0.12 12.6 6.6 1.91 3.6 12.2 0.95 8.6 2.8 211 171.2 102 106 34 PCO+
9 26 M 0 159 62 24.5 140/90 87 71 121 0.59     11.6 0.16 10.2 5.4 1.89 7.6 15.6 0.92 20.6 3.2 276 170 140 142 32.3 PCO+
10 28 M 0 154 58 24.5 120/80 87 82 116 0.71     18.8 0.23 12.6 4.6 2.74 2.4 13.4 0.73 3.6 3 270 226 88 93 38 PCO+
11 32 M 0 165 49.5 18.2 120/70 74 76 108 0.70     9.6 0.13 12.2 6.2 1.97 1.1 13.4 0.7 8.4 3 268 220 90 100 30 PCO+
12 30 M 0 165 78 28.7 114/82 96 78 102 0.76     17 0.22 14.4 5.2 2.77 8.1 13.2 1.1 16 1.8 260 220 106 150 32 PCO+
13 28 UM 0 152 55 23.8 110/70 86 88 110 0.80     9.6 0.11 12.6 6 2.10 3.7 10.4 0.5 7.6 2.1 280 230 148 90 34 PCO+
14 22 UM 0 164 52.5 19.5 110/80 78 84 100 0.84     7 0.08 12.4 4.2 2.95 3.3 10.6 1.04 4.07 3.8 309 162.1 77.1 85.1 34 PCO+
15 23 UM 0 151 48 21.1 110/80 80 74 110 0.67     7.6 0.10 8.2 3.4 2.41 2.86 7.6 0.9 5.8 3 262 170.6 150 143 34.3 PCO+
16 26 UM 0 162 77 29.3 130/80 96 92 112 0.82     10.6 0.12 14.6 5.6 2.61 5.2 18.2 0.95 7.6 4.4 304 234 124 155 45 PCO+
17 29 UM 0 164 61 22.7 130/90 84 60 77 0.78     3.5 0.06 10 5.2 1.92 2.19 4.9 0.2 8.8 1.77 211.5 180 100 140 35 PCO+
18 24 UM 0 158 58 23.2 130/80 84 83 95 0.87     15 0.18 7.9 3.4 2.32 1.8 4.9 0.5 8.8 1.7 162 220 90 100 36 PCO+
19 22 UM 0 172 65 22 90/80 82 78 97 0.80     5.6 0.07 12.4 4.3 2.88 2.6 15.2 0.1 9.6 2.14 200 171.2 103 106 35.4 PCO+
20 20 UM 0 156 47 19.3 112/80 76 74 94 0.79     9.6 0.13 8.8 3.6 2.44 2.7 13.21 0.8 7.6 2.24 207 170 140 142 30.4 PCO+
21 22 UM 0 154 60 25.3 120/80 87 94 84 1.12     18 0.19 12.8 4.6 2.78 3.2 11.3 0.9 8.6 2.2 260 190 92 110 30 PCO+
22 24 UM 0 158 74 29.6 120/80 98 92 78 1.18     15.8 0.17 10.8 4.6 2.35 3.4 10.4 1.04 9 2.2 275 174 96 140 35 PCO+
23 26 M 0 148 59 26.9 110/70 92 90 120 0.75     8.6 0.10 12.6 5.6 2.25 3.2 7.6 0.7 7.6 2.8 254 220 139 150 32 PCO+
24 26 M 0 160 66 25.8 100/70 90 78 104 0.75     9.2 0.12 12.6 4.5 2.80 2.4 10.6 0.7 8.2 2.8 270 216 130 160 34 PCO+
25 26 UM 0 160 65 25.4 130/80 87 88 110 0.80     18 0.20 10.6 5.2 2.04 3.4 11.6 1.2 15.2 2.26 264 180 100.2 120 35 PCO+
26 23 UM 0 168 74 26.2 110/80 90 92 117 0.79 9 0.10 12.6 4.3 2.93 2.24 13.2 1.4 19.4 2.26 288 180 100 140 35 PCO+
27 22 UM 0 170 60 20.8 90/70 80 90 120 0.75 10 0.11 12.6 3.2 3.94 3.2 7.6 0.6 10.4 2.26 280 182 94 140 30 PCO+
28 28 M 0 158 65 26 120/70 90 94 120 0.78 9 0.10 10.6 4.2 2.52 3 13.2 1.2 8.9 2.4 254 170 102 140 30 PCO+
29 24 M 0 154 68 28.7 110/70 96 82 116 0.71 9 0.11 14.2 6.2 2.29 2.8 12.2 0.7 8.2 2.4 260 180 104 140 28 PCO+
30 25 M 0 165 50 18.4 120/80 74 90 72 1.25 10 0.11 12.2 5.6 2.18 2.8 12.2 0.7 6.5 2.4 260 180 90 120 35 PCO+
1 27 M 4 160 66 25.8 120/80 90 86 108 0.80 13 0.15 10 4.2 2.38 3.1 17.6 0.9 25 2.26 270 189 100 121 28 PCO+
2 30 M 4 164 67 24.9 130/70 87 82 100 0.82 5.2 0.06 10.4 4.2 2.48 3.26 18.2 1 20.14 1.5 214 180 120 140 34 PCO+
3 25 M 4 158 62 24.8 110/70 87 79 67 1.18 8.6 0.11 10.6 5.6 1.89 3.6 10.2 1.18 10.7 2.1 212 190 92 134 35 PCO+
4 24 M 4 160 61 23.8 100/80 86 70 90 0.78 9.8 0.14 10.8 5.6 1.93 2.4 10.2 1.18 8.2 2.5 426 196 92.2 122 50 PCO+
5 24 M 4 148 52 23.7 130/80 86 90 120 0.75 9.6 0.11 12 6.2 1.94 2.8 9.4 0.9 9.4 2.4 240 178 88 122 34 PCO+
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6 29 M 4 165 52 19.1 130/70 76 90 84 1.07 10 0.11 12 6 2.00 2.8 10.8 0.8 11.8 0.43 263 178 86 118 32 PCO+
7 26 M 4 168 72 25.5 110/80 90 90 117 0.77 9 0.10 10.4 4.6 2.26 3.6 13.2 2.3 19 2.26 288 178 98 138 34 PCO+
8 28 M 4 170 64 22.1 110/70 82 80 104 0.77 9.2 0.12 10.4 6.6 1.58 3.2 12 0.95 8.6 2.8 210 170 100 103 32 PCO+
9 26 M 4 159 62 24.5 140/90 87 70 120 0.58 11.6 0.17 10.4 5.2 2.00 7.4 15.4 0.92 20.6 3.2 276 168 138 140 31 PCO+
10 28 M 4 154 58 24.5 120/70 87 80 114 0.70 18.8 0.24 12.4 4.4 2.82 2.2 12.4 0.73 3.6 3 270 220 84 90 35 PCO+
11 32 M 4 165 50 18.4 120/70 74 78 110 0.71 9.6 0.12 12.4 6.4 1.94 1.2 12 0.7 8.4 3 268 218 92 108 32 PCO+
12 30 M 4 165 74 27.2 114/80 92 99 104 0.95 17 0.17 14.2 5.4 2.63 8 13 1.1 16 1.8 260 218 104 148 34 PCO+
13 28 UM 4 152 54 23.4 114/80 84 90 114 0.79 9.6 0.11 12.6 6.2 2.03 3.6 10.6 0.5 7.6 2.1 280 228 146 88 32 PCO+
14 22 UM 4 164 50.5 18.8 110/80 76 73 93 0.78 7 0.10 12.6 4 3.15 3.2 10.2 1.04 4.07 3.8 309 160 76 82 32 PCO+
15 23 UM 4 151 46 20.2 114/82 78 76 100 0.76 7.6 0.10 8.6 3.6 2.39 2.63 7.4 0.9 5.8 3 260 168 148 140 32.2 PCO+
16 26 UM 4 162 76 29 130/80 96 92 110 0.84 10.6 0.12 14.3 5.4 2.65 5 17.6 0.95 7.6 4.4 304 230 120 156 45 PCO+
17 29 UM 4 154 60 22.3 130/80 82 64 79 0.81 3.5 0.05 10.6 5.4 1.96 2.18 4.6 0.2 8.8 1.77 211 178 98 138 34 PCO+
18 24 UM 4 158 56 22.4 130/80 82 110 90 1.22 15 0.14 7.6 3 2.53 1.6 4.8 0.2 8.8 1.7 160 218 88 98 34 PCO+
19 22 UM 4 172 64 21.6 90/70 82 76 96 0.79 5.6 0.07 12 4.6 2.61 15 0.1 9.6 2.14 200 170 100.2 100.6 34 PCO+
20 20 UM 4 156 46 18.9 110/80 76 74 94 0.79 9.6 0.13 8.4 3.2 2.63 2.6 13.2 2.8 7.6 2.24 207 168 138 140 30.2 PCO+
21 22 UM 4 154 58 24.5 120/84 87 96 84 1.14 18 0.19 12.6 4.2 3.00 3 11 0.9 8.6 2.2 260 188 90 106 32 PCO+
22 24 UM 4 158 70 28 120/70 94 90 82 1.10 15.8 0.18 10.6 4.2 2.52 3.3 9.8 1.04 9 2.25 275 174 94 138 34 PCO+
23 26 M 4 148 55 25.1 110/70 87 90 104 0.87 8.6 0.10 12 5 2.40 3.1 7.5 0.7 7.6 2.8 254 220 138 148 32 PCO+
24 26 M 4 160 66 25.8 100/70 90 78 100 0.78 9.2 0.12 12 4 3.00 2 9.4 0.7 8.2 2.8 270 215 128 158 32 PCO+
25 26 UM 4 160 65 25.4 132/84 87 95 110 0.86 18 0.19 10.8 5 2.16 3.2 11.4 1.2 15 2.2 264 178 98 118 34 PCO+
26 23 UM 4 168 74 26.2 112/84 90 92 117 0.79 9 0.10 12 4 3.00 2.24 13.2 1.4 19.2 2.26 288 178 98 138 34 PCO+
27 22 UM 4 170 58 20.1 90/70 78 90 120 0.75 10 0.11 12 3.6 3.33 3.4 7.6 0.6 10.4 2.26 280 180 90 138 28 PCO+
28 28 M 4 158 64 25.6 120/70 90 84 110 0.76 9 0.11 10 4 2.50 2.8 12.5 1.2 8.9 2.4 254 168 98 138 32 PCO+
29 24 M 4 154 65 27.4 120/70 92 80 114 0.70 9 0.11 14 6 2.33 2.6 10.6 0.7 8.2 2.4 260 178 102 138 30 PCO+
30 25 M 4 165 52 19.1 130/90 76 96 80 1.20 10 0.10 12.4 5.2 2.38 2.6 12 0.7 6.5 2.4 260 178 88 118 34 PCO+
1 27 M 8 160 65 25.4 120/80 87 88 110 0.80 13 0.15 10 6.2 1.61 3.1 17.4 0.9 25 2.2 270 190 98 119 30 PCO+
2 30 M 8 164 66 24.5 120/82 87 80 98 0.82 5.2 0.07 11.2 5.2 2.15 3.16 17.3 1 20.14 1.6 214 178 118 139 35 PCO+
3 25 M 8 158 4 24.8 100/70 87 80 97 0.82 8.6 0.11 11 5.8 1.90 3.8 10.3 1.1 10.6 2.1 212 197 94 140 34 PCO+
4 24 M 8 160 62.3 24.3 100/80 86 70 90 0.78 9.8 0.14 10.4 4.3 2.42 2.3 10 1.18 8.2 2.5 424 196 92 120 52 PCO+
5 24 M 8 148 53 24.2 120/80 86 90 120 0.75 9.4 0.10 10 5.4 1.85 3 9.6 0.9 9.2 2.6 240 178 88 122 34 PCO+
6 29 M 8 165 52 19.1 130/80 76 90 82 1.10 9.8 0.11 12.4 6.2 2.00 2.8 10.8 0.8 11.6 0.43 260 178 88 118 32 PCO+
7 26 M 8 168 74 26.2 120/80 90 90 110 0.82 9 0.10 10 4.2 2.38 3.4 13 2.3 18.6 2.26 288 178 98 140 33 PCO+
8 28 M 8 170 64 22.1 110/80 82 78 100 0.78 9.2 0.12 12.4 6.4 1.94 3.4 12 0.95 8.4 2.7 210 168 102 106 33 PCO+
9 26 M 8 159 62 24.5 140/80 87 80 118 0.68 11.6 0.15 10.4 5.4 1.93 7.4 15 0.92 20.6 3.2 276 168 138 140 32.2 PCO+
10 28 M 8 154 58 24.5 120/70 87 82 100 0.82 18.8 0.23 12.6 4.6 2.74 2.2 12.4 0.73 3.6 3 270 218 82 92 36 PCO+
11 32 M 8 165 49.5 18.2 130/80 74 82 110 0.75 9.6 0.12 12.2 6.2 1.97 1.1 12.4 0.7 8.4 3.1 268 218 92 104 32 PCO+
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12 30 M 8 165 74 27.2 110/80 92 98 84 1.17 17 0.17 14.4 5.6 2.57 7.8 13 1.1 16 1.8 258 220 104 150 34 PCO+
13 28 UM 8 152 55 23.8 110/70 86 96 110 0.87 9.6 0.10 12.4 6 2.07 3.6 9.6 0.5 7.6 2.1 80 228 146 88 32 PCO+
14 22 UM 8 164 52 19.3 120/80 76 84 93 0.90 7 0.08 12.4 4.6 2.70 3.3 10.4 1.04 4.07 3.8 308 158 76 82 32 PCO+
15 23 UM 8 151 48 21.1 114/82 80 74 100 0.74 7.6 0.10 8.2 3 2.73 2.63 7.4 0.9 5.2 3 260 168 146 140 32.2 PCO+
16 26 UM 8 162 77 29.3 114/82 96 92 110 0.84 10.6 0.12 14.2 5.6 2.54 5 17.4 0.95 7.6 4.4 304 232 120 154 45 PCO+
17 29 UM 8 164 60 22.3 130/80 82 69 84 0.82 3.5 0.05 10.2 4.6 2.22 2.16 4.6 0.2 8.8 1.7 211 178 98 138 34 PCO+
18 24 UM 8 158 58 23.2 132/84 84 110 90 1.22 15 0.14 7.2 3.3 2.18 1.6 4.6 0.2 8.7 1.7 162 218 88 98 34 PCO+
19 22 UM 8 172 64 21.6 90/70 82 76 96 0.79 5.6 0.07 12.4 4.2 2.95 14.8 0.1 9.6 2.14 198 168 100.2 106 34 PCO+
20 20 UM 8 156 46 18.9 112/82 76 74 92 0.80 9.6 0.13 8.6 3 2.87 2.4 13 0.8 7.6 2.24 207 168 138 138 32 PCO+
21 22 UM 8 154 58 24.5 120/84 87 96 84 1.14 18 0.19 10.6 4.8 2.21 3.1 10.8 0.9 8.4 2.2 260 186 88 106 30 PCO+
22 24 UM 8 158 70 28 120/80 94 90 84 1.07 15.8 0.18 8.4 3.2 2.63 3.2 9.8 1.04 9 2.25 275 174 94 138 34 PCO+
23 26 M 8 148 54 24.7 120/70 87 90 110 0.82 8.6 0.10 10.6 6.2 1.71 3 7 0.7 7.6 2.8 250 218 138 148 32 PCO+
24 26 M 8 160 65 25.4 110/70 87 80 110 0.73 9.2 0.12 10 5.6 1.79 2.3 10.6 0.8 8.2 2.8 265 215 125 158 32 PCO+
25 26 UM 8 160 65 25.4 130/80 87 88 110 0.80 17 0.19 12.6 6.2 2.03 3 10.2 1.2 15 2.2 264 178 98 118 34 PCO+
26 23 UM 8 168 74 26.2 112/84 90 92 110 0.84 9 0.10 12.4 4 3.10 2.2 13 1.4 19.2 2.2 286 178 96 138 34 PCO+
27 22 UM 8 170 60 20.8 90/70 80 90 100 0.90 10 0.11 11.8 3.8 3.11 3.2 7.4 0.6 10.4 2.2 280 180 90 138 28 PCO+
28 28 M 8 158 65 26 120/70 90 92 110 0.84 9 0.10 10 4.2 2.38 2.8 12.5 1.2 8.9 2.4 256 168 98 138 32 PCO+
29 24 M 8 154 68 28.7 110/70 96 82 100 0.82 9 0.11 13.8 5.8 2.38 2.5 10.6 0.7 8.2 2.4 260 178 102 138 32 PCO+
30 25 M 8 165 52 19.1 130/80 76 95 110 0.86 10 0.11 12 5 2.40 2.6 12.2 0.7 6.5 2.4 258 178 88 118 34 PCO+
1 27 M 12 160 67 26.2 120/70 90 86 108 0.80 14 0.16 12 4.2 2.86 3 18.3 0.9 24 2.26 268 189 100 128 28 PCO+
2 30 M 12 164 66 24.5 120/70 87 90 100 0.90 5.2 0.06 10.4 4.2 2.48 3.2 17.3 1 19.14 1.6 213 180 120 140 34 PCO+
3 25 M 12 158 62 24.8 110/70 87 80 110 0.73 8.6 0.11 10.2 5.4 1.89 3.8 10.2 1.18 10.6 2.1 214 190 90 140 35 PCO+
4 24 M 12 160 63 24.6 110/80 87 72 94 0.77 9.8 0.14 10 5.2 1.92 2 10.4 1.1 8 2.5 424 196 93 120 52 PCO+
5 24 M 12 148 54 24.7 120/80 87 90 123 0.73 9.4 0.10 12 6.2 1.94 2.8 9.4 1 9.2 2.6 236 180 92 120 36 PCO+
6 29 M 12 165 50 18.4 120/80 74 90 80 1.13 9.6 0.11 12.6 6.4 1.97 3 10.9 0.7 11.6 0.4 260 180 90 120 34 PCO+
7 26 M 12 168 74 26.2 120/80 90 94 112 0.84 8.8 0.09 12.4 6.4 1.94 3.4 13.2 1.9 18.6 2.2 280 180 100 138 34 PCO+
8 28 M 12 170 66 22.8 110/80 84 78 103 0.76 9.4 0.12 12.6 6.6 1.91 3.2 12 1 8.4 2.6 206 170 102.6 108 32 PCO+
9 26 M 12 159 60 23.7 130/80 86 90 110 0.82 11.4 0.13 10.2 5.2 1.96 7.4 14.8 0.9 20 3.1 274 170 140 140 32.2 PCO+
10 28 M 12 154 58 24.5 120/80 87 82 100 0.82 18.6 0.23 12 6 2.00 2.4 12.6 0.4 3.8 3.2 266 220 82 90 36 PCO+
11 32 M 12 165 49.5 18.2 120/80 74 76 108 0.70 9.4 0.12 12 6.2 1.94 1.1 13.4 0.6 8.2 3.1 264 220 90 104 30 PCO+
12 30 M 12 165 78 28.7 110/80 96 90 73 1.23 16 0.18 14 5.8 2.41 7.8 12.8 1 14.2 1.6 258 218 104 148 30 PCO+
13 28 UM 12 152 55 23.8 114/82 86 96 110 0.87 9.4 0.10 12.2 6.2 1.97 3.7 9.6 0.6 7.4 2 278 230 148 90 34 PCO+
14 22 UM 12 164 52 19.3 120/80 76 82 96 0.85 6.8 0.08 12.2 4.2 2.90 3.2 10.4 1 4.07 3.6 300 160.2 77 84 30 PCO+
15 23 UM 12 151 48 21.1 110/82 80 74 100 0.74 7.4 0.10 8.2 3 2.73 2.4 7.6 0.6 5.6 2.8 256 170.6 146 140 30.2 PCO+
16 26 UM 12 162 76 29 130/82 96 92 112 0.82 9.8 0.11 14 7.2 1.94 5.1 17.4 0.8 7.4 4.2 3.2 230 120 150 44 PCO+
17 29 UM 12 164 60 22.3 130/80 82 69 86 0.80 3.4 0.05 10.2 4.2 2.43 2.16 4.6 0.1 8.6 1.63 200 180 96 136 34 PCO+
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18 24 UM 12 158 58 23.2 134/82 84 93 95 0.98 12 0.13 7 3 2.33 1.6 4.6 0.1 8.6 1.6 160 220 86 100 36 PCO+
19 22 UM 12 172 64 21.6 90/74 82 82 92 0.89 5.4 0.07 12 4.3 2.79 2.4 15 0.1 9.4 2.1 198 168 103 104 34 PCO+
20 20 UM 12 156 46 18.9 110/80 76 82 90 0.91 9.4 0.11 8.8 3.6 2.44 2.6 12.4 0.6 7.4 2.3 204 170 138 138 28.6 PCO+
21 22 UM 12 154 56 23.6 120/80 86 90 100 0.90 15 0.17 9.6 4.6 2.09 3.1 9.8 0.8 8.2 2 255 190 90 110 32 PCO+
22 24 UM 12 158 68 27.2 120/70 92 90 84 1.07 13.3 0.15 8.6 3 2.87 3.4 8.6 1 8 2.2 270 170 96 140 32 PCO+
23 26 M 12 148 50 22.8 120/70 84 98 110 0.89 8.4 0.09 8.4 7.6 1.11 3 7.6 0.6 6.5 2.6 246 220 139 150 34 PCO+
24 26 M 12 160 64 25 90/70 87 82 98 0.84 8 0.10 8.6 4.2 2.05 2 9.4 0.8 7.6 2.8 265 214 130 156 32 PCO+
25 26 UM 12 160 64 25 120/80 87 90 110 0.82 17 0.19 12.6 6 2.10 3.2 10.4 1 14 2.2 260 180 100 120 35 PCO+
26 23 UM 12 168 73 25.9 110/80 90 90 110 0.82 8 0.09 12.8 6.2 2.06 2.2 12.8 1 18.2 2.2 280 180 98 140 35 PCO+
27 22 UM 12 170 58 20.1 100/70 78 90 110 0.82 9.8 0.11 12 3.8 3.16 3.2 7 0.7 9.8 2.2 278 182 94 140 30 PCO+
28 28 M 12 158 64 25.6 110/70 90 84 120 0.70 8.4 0.10 10.6 4 2.65 3 13 1 8 2 250 170 102 140 30 PCO+
29 24 M 12 154 68 28.7 110/70 96 84 110 0.76 8.8 0.10 14 6.2 2.26 2.8 12.2 0.4 8 2 256 180 104 140 32 PCO+
30 25 M 12 165 50 18.4 130/80 74 90 112 0.80 8.2 0.09 11.8 6.2 1.90 2 12.2 0.6 6.2 2 256 178 90 120 35 PCO+
1 27 M 16 160 65 25.4 120/70 87 86 110 0.78 14 0.16 12 4.2 2.86 3.1 18.2 0.9 24 2.26 268 190 100.2 121 30 PCO+
2 30 M 16 164 67 24.9 120/70 87 88 106 0.83 5.2 0.06 10.2 5.2 1.96 3.2 18.2 1 19.14 1.6 213 178 120 140 35 PCO+
3 25 M 16 158 62 24.8 110/70 87 80 97 0.82 8.6 0.11 10.2 5 2.04 3.6 10.3 1.16 10.6 2.1 214 190 94.8 140 35 PCO+
4 24 M 16 160 61 23.8 110/80 86 70 90 0.78 9.8 0.14 10.2 4.2 2.43 2.3 9.6 1.1 8 2.4 424 197 94 122 50 PCO+
5 24 M 16 148 53 24.2 110/80 86 90 120 0.75 9.4 0.10 12 6 2.00 3 9.2 1 9.2 2.6 236 178 90 118 36 PCO+
6 29 M 16 165 52 19.1 120/80 76 94 84 1.12 10 0.11 12 5.6 2.14 2.8 10 0.7 11.8 0.4 260 176 88 120 34 PCO+
7 26 M 16 168 72 25.5 120/80 90 90 117 0.77 8.8 0.10 10 6 1.67 3.6 12.6 1.9 18.6 2.2 280 176 96 140 33 PCO+
8 28 M 16 170 66 22.8 110/80 84 80 104 0.77 9.4 0.12 12.4 6 2.07 3.6 12.2 1 8.4 2.6 206 170 100.2 106 32 PCO+
9 26 M 16 159 62 24.5 130/80 87 80 120 0.67 11.4 0.14 10 5 2.00 7.4 14.8 0.9 20 3.1 274 172 142 138 30.3 PCO+
10 28 M 16 157 54 22.8 120/80 84 82 116 0.71 18.6 0.23 12.4 6.2 2.00 2.4 12.6 0.4 3.8 3.2 266 220 84 92 35 PCO+
11 32 M 16 165 49 18 120/80 74 76 108 0.70 9.4 0.12 12.4 6 2.07 1.1 13.4 0.6 8.2 3.1 264 218 88 108 30 PCO+
12 30 M 16 165 78 28.7 120/80 96 99 104 0.95 16 0.16 14.4 5 2.88 8 13 1 14 1.6 258 218 108 150 32 PCO+
13 28 UM 16 152 55 23.8 110/80 86 90 114 0.79 9.4 0.10 12 6 2.00 3.7 10 0.6 7.4 2 278 228 148 92 34 PCO+
14 22 UM 16 164 52 19.3 120/80 76 84 92 0.91 6.8 0.08 12.4 4.6 2.70 3.3 10.6 1 4.07 3.6 300 160.2 77 86 34 PCO+
15 23 UM 16 151 48 21.1 110/80 80 76 110 0.69 7.4 0.10 8 3.2 2.50 2.4 7.8 0.6 5.6 2.8 256 170.4 146 142 30.2 PCO+
16 26 UM 16 162 76 29 130/80 96 90 110 0.82 9.8 0.11 14 7.2 1.94 5.2 17.4 0.8 7.4 4.2 302 232 126 150 43 PCO+
17 29 UM 16 164 61 22.7 130/84 84 69 84 0.82 3.4 0.05 10.6 4.6 2.30 2.18 4.6 0.1 8.6 1.6 200 180 100 136 35 PCO+
18 24 UM 16 158 58 23.2 130/80 84 100 90 1.11 12 0.12 7.6 3 2.53 1.8 4.9 0.1 8.6 1.6 160 218 90 98 34 PCO+
19 22 UM 16 172 65 22 90/74 82 76 84 0.90 5.4 0.07 12.4 4.3 2.88 15 0.1 9.4 2.1 198 170.2 103 104 35 PCO+
20 20 UM 16 156 47 19.3 110/80 76 76 94 0.81 9.4 0.12 8.4 3.2 2.63 2.4 13 0.6 7.4 2.3 204 172 140 140 28.6 PCO+
21 22 UM 16 154 56 23.6 120/80 86 92 110 0.84 15 0.16 9.6 4.6 2.09 3 10.8 0.8 8.2 2 255 190 88 110 32 PCO+
22 24 UM 16 158 67 26.8 120/70 92 92 82 1.12 13.8 0.15 7.4 3.6 2.06 3.4 8.6 1 8 2.2 270 170 94 140 32 PCO+
23 26 M 16 148 50 22.8 110/70 84 92 123 0.75 8.4 0.09 8.2 9.6 0.85 2.8 7.5 0.6 6.5 2.6 246 219 138 148 34 PCO+
Pa
t
i
e
n
t
 
I
D
A
g
e
M
S
W
k
s
H
T
W
T
B
M
I
B
P
A
C
F
B
S
P
P
B
S
F
B
S
/
P
P
B
S
F
.
I
I
/
G
L
H
F
S
H
L
H
/
F
S
H
T
S
H
P
R
O
T
.
T
e
s
t
o
F
.
T
e
s
t
o
S
e
r
u
m
 
A
n
d
r
o
D
H
E
A
S
T
C
T
G
L
L
D
L
H
D
L
U
S
G
P
I
24 26 M 16 160 64 25 100/70 87 90 106 0.85 8 0.09 7.6 4 1.90 2.3 9.4 0.7 7.6 2.8 265 216 128 160 34 PCO+
25 26 UM 16 160 64 25 120/80 87 84 100 0.84 17 0.20 10.8 5.2 2.08 3.4 11.2 1 14 2.2 260 178 98 118 34 PCO+
26 23 UM 16 168 73 25.9 110/80 90 92 117 0.79 8 0.09 12.8 6 2.13 2.2 12.8 1 18.2 2.2 280 178 96 140 34 PCO+
27 22 UM 16 170 60 20.8 100/70 80 90 124 0.73 9.8 0.11 12.6 3 4.20 3 7.4 0.7 9.8 2.2 278 180 90 138 32 PCO+
28 28 M 16 158 64 25.6 110/70 90 90 120 0.75 8.4 0.09 10.2 4.6 2.22 2.8 12.2 1 8.6 2 250 168 98 138 32 PCO+
29 24 M 16 154 68 28.7 112/82 96 86 100 0.86 8.8 0.10 14.2 6.4 2.22 2.6 12 0.4 8 2 256 178 103 138 30 PCO+
30 25 M 16 165 50 18.4 120/82 74 90 110 0.82 8.2 0.09 12 4.8 2.50 2.8 12 0.6 6.2 2 256 180 88 121 34 PCO+
1 27 M 20 160 66 25.8 120/70 90 84 108 0.78 14 0.17 10 5.6 1.79 3.1 18.3 0.9 24 2.25 268 189 98 119 30 PCO+
2 30 M 20 164 66 24.5 120/70 87 102 110 0.93 5.2 0.05 10.6 4.2 2.52 3.16 18.2 1 19.14 1.5 213 180 120 140 35 PCO+
3 25 M 20 158 62 24.8 110/70 87 18 110 0.16 8.6 0.48 10.6 5.2 2.04 3.16 10.3 1.16 10.6 2.1 212 190 94 134 35 PCO+
4 24 M 20 160 61 23.8 100/80 86 64 90 0.71 9.8 0.15 10.2 5.6 1.82 2.3 10.4 1.1 8 2.5 424 196 93 124 52 PCO+
5 24 M 20 148 54 24.7 110/80 87 90 110 0.82 9.6 0.11 12 6 2.00 3 9.4 0.9 9.4 2.4 236 178 90 120 35 PCO+
6 29 M 20 165 50 18.4 120/80 74 90 80 1.13 9.8 0.11 12.6 5.6 2.25 2.8 10.9 0.7 11.8 0.4 263 176 88 118 32 PCO+
7 26 M 20 168 72 25.5 120/80 90 94 112 0.84 9 0.10 10.4 4.2 2.48 3.6 12.6 1.9 18.6 2.2 280 176 96 140 35 PCO+
8 28 M 20 170 65 22.5 110/80 84 80 100 0.80 9.4 0.12 12 6 2.00 3.4 12.4 1 8.4 2.6 206 168 98 106 32 PCO+
9 26 M 20 159 62 24.5 130/80 87 80 110 0.73 11.6 0.15 10.2 5.2 1.96 7.6 15 0.9 20 3.1 274 172 142 138 30.3 PCO+
10 28 M 20 154 54 22.8 120/80 84 80 116 0.69 18.6 0.23 12.4 6.2 2.00 2.2 13.4 0.4 3.8 3.2 266 226 84 92 35 PCO+
11 32 M 20 165 50 18.4 120/80 74 78 110 0.71 9.6 0.12 12.4 6.4 1.94 1.4 13.4 0.6 8.2 3 264 216 90 108 30 PCO+
12 30 M 20 165 78 28.7 120/80 96 78 102 0.76 16 0.21 14 5 2.80 8 13.2 1 14 1.6 258 222 106 152 34 PCO+
13 28 UM 20 152 55 23.8 110/80 86 88 114 0.77 9.4 0.11 12.6 6.2 2.03 3.7 10.6 0.6 7.4 2 278 226 148 92 32 PCO+
14 22 UM 20 164 52 19.3 120/80 76 84 92 0.91 6.8 0.08 12.4 4.6 2.70 3 11.2 1 4.07 3.6 300 160.2 76 86 34 PCO+
15 23 UM 20 151 46 20.2 110/80 78 74 100 0.74 7.4 0.10 8.2 3.4 2.41 2.86 7.6 0.6 5.6 2.8 256 168 148 142 34 PCO+
16 26 UM 20 162 76 29 120/80 96 90 110 0.82 9.8 0.11 14.3 7.3 1.96 5.1 17.2 0.8 7.4 4.2 302 234 126 154 44 PCO+
17 29 UM 20 164 61 22.7 130/84 84 64 82 0.78 3.4 0.05 10.6 5.4 1.96 2 4.9 0.1 8.6 1.6 200 178 98 140 35 PCO+
18 24 UM 20 158 56 22.4 130/80 82 84 96 0.88 12 0.14 7.6 3 2.53 1.8 4.9 0.1 8.6 1.6 160 216 88 96 34 PCO+
19 22 UM 20 172 65 22 100/70 82 82 92 0.89 5.4 0.07 12 5.2 2.31 15 0.1 9.4 2.1 198 170.2 103 104 35 PCO+
20 20 UM 20 156 47 19.3 100/80 76 76 94 0.81 9.4 0.12 8.2 3.6 2.28 2.7 12.4 0.6 7.4 2.3 204 172 140 142 30.2 PCO+
21 22 UM 20 154 55 23.2 120/82 81 90 100 0.90 12 0.13 7.6 8.4 0.90 3 11.2 0.9 7.6 2.2 250 190 92 106 30 Cyc.Reg
22 24 UM 20 158 65 26 120/70 90 90 100 0.90 10.6 0.12 6.2 12.4 0.50 3 8.4 1 7 2.25 268 174 94 138 34 Cyc.Reg
23 26 M 20 148 48 21.9 120/70 82 90 120 0.75 8.6 0.10 8.2 10.6 0.77 3.1 7.6 0.7 5.4 2.8 240 220 138 150 34 GES.SAC
24 26 M 20 160 62 24.2 100/70 86 90 110 0.82 6.2 0.07 6.5 10.6 0.61 2.4 9.4 0.7 7 2.8 260 216 128 160 34 GES.SAC
25 26 UM 20 160 65 25.4 120/80 87 82 114 0.72 17 0.21 10.6 5 2.12 3.4 11.4 1 14 2.2 260 178 98 118 34 PCO+
26 23 UM 20 168 73 25.9 110/80 90 92 117 0.79 8 0.09 12.4 6 2.07 2.24 13 1 18.2 2.2 280 178 96 138 34 PCO+
27 22 UM 20 170 60 20.8 100/70 80 90 124 0.73 9.8 0.11 12.6 3.2 3.94 3.2 7.6 0.7 9.8 2.2 278 180 90 138 30 PCO+
28 28 M 20 158 65 26 110/70 90 90 120 0.75 8.4 0.09 9.8 4.2 2.33 2.8 12.2 1 8.6 2 250 168 102 136 30 PCO+
29 24 M 20 154 67 28.3 110/80 94 90 110 0.82 8.8 0.10 14.2 6.2 2.29 2.6 12 0.4 8 2 256 178 102 138 30 PCO+
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1 29 M 0 164 69 25.7 110/90 90 84 101 0.83 15 0.18 14.2 5.2 2.73 2.4 12.4 1.08 10.86 2.3 286 180 104 140 28 PCO+
2 27 M 0 166 67 24.3 150/110 86 78 71 1.10 8 0.10 12.4 6.4 1.94 3.14 12.6 0.9 6.8 4.46 318 190 100 120 40 PCO+
3 25 M 0 162 80 30.5 110/70 99 89 126 0.71 3.9 0.04 14.2 5.2 2.73 2.4 14.6 1.1 7.6 3.6 273 220 92 98 32 PCO+
4 29 M 0 156 64 26.3 140/100 90 90 110 0.82 15.6 0.17 12.4 4.2 2.95 4.4 10.6 0.1 9 2.6 302 210 90 110 30 PCO+
5 26 M 0 164 49 18.2 120/80 74 90 76 1.18 8.3 0.09 12.6 6.4 1.97 4 10.1 0.8 11 0.4 282 200 94 100 32 PCO+
6 24 M 0 160 58 22.7 120/70 84 96 84 1.14 6.2 0.06 12.4 6 2.07 3.4 9.6 0.9 9.3 2.26 250 190 102 92 30 PCO+
7 24 M 0 164 63 23.4 120/80 84 89 126 0.71 4.2 0.05 10.6 4.6 2.30 2.44 10.3 1.12 7.2 3.8 273 210 102 92 30 PCO+
8 26 M 0 156 50 20.5 140/90 80 80 76 1.05 17.2 0.22 10.4 5.2 2.00 2.76 12.2 0.8 8.6 2.24 207 214 100 94 32 PCO+
9 23 M 0 164 61 22.7 90/70 84 60 77 0.78 3.5 0.06 12.2 4.6 2.65 2.2 10.4 0.7 12.2 1.8 212.3 220 92 98 32 PCO+
10 24 M 0 166 52 18.9 140/90 76 76 108 0.70 9.2 0.12 10.2 4.5 2.27 7.1 13.4 0.7 7.2 3.1 268 210 102 72 32 PCO+
11 19 UM 0 152 66 28.6 100/70 96 88 110 0.80 17 0.19 12.6 6.2 2.03 4.2 10 1.1 10.6 2.1 280 210 98 102 32 PCO+
12 22 UM 0 152 40 17.3 100/70 72 74 110 0.67 7.6 0.10 10.8 5.2 2.08 2.86 9.2 0.9 7.6 3 262 210 90 110 30 PCO+
13 22 UM 0 162 77 29.3 120/801 98 92 112 0.82 8.2 0.09 10.3 5.6 1.84 5.1 5 0.9 6.2 4.2 428 200 92 100 30 PCO+
14 20 UM 0 150 58 25.8 100/70 90 82 112 0.73 10.1 0.12 14.2 5.2 2.73 3.1 13.2 0.7 8.2 2.1 263 170 102 140 30 PCO+
15 20 UM 0 160 61 23.8 110/70 86 70 91 0.77 7.6 0.11 16.2 7.6 2.13 3.2 10.6 1.04 9.4 2.35 355 200 100 94 32 PCO+
16 24 UM 0 154 63 26.6 90/70 92 96 84 1.14 18 0.19 12.8 4.6 2.78 4 10.3 0.9 8.9 2.26 302 198 92 98 30 PCO+
17 30 M 0 164 60 22.3 90/70 82 90 76 1.18 6.5 0.07 12.4 6.5 1.91 4 9.6 1.2 10.3 2.4 270 190 90 100 30 PCO+
18 28 M 0 158 62 24.8 150/100 87 96 84 1.14 10.3 0.11 14.2 4.2 3.38 3.8 9.2 0.8 8.6 2.8 245 190 100 90 30 PCO+
19 24 M 0 160 62 24.2 100/70 86 90 76 1.18 6.5 0.07 12.2 6.3 1.94 3.2 10.3 0.9 10.6 2.8 243 180 92 100 30 PCO+
20 20 UM 0 160 58 22.7 120/80 84 96 84 1.14 7.5 0.08 14.2 6.2 2.29 3.4 10.6 1.2 10.8 2.26 250 180 100 95 30 PCO+
21 28 M 0 160 74 28.9 120/80 96 90 76 1.18 15.2 0.17 12.6 5.2 2.42 4.5 13.2 1.2 11.6 0.4 292 200 96 140 28 PCO+
22 26 M 0 166 65 23.6 120/80 86 84 101 0.83 9 0.11 14.2 5.2 2.73 3.4 10.3 1.1 12 2.4 260 210 90 110 30 PCO+
23 26 M 0 152 70 30.3 110/70 98 88 100 0.88 10.2 0.12 12.4 4.2 2.95 8.8 10.3 1 25 2.8 280 263 168 195 34 PCO+
24 24 M 0 160 65 25.4 120/80 87 88 110 0.80 22 0.25 10.2 4.2 2.43 4.2 9.6 1.2 12.3 2.3 272 180 120 140 32 PCO+
25 28 M 0 166 68 24.7 90/70 87 80 98 0.82 6.8 0.09 10.3 5.6 1.84 4.2 11.6 1.2 19.4 1.5 294 180 120 140 32 PCO+
26 22 UM 0 160 65 25.4 120/80 87 67 91 0.74 9.8 0.15 10.9 5.6 1.95 3.2 11.6 0.9 18.6 2.6 365 176 94 140 32 PCO+
27 20 UM 0 160 65 25.4 100/70 87 67 91 0.74 7.2 0.11 14.2 5.2 2.73 4.1 0.2 1.4 7.9 3.6 365 176 94 140 32 PCO+
28 24 UM 0 158 65 26 90/70 90 67 94 0.71 15.2 0.23 10.9 5.6 1.95 2.8 8.6 1.1 15.2 2.8 280 197 93 124 30 PCO+
29 22 UM 0 164 66 24.5 110/70 87 88 110 0.80 6.2 0.07 10.2 4.2 2.43 3.14 12.3 0.9 15.4 2.26 294 190 100 120 40 PCO+
30 20 UM 0 158 64 25.6 130/80 90 79 68 1.16 9.2 0.12 12.6 4.2 3.00 2.3 7.6 1.18 8.9 3.6 525 197 93.4 124 30 PCO+
1 29 M 4 164 69 25.7 110/92 90 80 90 0.89 14 0.18 12.2 5 2.44 2.6 12 1.08 10.86 2.2 286 180 104 140 30 PCO+
2 27 M 4 166 67 24.3 150/100 86 84 110 0.76 8 0.10 12 6 2.00 3.14 12.6 0.9 6.5 4.46 300 188 100 120 41 PCO+
3 25 M 4 162 78 29.7 110/70 98 89 126 0.71 3.9 0.04 14 5 2.80 2.4 14 1.1 7.6 3.4 270 200 90 98 32 PCO+
GROUP 2  - METFORMIN
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4 29 M 4 156 64 26.3 140/100 90 92 106 0.87 15 0.16 12 4 3.00 4 10.6 0.1 8 2.6 300 208 92 100 32 PCO+
5 26 M 4 164 48 17.8 120/80 74 90 86 1.05 8.3 0.09 12 6 2.00 4 10.1 0.8 11 0.4 280 198 96 32 PCO+
6 24 M 4 160 58 22.7 120/70 84 96 84 1.14 6.2 0.06 12 6.2 1.94 3.2 9.6 0.9 9.3 2.26 250 188 100 94 30 PCO+
7 24 M 4 164 63 23.4 120/80 84 88 124 0.71 4.2 0.05 10.3 4.3 2.40 2.44 10.3 1.12 7.2 3.8 270 208 98.4 94 30 PCO+
8 26 M 4 156 50 20.5 140/92 80 88 110 0.80 9.2 0.10 10.4 5 2.08 2.76 12 0.8 8.6 2.24 206 212 98 94 32 PCO+
9 23 M 4 164 60 22.3 100/70 82 64 79 0.81 16 0.25 10.4 5.2 2.00 2.2 10.2 1.1 10.6 2.1 280 200 90 98 32 PCO+
10 24 M 4 166 52 18.9 100/70 76 78 110 0.71 9.2 0.12 10 4 2.50 1.2 13.4 0.7 7.2 3.1 268 208 100 90 32 PCO+
11 19 UM 4 152 65 28.1 100/70 94 90 114 0.79 16 0.18 12 6 2.00 4.2 10 1.1 10.6 2.1 280 208 96 100 32 PCO+
12 22 UM 4 152 40 17.3 100/70 92 74 110 0.67 7.6 0.10 10 5 2.00 2.8 9.2 0.9 7.5 3 260 208 88 108 30 PCO+
13 22 UM 4 162 76 29 100/70 98 92 110 0.84 8 0.09 10 5.2 1.92 5 5.2 0.9 6.2 4.2 428 198 90 98 32 PCO+
14 20 UM 4 150 57 25.3 100/70 87 86 110 0.78 10.1 0.12 14 5.6 2.50 3.1 13.2 0.7 8.2 2.1 260 168 100 136 30 PCO+
15 20 UM 4 160 60 23.4 100/70 84 79 67 1.18 7.6 0.10 15.3 7.2 2.13 3.2 10.6 1.04 9.1 2.3 350 198 98 90 32 PCO+
16 24 UM 4 154 63 26.6 90/70 92 98 84 1.17 17 0.17 12 4 3.00 4 10.3 0.9 8.7 2.26 300 196 90 96 30 PCO+
17 30 M 4 164 60 22.3 90/70 82 90 86 1.05 6.5 0.07 12 6 2.00 4 9.6 1.2 10.3 2.4 262 188 88 98 30 PCO+
18 28 M 4 158 60 24 150/100 86 96 82 1.17 10.3 0.11 14 4 3.50 3.8 9.2 8.6 0.8 2.8 240 188 98 88 30 PCO+
19 24 M 4 160 62 24.2 100/70 86 90 88 1.02 6.5 0.07 12 6 2.00 3.2 10.3 0.9 10.4 2.8 240 178 90 98 30 PCO+
20 20 UM 4 160 58 22.7 120/80 84 96 82 1.17 7.5 0.08 14 6 2.33 3.4 10.4 1.2 10.8 2.26 248 182 98 93 30 PCO+
21 28 M 4 160 74 28.9 130/80 96 90 86 1.05 15 0.17 12 5 2.40 4 13.2 1.2 11.6 0.4 290 198 94 138 30 PCO+
22 26 M 4 166 65 23.6 120/80 86 80 90 0.89 9 0.11 14 5 2.80 3.4 10.3 1.1 12 2.4 260 208 88 108 30 PCO+
23 26 M 4 152 70 30.3 110/70 98 88 110 0.80 10.2 0.12 12.6 4 3.15 3.8 10.3 1 25 2.8 276 260 150 90 34 PCO+
24 24 M 4 160 65 25.4 220/70 87 88 110 0.80 22 0.25 10 4.6 2.17 4.2 9.6 1.2 12 2.3 270 178 118 138 32 PCO+
25 28 M 4 166 68 24.7 90/70 87 80 98 0.82 6.8 0.09 10 5 2.00 4.2 11.6 1.2 19 1.5 290 178 118 138 32 PCO+
26 22 UM 4 160 65 25.4 124/82 87 62 94 0.66 9.8 0.16 10.9 5.6 1.95 3.2 11.6 0.9 18 2.6 360 174 90 138 32 PCO+
27 20 UM 4 160 65 25.4 110/70 87 70 90 0.78 7.2 0.10 14 5 2.80 4.1 10 1.4 7.9 3.6 360 174 92 138 32 PCO+
28 24 UM 4 158 95 26 90/70 90 67 91 0.74 15 0.22 10 5 2.00 2.8 8.4 1.1 15 2.8 280 196 92 124 30 PCO+
29 22 UM 4 164 66 24.5 110/70 87 88 110 0.80 6.2 0.07 10 4 2.50 3.14 12 0.9 15 2.26 290 188 98 118 41 PCO+
30 20 UM 4 158 64 25.6 130/80 90 80 97 0.82 9.2 0.12 12 4 3.00 2.3 7.6 1.18 8.9 3.6 520 196 90.2 122 30 PCO+
1 29 M 8 164 68 25.3 110/70 87 80 94 0.85 14 0.18 14 5 2.80 2.4 12.6 1.08 10.8 2.2 280 180 104 140 30 PCO+
2 27 M 8 166 67 24.3 150/90 86 84 106 0.79 8 0.10 12.3 6.2 1.98 3.1 10.4 0.8 6.5 4.4 300 188 100.2 120 41 PCO+
3 25 M 8 162 78 29.7 100/70 98 88 124 0.71 3.9 0.04 12.2 6 2.03 2.3 13.8 1 7.5 3.4 270 210 90 98 32 PCO+
4 29 M 8 156 62 25.5 140/94 90 90 106 0.85 14.8 0.16 11.2 5.2 2.15 4 10.4 0.1 8 2.6 300 208 92 110 32 PCO+
5 26 M 8 164 48 17.8 120/80 74 90 76 1.18 8.3 0.09 10.2 5.8 1.76 3.8 10 0.8 11 0.4 280 198 96 32 PCO+
6 24 M 8 160 56 21.9 120/80 82 96 82 1.17 6.2 0.06 10.2 5.6 1.82 3.2 9.6 0.9 9 2.2 250 188 100 94 32 PCO+
7 24 M 8 164 62 23.1 120/70 84 89 124 0.72 4.2 0.05 9.2 4 2.30 2.4 9.8 1.12 7.2 3.8 270 208 98.4 92 30 PCO+
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8 26 M 8 156 50 20.5 144/92 80 80 78 1.03 16 0.20 10 5.1 1.96 2.6 12.2 0.8 8.6 2.24 206 212 98 92 34 PCO+
9 23 M 8 164 61 22.7 100/70 84 64 80 0.80 3.5 0.05 10 5 2.00 2.18 10 0.7 12 1.8 212 210 90 98 32 PCO+
10 24 M 8 166 52 18.9 140/90 76 78 110 0.71 9.2 0.12 10 4.4 2.27 1.1 13.2 0.7 7.2 3.1 268 208 98 90 32 PCO+
11 19 UM 8 152 65 28.1 120/70 94 90 114 0.79 16 0.18 10.2 5.6 1.82 4 9.8 1.1 10 2.1 280 208 96 98 32 PCO+
12 22 UM 8 152 40 17.3 90/70 72 76 96 0.79 7.6 0.10 9.2 6.2 1.48 2.7 9.2 0.9 7.5 3 260 208 86 108 30 PCO+
13 22 UM 8 162 75 28.6 110/70 98 94 114 0.82 8 0.09 9.6 5 1.92 5 5.2 0.9 6.2 4.2 420 196 90 98 30 PCO+
14 20 UM 8 150 57 25.3 90/70 87 86 110 0.78 10.1 0.12 12.4 6 2.07 3 13 0.7 8.2 2.1 260 168 98 136 32 PCO+
15 20 UM 8 160 60 23.4 100/70 84 84 102 0.82 7.4 0.09 14.8 7.6 1.95 3.1 10.6 1.04 9.1 2.6 350 198 96 90 34 PCO+
16 24 UM 8 154 60 25.3 100/70 87 102 84 1.21 17 0.17 11.2 4.2 2.67 4 10.3 0.9 8.7 2.26 300 196 90 96 32 PCO+
17 30 M 8 164 58 21.6 100/70 82 90 100 0.90 6.5 0.07 11.6 5.2 2.23 4 9.6 1.2 10 2.4 262 186 90 98 30 PCO+
18 28 M 8 158 60 24 140/90 86 96 100 0.96 10.3 0.11 12.6 4.2 3.00 3.8 9.2 0.8 8 2.6 232 190 98 90 30 PCO+
19 24 M 8 160 60 23.4 90/70 84 90 76 1.18 6.5 0.07 10.2 5.6 1.82 3.1 10.2 0.8 8.2 2.6 230 180 90 98 32 PCO+
20 20 UM 8 160 58 22.7 120/80 84 96 100 0.96 7.5 0.08 11.6 5.2 2.23 3 10.4 1.2 10.8 2.2 248 182 100 95 32 PCO+
21 28 M 8 160 72 28.1 132/82 94 90 70 1.29 15 0.17 11.6 5.2 2.23 4 13.2 1.2 11.4 0.4 290 198 94 138 30 PCO+
22 26 M 8 166 64 23.2 120/80 84 84 100 0.84 9.2 0.11 12.2 6 2.03 3.3 10.2 1.1 12 2.4 260 208 90 108 30 PCO+
23 26 M 8 152 68 29.4 110/70 96 88 100 0.88 10 0.11 11.8 4.2 2.81 3.6 10.4 1 25 2.8 276 260 150 190 36 PCO+
24 24 M 8 160 65 25.4 120/80 87 86 107 0.80 20 0.23 10.3 5.2 1.98 4 9.6 1.2 12 2.3 270 178 118 136 32 PCO+
25 28 M 8 166 68 24.7 100/70 87 88 106 0.83 6.8 0.08 9.6 5.8 1.66 4 11 1.2 18 1.5 290 178 118 138 32 PCO+
26 22 UM 8 160 64 25 120/70 87 70 94 0.74 9.8 0.14 10 5.2 1.92 3.2 11.6 0.9 18 2.6 356 174 90 138 32 PCO+
27 20 UM 8 160 64 25 110/70 87 70 90 0.78 7.2 0.10 13.3 6.2 2.15 10.2 4.1 1.4 7.9 3.5 360 174 92 138 34 PCO+
28 24 UM 8 158 64 25.6 100/70 90 70 91 0.77 15 0.21 10.6 5.2 2.04 2.6 8.4 1.1 15 2.8 280 196 92 120 32 PCO+
29 22 UM 8 164 65 24.2 100/70 86 86 108 0.80 6.2 0.07 8.6 4 2.15 3.1 12.4 0.9 15 2.26 290 188 96 118 41 PCO+
30 20 UM 8 158 63 25.2 120/80 87 80 97 0.82 9.2 0.12 11.6 5 2.32 2.2 7.5 1.18 8.9 3.6 520 196 90 122 32 PCO+
1 29 M 12 164 68 25.3 100/70 87 82 104 0.79 12 0.15 12.6 6.2 2.03 2 12 0.07 9.6 2 276 178 100 138 32 PCO+
2 27 M 12 166 66 24 140/90 86 84 110 0.76 7.8 0.09 10.4 4.3 2.42 3.1 10.4 0.8 5.8 4.4 290 186 100.2 121 42 PCO+
3 25 M 12 162 76 29 110/70 96 89 124 0.72 3.9 0.04 10.4 5.2 2.00 2.3 13.6 1 6.2 3.2 269 210 92 98 34 PCO+
4 29 M 12 156 62 25.5 140/90 90 94 110 0.85 13.2 0.14 10.6 5 2.12 4.2 10.4 0.1 6.9 2.5 282 210 90 100 34 PCO+
5 26 M 12 164 49 18.2 120/70 74 90 76 1.18 8.4 0.09 10.4 5.6 1.86 3.8 10 0.8 9.6 0.4 278 200 94 34 PCO+
6 24 M 12 156 56 21.9 120/70 82 96 100 0.96 6.1 0.06 9.2 5.4 1.70 3.2 9.2 0.8 8.2 2.2 248 190 102 92 32 PCO+
7 24 M 12 162 62 23.1 120/70 84 89 120 0.74 4.2 0.05 9 4.2 2.14 2.4 9.8 1.1 7 3.5 268 210 102 92 30 PCO+
8 26 M 12 156 52 21.4 140/90 80 80 78 1.03 14.2 0.18 9.2 4.8 1.92 2.6 12 0.7 7 2.2 204 214 100 94 34 PCO+
9 23 M 12 164 60 22.3 100/70 82 64 82 0.78 3.5 0.05 8.6 4.2 2.05 2.2 10.2 0.7 10 1.7 210 220 92 98 34 PCO+
10 24 M 12 166 50 18.1 138/90 74 76 8 9.50 9.2 0.12 4.9 0.00 1.2 13.2 0.6 7 2.8 263 210 102 92 34 PCO+
11 19 UM 12 152 63 27.3 110/70 92 96 110 0.87 14 0.15 9.4 5.2 1.81 4 9.8 1 8 2 272 210 98 100 34 PCO+
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12 22 UM 12 152 40 17.3 90/70 72 82 96 0.85 7.6 0.09 8.4 6 1.40 2.7 9.2 0.8 7.1 3 255 210 90 110 32 PCO+
13 22 UM 12 162 70 26.7 110/70 92 96 12 8.00 8.2 0.09 9 4.8 1.88 4.8 5.2 0.9 5.8 3.8 396 200 92 100 32 PCO+
14 20 UM 12 150 57 24.9 90/70 87 86 110 0.78 10 0.12 12 6.4 1.88 3 12.2 0.7 8 2.1 242 170 102 138 32 PCO+
15 20 UM 12 160 60 23.4 100/70 84 84 100 0.84 7.4 0.09 14 7 2.00 3 10.6 1 7.2 2.3 300 200 100 94 34 PCO+
16 24 UM 12 154 58 24.5 100/70 87 110 90 1.22 12.3 0.11 10.3 5.2 1.98 3.8 10.3 0.8 6.4 2.2 280 198 92 98 32 PCO+
17 30 M 12 164 58 21.6 100/80 82 90 76 1.18 6.5 0.07 10.3 5.4 1.91 3.8 9.5 1 8.6 2 240 190 88 100 32 PCO+
18 28 M 12 158 58 23.2 140/90 84 96 82 1.17 10.3 0.11 12 4 3.00 3.6 9.1 0.7 8 2.6 232 188 100 88 32 PCO+
19 24 M 12 160 60 23.4 90/70 84 90 76 1.18 6.5 0.07 10 5.2 1.92 3.1 10.2 0.8 8 2.6 230 178 92 100 32 PCO+
20 20 UM 12 160 58 22.7 110/70 84 96 82 1.17 7.5 0.08 10.6 5.3 2.00 3 10.6 1.1 8.6 2.2 242 180 98 95 32 PCO+
21 28 M 12 160 72 28.1 120/82 94 90 76 1.18 14.2 0.16 11 4.8 2.29 3.8 13 1.2 10.3 0.4 282 200 96 140 30 PCO+
22 26 M 12 166 65 23.6 120/70 86 84 101 0.83 8.8 0.10 12 6 2.00 3.3 10.2 1.1 11 2 255 210 88 110 32 PCO+
23 26 M 12 152 68 29.4 110/70 96 96 110 0.87 9.8 0.10 11.6 4 2.90 3.6 10.3 1 20 2.6 270 263 158 190 36 PCO+
24 24 M 12 160 64 25 110/70 87 86 108 0.80 20 0.23 9.6 4.9 1.96 4 9.5 1.1 11.6 2.2 268 176 118 140 32 PCO+
25 28 M 12 166 66 24 100/70 86 88 106 0.83 6.6 0.08 9.6 5 1.92 4 11.6 1.2 15.2 1.4 280 178 118 140 34 PCO+
26 22 UM 12 160 64 25 120/80 87 70 100 0.70 9.8 0.14 9.8 5.2 1.88 3.2 11.6 0.9 15.2 2.5 324 176 94 140 34 PCO+
27 20 UM 12 160 64 25 100/70 87 80 100 0.80 7.2 0.09 13 6 2.17 4 10.4 1.3 7.7 3.2 358 176 94 140 34 PCO+
28 24 UM 12 158 64 25.6 100/70 90 78 94 0.83 14.6 0.19 10 4.2 2.38 2.6 8.6 1.1 13.2 2.7 270 197 93 120 32 PCO+
29 22 UM 12 164 65 24.2 110/70 86 86 110 0.78 6.2 0.07 8.8 4.2 2.10 3.1 12.3 0.8 12.3 2.24 283 190 98 120 42 PCO+
30 20 UM 12 158 63 25.2 120/80 87 84 102 0.82 9.2 0.11 11.8 5.2 2.27 2.2 7.5 1.18 8.6 3.5 500 197 90 124 32 PCO+
1 29 M 16 164 65 24.2 110/70 86 84 100 0.84 12 0.14 12.4 6 2.07 2 12.4 0.07 9.6 2 270 178 100 138 32 PCO+
2 27 M 16 166 66 24 140/90 86 84 106 0.79 7.8 0.09 10.4 4.4 2.36 3.1 6.2 0.9 5.6 4.4 280 186 100.2 120 42 PCO+
3 25 M 16 162 74 28.2 100/70 94 88 126 0.70 3.9 0.04 8.4 6.4 1.31 2 13.6 1 6 3.2 268 200 92 98 34 PCO+
4 29 M 16 156 60 24.7 140/90 87 94 110 0.85 13 0.14 2.8 10.4 0.27 4.2 10 0.1 6.9 2.5 282 208 92 110 34 PCO+
5 26 M 16 164 50 18.6 120/70 76 100 80 1.25 8.4 0.08 9.6 5 1.92 3.7 10.2 0.8 9.6 0.4 278 198 96 34 PCO+
6 24 M 16 160 52 22.7 120/70 84 96 100 0.96 6.1 0.06 8.3 5.2 1.60 3.4 9.2 0.8 8.2 2.2 248 188 100 94 34 PCO+
7 24 M 16 164 62 23.1 120/70 84 89 124 0.72 4.2 0.05 8.8 4 2.20 2.3 9.8 1.1 7 3.5 268 208 102 94 32 PCO+
8 26 M 16 156 52 21.4 130/90 80 88 110 0.80 14 0.16 9.2 4.8 1.92 2.5 12 0.7 7 2.2 204 212 98 92 34 PCO+
9 23 M 16 164 59 21.9 100/70 82 64 8 8.00 3.5 0.05 7.6 6.2 1.23 2.2 10.4 0.7 7 1.7 200 210 92 98 34 GES.SAC
10 24 M 16 166 150 18.1 130/90 74 76 110 0.69 9.2 0.12 6.4 5.8 1.10 1.1 13 0.6 6.6 3.1 260 210 102 92 34 GES.SAC
11 19 UM 16 152 60 26 110/70 90 88 112 0.79 12 0.14 8 5.2 1.54 3.8 10 1 8 2 272 208 96 100 34 PCO+
12 22 UM 16 152 42 18.2 100/70 74 76 100 0.76 7.6 0.10 8.1 4.6 1.76 2.6 9.2 0.8 7.1 3 255 208 90 110 32 PCO+
13 22 UM 16 162 70 26.7 100/70 92 94 114 0.82 8.2 0.09 8.1 7.6 1.07 4.7 5 0.9 5.6 3.8 396 198 90 98 32 PCO+
14 20 UM 16 150 54 24 90/70 86 62 112 0.55 10 0.16 12 6.2 1.94 3.1 13.2 0.7 8 2.1 240 168 100 138 32 PCO+
15 20 UM 16 160 58 22.7 90/70 84 84 102 0.82 7.4 0.09 12.6 6.2 2.03 3 10.6 1 7.2 2.2 300 198 98 90 34 PCO+
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16 24 UM 16 154 58 24.5 100/70 87 112 90 1.24 12 0.11 10 5.4 1.85 3.8 10.3 0.8 6.4 2.2 280 196 90 96 32 PCO+
17 30 M 16 164 60 22.3 100/70 82 90 76 1.18 6.5 0.07 9.6 7.5 1.28 3.8 9.5 1 8 2.4 240 188 90 98 32 PCO+
18 28 M 16 158 58 23.2 140/90 84 96 84 1.14 10.3 0.11 10.3 6.2 1.66 3.6 9.1 0.7 7.2 2.5 210 190 98 90 32 GES.SAC
19 24 M 16 160 60 23.4 90/70 84 90 82 1.10 6.5 0.07 8.3 4.2 1.98 3.2 10.2 0.8 8 2.6 230 178 92 100 32 PCO+
20 20 UM 16 160 57 22.3 110/70 82 76 84 0.90 7.5 0.10 8.8 6 1.47 2.8 10.4 1 8.4 2.2 242 180 98 95 32 PCO+
21 28 M 16 160 70 27.3 120/80 92 90 96 0.94 14.2 0.16 10.3 4.6 2.24 3.8 13 1.2 10.3 0.4 280 198 96 140 30 PCO+
22 26 M 16 166 67 24.3 110/70 86 84 110 0.76 8.8 0.10 10.4 5.2 2.00 3.4 10.2 1.1 11 2 255 208 90 108 32 PCO+
23 26 M 16 152 66 28.6 100/80 96 96 110 0.87 9.8 0.10 11.8 4.2 2.81 3.6 10.3 1 20 2.6 270 283 58 195 36 PCO+
24 24 M 16 160 64 25 110/70 87 88 110 0.80 20 0.23 9.8 4.2 2.33 4.1 9.5 1.1 11.6 2.2 268 180 120 140 35 PCO+
25 28 M 16 166 68 24.7 108/70 87 80 98 0.82 6.6 0.08 9.8 5.2 1.88 3.8 11 1.2 15.2 1.4 280 180 120 140 34 PCO+
26 22 UM 16 160 63 24.6 110/80 87 82 110 0.75 9.8 0.12 9.7 5 1.94 3.1 11.6 0.9 15.2 2.5 320 174 90 138 34 PCO+
27 20 UM 16 160 63 24.6 100/70 87 80 102 0.78 7.2 0.09 11.6 5.2 2.23 4 10.2 1.3 7.7 3.2 358 174 92 140 34 PCO+
28 24 UM 16 158 62 24.8 110/70 87 78 94 0.83 13 0.17 9.6 4 2.40 2.6 8.6 1.1 13 2.7 270 197 92 124 32 PCO+
29 22 UM 16 164 64 23.8 100/70 86 88 108 0.81 6.2 0.07 8.6 5.2 1.65 3.1 12.3 0.9 12.3 2.24 283 188 96 118 42 PCO+
30 20 UM 16 158 62 24.8 120/84 87 84 100 0.84 9.2 0.11 10.6 4.6 2.30 2.2 7.6 1.18 8.6 3.5 500 196 93 124 32 PCO+
1 29 M 20 164 64 23.8 110/80 86 84 101 0.83 10 0.12 12.4 6.1 2.03 2 12 1 7 1.9 220 178 100 138 32 GES.SAC
2 27 M 20 166 63 22.9 140/90 84 84 110 0.76 7.8 0.09 10.4 4.3 2.42 3.1 6.2 0.9 4.2 3 275 180 100 120 42 GES.SAC
3 25 M 20 162 72 27.4 110/70 92 90 120 0.75 3.9 0.04 8.4 6 1.40 2 13.6 1 4.8 2.9 264 200 90 98 34 PCO+
4 29 M 20 156 60 24.7 140/90 87 90 106 0.85 10.2 0.11 8.4 9.2 0.91 3.9 10 0.1 7 2.2 270 210 90 110 34 GES.SAC
5 26 M 20 164 50 18.6 120/70 76 110 80 1.38 8.4 0.08 9.6 4.2 2.29 3.7 10.2 0.8 9.6 0.3 278 198 94 34 PCO+
6 24 M 20 160 58 22.7 120/80 84 96 82 1.17 6.2 0.06 8.4 5 1.68 3.2 9.6 0.8 8.2 2.2 248 188 100 92 34 PCO+
7 24 M 20 164 62 23.1 120/70 84 88 126 0.70 4.2 0.05 8.8 4.1 2.15 2.3 9.8 1.1 7 3.4 268 208 100 92 32 PCO+
8 26 M 20 156 52 21.4 130/90 80 80 78 1.03 14 0.18 8 5.9 1.36 2.5 12.2 0.7 7 2.2 204 212 98 92 34 PCO+
9 23 M 20
10 24 M 20
11 19 UM 20 152 59 25.5 110/70 90 88 110 0.80 9 0.10 7.6 5.6 1.36 3.8 10 1 6.2 2 263 210 98 102 34 CYC.REG
12 22 UM 20 152 40 17.3 100/70 72 76 110 0.69 7.6 0.10 7.2 8.6 0.84 2.6 9.2 0.8 7 2.8 243 210 90 110 32 CYC.REG
13 22 UM 20 162 68 25.9 100/70 90 94 112 0.84 8.2 0.09 7.8 5.2 1.50 4.7 5 0.9 5.6 3.8 396 198 90 98 32 PCO+
14 20 UM 20 150 54 24 90/70 86 86 110 0.78 10 0.12 10.3 5.2 1.98 3.1 13.6 0.7 8 2.1 240 168 102 140 32 PCO+
15 20 UM 20 160 58 22.7 90/70 84 79 102 0.77 7.6 0.10 10.3 6 1.72 2.8 10.6 1 7 2.2 300 198 98 90 34 PCO+
16 24 UM 20 154 55 23.2 100/70 84 112 80 1.40 9.6 0.09 8.2 6.4 1.28 3.8 10.3 0.8 5.2 2 275 198 92 98 32 CYC.REG
17 30 M 20 164 60 22.3 100/70 82 90 76 1.18 6.5 0.07 8.4 5.2 1.62 3.8 9.5 0.9 7 2.3 220 190 90 100 37 GES.SAC
18 28 M 20
19 24 M 20 160 60 23.4 90/70 84 90 110 0.82 6.5 0.07 7.5 5.8 1.29 3.2 10.2 0.8 6.5 2.6 115 180 92 100 32 GES.SAC
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20 20 UM 20 160 57 22.3 100/70 82 96 84 1.14 7.5 0.08 8.6 7.2 1.19 2.8 10.6 1 7.2 2.03 230 180 100 94 32 CYC.REG
21 28 M 20 160 69 27 120/80 92 90 82 1.10 14 0.16 10.2 4.2 2.43 3.8 13 1.2 10.2 0.4 280 200 96 140 30 PCO+
22 26 M 20 166 67 24.3 110/70 86 84 100 0.84 8.8 0.10 10.2 5.4 1.89 3.4 10.2 1.1 10.8 2 255 208 90 108 32 PCO+
23 26 M 20 152 66 28.6 110/70 96 96 108 0.89 9.8 0.10 11 5.2 2.12 3.4 10.2 1 18 2.6 270 260 158 195 36 PCO+
24 24 M 20 160 64 25 110/70 87 88 110 0.80 20 0.23 9.8 4.2 2.33 4.1 9.6 1.1 11 2.2 268 180 120 140 35 PCO+
25 28 M 20 166 66 24 108/90 86 84 108 0.78 6.6 0.08 9.8 5.6 1.75 3.8 11 1.2 5 1.4 280 178 120 140 34 PCO+
26 22 UM 20 160 63 24.6 110/80 87 82 110 0.75 9.8 0.12 9 6.2 1.45 3 11.6 0.9 15 2.5 320 174 90 138 34 PCO+
27 20 UM 20 160 63 24.6 110/70 87 80 110 0.73 7.2 0.09 10.4 5.2 2.00 4 10.2 1.2 7.7 3.2 358 174 92 138 34 PCO+
28 24 UM 20 158 62 24.8 110/70 87 78 90 0.87 13 0.17 9.4 5.1 1.84 2.6 8.6 1.1 13 2.7 270 196 92 124 34 PCO+
29 22 UM 20 164 63 23.4 110/70 86 84 110 0.76 6.2 0.07 7.8 5 1.56 3 12.3 0.9 12 2.24 283 188 98 118 42 PCO+
30 20 UM 20 158 62 24.8 124/84 87 84 102 0.82 9.2 0.11 10.8 4.2 2.57 2.1 7.6 1.18 8.5 3.5 500 196 94 124 30 PCO+
1 29 M 24
2 27 M 24
3 25 M 24
4 29 M 24
5 26 M 24 164 49 18.2 120/70 74 90 86 1.05 8.3 0.09 8 6.2 1.29 3.7 10.2 0.7 6.9 0.3 272 200 94 34 PCO+
6 24 M 24 160 58 22.7 120/80 84 96 84 1.14 6.2 0.06 6.9 5.6 1.23 3.2 9.6 0.8 6.2 2 243 190 102 94 34 GES.SAC
7 24 M 24 164 62 23.1 110/70 84 88 126 0.70 4.2 0.05 7 4.3 1.63 2.3 9.8 1.1 6.4 3 260 110 102 92 32 GES.SAC
8 26 M 24 156 52 21.4 130/90 80 80 98 0.82 10.1 0.13 7.2 5.9 1.22 2.7 12.2 0.7 6.2 2.18 200 214 100 94 34 GES.SAC
9 23 M 24
10 24 M 24
11 19 UM 24
12 22 UM 24
13 22 UM 24 162 68 25.9 100/70 90 94 112 0.84 8.2 0.09 7.8 5 1.56 4.7 5 0.9 5 3.3 352 200 92 100 32 CYC.REG
14 20 UM 24 150 52 23.1 90/70 84 86 110 0.78 10.1 0.12 8.6 5 1.72 3.1 13.2 0.7 7.1 2.1 220 270 102 138 32 CYC.REG
15 20 UM 24 160 58 22.7 100/70 84 99 102 0.97 7.6 0.08 7.2 8.6 0.84 2.8 10.6 1 6.5 2.2 270 200 100 94 34 CYC.REG
16 24 UM 24
17 30 M 24
18 28 M 24
19 24 M 24
20 20 UM 24
21 28 M 24 160 69 27 120/90 92 90 82 1.10 12.1 0.13 10.4 5.2 2.00 3.8 13 1 9.2 0.4 278 200 96 140 30 PCO+
22 26 M 24 166 68 24.7 120/80 87 84 100 0.84 8.8 0.10 10.2 5.4 1.89 3.4 10.2 1.1 10.6 2 250 208 90 110 32 PCO+
23 26 M 24 152 65 28.1 100/70 94 96 110 0.87 9 0.09 11 5.2 2.12 3 10.2 0.8 15 2.6 270 263 158 190 36 PCO+
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24 24 M 24 160 64 25 110/70 87 88 110 0.80 18 0.20 9.8 4.2 2.33 4 9.6 1 10.3 2 265 180 120 140 35 PCO+
25 28 M 24 166 70 25.4 110/70 87 84 100 0.84 6.8 0.08 9.6 5.8 1.66 3.8 11 1.1 10 1.4 278 180 120 140 34 PCO+
26 22 UM 24 160 63 24.6 110/80 87 82 110 0.75 9.8 0.12 9.2 6 1.53 3 11.5 0.8 11.6 2.4 300 176 94 140 34 PCO+
27 20 UM 24 160 63 24.6 100/70 87 80 110 0.73 7.2 0.09 10.4 5.2 2.00 4 10.2 1.1 7 3.1 350 176 94 140 34 PCO+
28 24 UM 24 158 60 24 110/70 86 78 94 0.83 12.2 0.16 9.2 5.2 1.77 2.6 8.6 1 11.4 2.7 262 196 90 120 34 PCO+
29 22 UM 24 164 63 23.4 110/70 86 84 106 0.79 6.2 0.07 7.8 5 1.56 3 12 0.8 10.4 2.24 278 190 100 120 42 PCO+
30 20 UM 24 158 60 24 124/84 86 84 102 0.82 9.2 0.11 8.4 5.2 1.62 2.1 7.6 1.18 8.4 3.5 482 197 94 124 32 PCO+
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30 25 M 20 165 50 18.4 120/82 74 96 80 1.20 8.2 0.09 12.2 5.6 2.18 2.8 12 0.6 6.2 2 256 180 88 121 34 PCO+
1 27 M 24 160 66 25.8 120/70 90 88 110 0.80 14 0.16 12 4.2 2.86 3.1 17.4 1 25 2.25 268 189 100.2 120 28 PCO+
2 30 M 24 164 67 24.9 120/70 87 100 110 0.91 5.2 0.05 10.2 5.1 2.00 3.1 18 1 20.14 1.5 214 180 120 140 35 PCO+
3 25 M 24 158 62 24.8 110/70 87 8.6 #DIV/0! 10.2 5 2.04 3.16 10.4 1.18 10.7 2.1 212 190 94 140 35 PCO+
4 24 M 24 160 61 23.8 110/80 86 79 90 0.88 9.8 0.12 10.2 5.2 1.96 2.3 9.6 1 8.2 2.5 426 196 93 120 52 PCO+
5 24 M 24 148 54 24.7 114/84 87 90 110 0.82 9.6 0.11 12.4 6 2.07 3 9.6 0.9 9.4 2.4 240 180 90 120 35 PCO+
6 29 M 24 165 50 18.4 120/80 74 94 84 1.12 10 0.11 12.6 6.4 1.97 3 10.8 0.8 11.8 0.43 263 180 90 118 34 PCO+
7 26 M 24 168 74 26.2 120/80 90 92 117 0.79 9 0.10 10.4 4.2 2.48 3.6 13 2 19 2.26 288 180 100 140 34 PCO+
8 28 M 24 170 66 22.8 110/70 84 78 103 0.76 9.2 0.12 12.6 6.6 1.91 3.4 12.2 0.9 8.6 2.8 211 170 100 106 34 PCO+
9 26 M 24 159 62 24.5 130/80 87 80 120 0.67 11.6 0.15 10.4 5.2 2.00 7.6 15 0.9 20 3.2 276 170 140 140 32 PCO+
10 28 M 24 154 54 22.8 120/80 84 80 116 0.69 18.8 0.24 12.6 6.2 2.03 2.4 13 0.7 3.8 3 270 226 88 92 38 PCO+
11 32 M 24 165 52 19.1 120/80 76 76 108 0.70 9.6 0.13 12 6.2 1.94 1.1 13.4 0.7 8.4 3 268 220 90 104 30.2 PCO+
12 30 M 24 165 78 28.7 120/80 96 78 102 0.76 17 0.22 14 5.2 2.69 8.1 13.2 1 16 1.8 260 220 106 150 32 PCO+
13 28 UM 24 152 55 23.8 110/80 86 88 112 0.79 9.6 0.11 12.6 6.4 1.97 3.7 10.4 0.5 7.6 2.1 280 230 148 90 34 PCO+
14 22 UM 24 164 52 19.3 120/70 76 84 92 0.91 7 0.08 12.6 4.2 3.00 3.3 10.6 1.04 4.07 3.8 309 160.2 77 85 30 PCO+
15 23 UM 24 151 48 21.1 110/80 80 74 110 0.67 7.6 0.10 8.2 3.4 2.41 2.8 7.6 0.9 5.8 3 262 170 148 142 34 PCO+
16 26 UM 24 162 76 29 120/80 96 92 112 0.82 10.2 0.11 14.4 7.2 2.00 5.2 18 0.9 7.6 4.42 304 234 124 155 44 PCO+
17 29 UM 24 164 61 22.7 130/80 84 64 82 0.78 3.5 0.05 10 5.6 1.79 2 4.9 0.1 8 1.73 212 180 100 140 35 PCO+
18 24 UM 24 158 56 22.4 130/80 82 84 96 0.88 15 0.18 9.6 3 3.20 1.8 4.9 0.1 8.7 1.7 162 220 90 98 36 PCO+
19 22 UM 24 172 65 22 100/70 82 76 84 0.90 5.6 0.07 12.4 6.2 2.00 2.6 14.6 0.1 9.6 2.14 200 170.2 102 106 35 PCO+
20 20 UM 24 156 47 19.3 100/70 76 76 98 0.78 9.6 0.13 8.8 3.6 2.44 2.7 13.21 0.8 7.6 2.24 207 170 140 142 30.2 PCO+
21 22 UM 24 154 55 23.2 120/80 84 96 84 1.14 12 0.13 7.4 8.6 0.86 3.2 11 0.9 7.6 2.2 250 190 92 110 30
22 24 UM 24 158 65 26 120/70 90 96 88 1.09 10.2 0.11 6.4 12 0.53 3 8.6 1 6.8 2.25 266 174 94 138 34
23 26 M 24 148 48 21.9 100/70 82 90 110 0.82 8.6 0.10 3.2 7.6 0.7 5.4 2.8 239 220 138 150 32
24 26 M 24 160 62 24.2 100/70 86 78 104 0.75 0.00 6.4 10.4 0.62 2.4 10.6 0.7 7 2.8 260 216 130 160 34
25 26 UM 24 160 65 25.4 120/80 87 84 100 0.84 18 0.21 10.2 5.4 1.89 3.4 11.6 1.2 15 2.26 264 180 100 120 35 PCO+
26 23 UM 24 168 74 25.9 110/82 90 90 110 0.82 9 0.10 12.4 6 2.07 2.2 13.2 1.4 19.4 2.26 286 180 100 140 35 PCO+
27 22 UM 24 170 60 20.8 100/70 80 90 124 0.73 10.2 0.11 12.4 3.2 3.88 3.2 7.6 0.6 10.2 2.26 280 182 94 140 30 PCO+
28 28 M 24 158 65 26 110/70 90 94 110 0.85 9 0.10 10.4 4 2.60 3 13 1.2 8.9 2.4 254 170 102 140 32 PCO+
29 24 M 24 154 68 28.7 110/80 96 90 118 0.76 9 0.10 14.2 6 2.37 2.8 12.2 0.7 8.2 2.4 260 180 104 140 30 PCO+
30 25 M 24 165 50 18.4 120/82 74 90 110 0.82 10 0.11 12 5.2 2.31 2.8 12.2 0.7 6.5 2.4 260 180 90 120 35 PCO+
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1 12 UM 0 160 65 25.4 120/90 87 82 110 0.75 16 0.20 10.4 4.2 2.48 3.14 10 1 19.2 2.3 294 190 100.2 120 32 PCO+
2 24 UM 0 164 66 24.5 100/70 87 80 98 0.82 3.5 0.04 12.6 5.2 2.42 3.2 18.2 1 19.14 1.53 214 180 120 140 32 PCO+
3 22 UM 0 158 75 30 110/80 98 79 67 1.18 15.86 0.20 16.4 5.2 3.15 4.1 15.6 1.04 9.1 2.25 365.4 176 94 140 32 PCO+
4 22 UM 0 160 61.1 23.9 120/70 86 67 91 0.74 9.8 0.15 10.9 5.6 1.95 2.33 7.6 1.18 6.4 3.6 424 197 93.4 124 40 PCO+
5 26 UM 0 148 59 26.9 90/70 92 90 123 0.73 7.6 0.08 12.6 4.6 2.74 2.5 7.6 0.6 10.8 2.9 343 226 139 160 34 PCO+
6 22 UM 0 165 49 18 110/80 74 90 72 1.25 10 0.11 12.6 6.4 1.97 3.07 13.29 0.8 11.8 0.4 293 180 90 120 35 PCO+
7 23 UM 0 168 74 26.2 140/35 90 92 117 0.79 9 0.10 10.07 3.8 2.65 3.6 13.4 4.3 19.14 2.26 288 180 100 140 35 PCO+
8 22 UM 0 170 66 22.8 110/70 84 78 103 0.76 9.2 0.12 12.6 6.6 1.91 2.3 16.2 0.9 8 3.2 211 171 102 106 35 PCO+
9 20 UM 0 159 63 24.9 120/70 87 71 121 0.59 11.6 0.16 10.6 4.9 2.16 3.2 18.2 0.9 26.6 3.2 276 170 140 142 35 PCO+
10 22 UM 0 154 68 28.7 100/70 96 82 116 0.71 12.6 0.15 12.6 4.6 2.74 2.4 10.4 0.7 8.3 3 270 226 88 93 32 PCO+
11 24 UM 0 165 49.5 18.2 120/80 74 76 108 0.70 9.6 0.13 10.6 3.4 3.12 2.4 13.4 0.7 8.8 3 268 220 90 100 35 PCO+
12 24 M 0 165 78 28.7 112/82 96 78 102 0.76 17 0.22 14.4 4.6 3.13 4.2 12.5 1.1 20.6 1.8 260 229.7 106 172.3 36 PCO+
13 26 M 0 152 64 27.7 150/100 94 88 110 0.80 10.4 0.12 10.8 5.6 1.93 3.7 15.4 0.5 8.4 2.1 280 263 168 195 34 PCO+
14 28 M 0 164 52.5 19.5 130/80 78 84 100 0.84 7 0.08 12.6 4 3.15 3.3 21.8 1.04 4.07 3.8 309 162.1 77.1 85.5 61.2 PCO+
15 30 M 0 151 40 17.5 140/90 74 74 110 0.67 7.6 0.10 12.6 4.8 2.63 2.86 10.3 0.9 5.6 3 262 170.6 150 143 32.3 PCO+
16 28 M 0 162 77.5 29.5 130/70 98 92 112 0.82 12.7 0.14 10.6 5.2 2.04 4.1 15.3 0.95 9.2 4.4 646 234.3 124.1 155 42 PCO+
17 26 M 0 164 61 22.7 150/100 84 60 77 0.78 5.6 0.09 10 4.6 2.17 2.19 14.2 0.6 19.5 1.53 211 180 100 140 35 PCO+
18 24 M 0 158 58 23.2 170/80 84 83 95 0.87 18.3 0.22 12.6 4.8 2.63 1.8 4.9 0.5 8.8 1.7 162 220 90 100 36 PCO+
19 24 M 0 172 65 22 130/80 82 78 97 0.80 5.6 0.07 12.4 4.3 2.88 2.64 18.26 0.1 9.6 2.1 200 181 103 106 35.4 PCO+
20 28 M 0 156 47 19.3 140/100 76 74 94 0.79 8.6 0.12 10.8 5.3 2.04 2.7 13.2 0.16 6.2 2.24 207 170 140 142 30.4 PCO+
21 24 M 0 154 63 26.6 130/80 92 94 84 1.12 6.6 0.07 12.8 4.6 2.78 4.2 11.3 0.9 9.3 2.26 302 190 92 110 30 PCO+
22 22 M 0 158 74 29.6 130/80 98 92 78 1.18 12.8 0.14 10.6 4.6 2.30 3.4 17.6 1.04 9 2.2 360 176 96 140 35 PCO+
23 26 M 0 148 59 26.9 120/70 92 90 120 0.75 8.6 0.10 12.6 5.6 2.25 3.2 7.6 0.6 4.9 2.8 270 226 139 162 39 PCO+
24 28 M 0 170 64 22.1 140/90 82 78 104 0.75 9.2 0.12 11.6 4.6 2.52 2.4 8.6 1.04 5.69 2.24 214 176 94 140 35 PCO+
25 30 M 0 160 65 25.4 130/80 87 92 117 0.79 9.6 0.10 12.6 4.2 3.00 3.4 18.25 1.5 25 2.26 294 190 100.2 120 35 PCO+
26 30 M 0 168 74 26.2 150/100 90 96 110 0.87 9 0.09 12.6 4.8 2.63 2.24 13.4 1.4 19.4 2.26 288 180 100 140 35 PCO+
27 20 UM 0 170 64 22.1 120/90 82 90 120 0.75 18 0.20 12.6 4.6 2.74 3.56 7.6 0.8 10.4 2.26 280 182 100 140 30 PCO+
28 22 UM 0 158 74 29.6 124/84 98 94 120 0.78 9 0.10 10.2 5.2 1.96 3.4 13.4 4.9 8.6 2.4 288 170 102 140 30 PCO+
29 26 M 0 154 68 28.7 120/80 96 82 160 0.51 9 0.11 14.2 5.2 2.73 2.8 13.5 0.7 4.7 2.4 260 180 104 140 28 PCO+
30 28 M 0 165 50 18.4 120/80 74 94 82 1.15 10 0.12 12.2 5.6 2.18 3.8 13.2 0.87 19.1 0.7 294 180 90 120 35 PCO+
1 12 UM 4 160 64 25 120/80 87 86 108 0.80 14 0.16 10 4 2.50 3.14 9.2 1 13 2.8 182 182 96 114 34
2 24 UM 4 164 66 24.5 100/70 87 80 98 0.82 3.5 0.04 10.6 5.2 2.04 3.2 16.2 1 19.1 1.5 214 178 118 135 32
3 22 UM 4 158 73 29.2 110/80 96 80 97 0.82 15.8 0.20 14.3 5 2.86 4.1 12.3 1.04 9 2.25 360 176 92 134 32
4 22 UM 4 160 60.03 23.4 120/80 84 67 91 0.74 9.8 0.15 10.8 5.4 2.00 2.33 7.6 1.1 6.4 3.6 400 196 90 120 42
5 26 UM 4 148 57 26 90/70 90 92 123 0.75 7.6 0.08 12 4.8 2.50 2.5 7.5 0.6 9.8 2.9 336 224 35 158 34
GROUP 3 - MYOINOSITOL
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6 22 UM 4 165 46 16.9 110/80 72 90 82 1.10 10 0.11 12 6 2.00 3.07 12.04 0.8 10.8 0.4 282 180 92 118 35
7 23 UM 4 168 74 26.2 120/90 90 90 117 0.77 9 0.10 10 3.6 2.78 3.5 12.2 4.3 10.14 2.25 280 178 98 134 35
8 22 UM 4 170 64 22.1 110/70 82 78 100 0.78 9.2 0.12 12 6 2.00 2.3 14.3 0.9 8 3.2 211 170 100 104 36
9 20 UM 4 159 63 24.9 120/80 87 80 118 0.68 11.6 0.15 10.9 4.2 2.60 3.2 17.6 0.9 24.6 3.2 290 168 138 140 36
10 22 UM 4 154 67 28.3 100/70 94 86 110 0.78 12 0.14 12 4 3.00 2.4 9.6 0.7 8.3 3 268 224 86 90 32
11 24 UM 4 165 49.5 18.2 120/70 74 78 110 0.71 9.6 0.12 10.6 3.8 2.79 2.4 13 0.7 8.6 3 265 218 88 98 35
12 24 M 4 165 76 27.9 112/80 94 99 100 0.99 15 0.15 14 4 3.50 4.2 11.6 1.1 21.6 1.8 258 229 102 170 36 PCO+
13 26 M 4 152 64 27.7 150/100 94 86 100 0.86 10 0.12 8.6 4.9 1.76 3.7 14.6 0.5 8 2.1 278 258 162 183 34 PCO+
14 28 M 4 164 52.5 19.5 130/80 78 86 100 0.86 7 0.08 12.4 4.2 2.95 3.3 17.6 1.04 4 3.8 300 160 77 85 61.4 PCO+
15 30 M 4 151 40 17.5 140/92 74 76 100 0.76 7.6 0.10 10.4 4.2 2.48 2.86 10 0.9 5.5 3 200 168 148 142 32 PCO+
16 28 M 4 162 76 29 130/80 96 92 110 0.84 12.7 0.14 9.6 5.6 1.71 4.1 13.2 0.9 9 4.4 640 232 120 154 42 PCO+
17 26 M 4 164 60 22.3 150/90 82 60 78 0.77 5.6 0.09 10.2 4.4 2.32 2.19 12.2 0.6 17.5 1.5 210 178 98 138 35 PCO+
18 24 M 4 158 57 22.8 130/80 84 111 90 1.23 18 0.16 10.6 4.2 2.52 1.8 4.8 0.5 8 1.7 160 218 88 98 36 PCO+
19 24 M 4 172 64 21.6 130/80 82 76 96 0.79 5.6 0.07 12 4 3.00 2.64 17.26 0.1 9 2.1 198 168 100 102 35.4 PCO+
20 28 M 4 156 47 19.3 140/90 76 72 92 0.78 8.6 0.12 8.4 5.2 1.62 2.7 12.4 0.16 6 2.2 200 168 138 139 32.6 PCO+
21 24 M 4 154 62 26.1 132/82 90 96 84 1.14 6.6 0.07 12 4.2 2.86 4.2 9.6 0.9 9 2.26 300 186 84 104 32.6 PCO+
22 22 M 4 158 70 28 134/80 94 90 82 1.10 11.6 0.13 7.3 5 1.46 3.4 15.2 1.04 9 2.2 358 174 94 138 36 PCO+
23 26 M 4 148 57 26 120/70 90 94 108 0.87 8.6 0.09 9.6 5.2 1.85 3.2 7.4 0.6 4.9 2.8 260 224 134 160 42 PCO+
24 28 M 4 170 64 22.1 140/90 82 80 110 0.73 9.2 0.12 8.2 4 2.05 2.4 8 1.04 5.6 2.24 214 174 92 138 35 PCO+
25 30 M 4 160 65 25.4 130/90 87 90 110 0.82 9.6 0.11 12 4.1 2.93 3.4 16.2 1.5 20 2.26 290 188 98 118 36 PCO+
26 30 M 4 168 74 26.2 150/100 90 92 117 0.79 9 0.10 12.4 4.3 2.88 2.26 10.2 1.4 19 2.26 280 178 98 138 35 PCO+
27 20 UM 4 170 64 22.1 130/90 82 92 118 0.78 18 0.20 12 4.2 2.86 3.54 7.6 0.8 10 2.26 280 180 98 138 30 PCO+
28 22 UM 4 158 74 29.6 124/82 98 96 110 0.87 9 0.09 10 5.4 1.85 3.4 13.2 4.9 8.6 2.4 288 168 100 138 32 PCO+
29 26 M 4 154 68 28.7 120/80 96 84 110 0.76 9 0.11 14 5 2.80 2.8 13 0.7 4.7 2.4 260 178 100 138 28 PCO+
30 28 M 4 165 50 18.4 124/82 74 96 80 1.20 9 0.09 12 5 2.40 3.8 13 0.8 19 0.7 290 178 88 118 36 PCO+
1 12 UM 8 160 62 24.2 120/80 86 86 110 0.78 12 0.14 8.6 4.2 2.05 3.1 8.7 1 9 1.5 260 172 90 110 34
2 24 UM 8 164 65 24.2 120/70 86 90 100 0.90 3.5 0.04 9.6 4.2 2.29 3.1 14 1 18.1 1.5 213 174 115 133 34
3 22 UM 8 158 70 28 110/70 94 84 102 0.82 13.1 0.16 11.6 5 2.32 4 9.2 1 9 2.24 300 170 94 126 34
4 22 UM 8 160 59.3 23.2 110/70 84 70 90 0.78 9.8 0.14 8.6 5.3 1.62 2.3 7.5 1.1 6.3 3.6 350 192 90 120 40
5 26 UM 8 148 54 24.7 100/70 87 92 120 0.77 7.6 0.08 10.4 4.3 2.42 2.5 7.5 0.6 9.8 2.9 320 220 136 156 36
6 22 UM 8 165 46 16.9 110/70 72 90 80 1.13 9.8 0.11 8.4 6 1.40 3.06 11.2 0.8 10.8 0.4 280 178 89 112 36
7 23 UM 8 168 70 24.8 110/70 87 90 110 0.82 8.8 0.10 8.1 3.9 2.08 3.5 11.6 4.3 10.14 2.25 280 178 98 134 36
8 22 UM 8 170 66 22.8 120/80 84 78 103 0.76 9.2 0.12 9.4 6 1.57 2.3 13.2 0.9 7.8 3.2 211 168 98 102 36
9 20 UM 8 159 62 24.5 110/70 87 82 118 0.69 11 0.13 9.6 5.2 1.85 3.1 15.2 0.9 24.6 3.2 260 168 138 142 36
10 22 UM 8 154 67 28.3 110/70 94 86 110 0.78 12 0.14 10.2 4.6 2.22 2.3 9 0.7 8 3 268 224 86 90 34
11 24 UM 8 165 49.5 18.2 110/70 74 78 110 0.71 9.6 0.12 8.3 4.2 1.98 2.3 12.3 0.7 8.6 3 265 218 88 98 36
12 24 M 8 165 73 26.8 110/80 92 99 104 0.95 15 0.15 10.6 4.6 2.30 4.1 10.2 1.1 20.6 1.8 258 230 102 170 38 PCO+
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13 26 M 8 152 62 26.8 140/90 92 90 114 0.79 10 0.11 8.1 4 2.03 3.6 10.3 0.5 8 2.1 278 250 158 168 34 PCO+
14 28 M 8 164 50.3 18.7 230/70 76 73 93 0.78 7 0.10 12.1 4.6 2.63 3.3 15.6 1.04 4 3.8 300 158 74.3 84.3 62 PCO+
15 30 M 8 151 38 16.7 130/80 72 76 100 0.76 7.6 0.10 9.6 4.1 2.34 2.8 9.6 0.9 5.5 3 258 168 148 140 34 PCO+
16 28 M 8 162 73 27.8 130/70 94 92 110 0.84 12 0.13 9.2 4.6 2.00 4 11.6 0.9 9 4.4 640 230 120 152 44 PCO+
17 26 M 8 164 60 22.3 140/90 82 64 79 0.81 5.6 0.09 8.6 4.3 2.00 2.1 11 0.6 17.5 1.5 210 178 98 138 36 PCO+
18 24 M 8 158 57 22.8 130/80 84 106 90 1.18 15 0.14 8.3 4.4 1.89 1.8 4.7 0.5 8 1.7 160 216 86 96 38 PCO+
19 24 M 8 172 64 21.6 126/80 82 82 92 0.89 5.6 0.07 9.6 4.2 2.29 2.62 16.3 0.1 9 2.1 198 168 98 102 36 PCO+
20 28 M 8 156 47 19.3 130/90 76 82 90 0.91 8.6 0.10 7.2 5 1.44 2.7 10.2 0.16 6 2.2 200 164 134 136 32.3 PCO+
21 24 M 8 154 60 25.3 120/80 87 90 100 0.90 6.4 0.07 8.4 4.2 2.00 4 8.4 0.9 9 2.26 300 186 82 104 34 PCO+
22 22 M 8 158 68 27.2 120/80 92 90 100 0.90 10.2 0.11 6.4 4.8 1.33 3.3 12.4 1.04 8.8 2.2 358 170 94 136 38.4 PCO+
23 26 M 8 148 54 24.7 110/70 87 90 110 0.82 8.6 0.10 7.4 5 1.48 3.2 6.8 0.6 4.9 2.8 260 222 134 158 42 PCO+
24 28 M 8 170 66 22.8 130/80 84 82 98 0.84 9.2 0.11 7.2 4.4 1.64 2.4 7.8 1.04 5.6 2.24 214 174 92 134 37.2 PCO+
25 30 M 8 160 64 25 130/80 87 88 110 0.80 9.6 0.11 10.6 5.4 1.96 3.2 16 1.5 20 2.26 290 186 96 118 37 PCO+
26 30 M 8 168 72 25.5 140/100 90 92 117 0.79 9 0.10 12 4.1 2.93 2.24 10 1.4 19 2.24 280 178 98 138 36 PCO+
27 20 UM 8 170 64 22.1 132/92 82 92 118 0.78 17 0.18 12 4.8 2.50 3.5 7.4 0.8 10.4 2.26 280 178 98 138 30 PCO+
28 22 UM 8 158 73 29.2 120/80 96 84 110 0.76 9 0.11 9.6 5.2 1.85 3.4 12.8 4.9 8.6 2.4 287 168 100 136 32 PCO+
29 26 M 8 154 66 27.8 120/70 94 80 110 0.73 9 0.11 12.6 5 2.52 2.8 12.6 0.7 5 2.4 260 178 100 138 30 PCO+
30 28 M 8 165 50 18.4 120/80 74 90 72 1.25 10 0.11 10.6 4.2 2.52 3.7 12.4 0.8 19 0.7 290 178 88 118 36 PCO+
1 12 UM 12 160 60 23.4 120/80 84 84 108 0.78 7 0.08 6.4 5.2 1.23 3.14 6.2 1 6.2 2.5 252 160 82 110 34 CYC.REG
2 24 UM 12 164 65 24.2 110/70 86 88 106 0.83 3.5 0.04 8.1 5.1 1.59 3.2 12.1 1 10.4 1.53 210 169 110 125 34
3 22 UM 12 158 68 27.2 110/70 92 84 106 0.79 8.1 0.10 8.1 5.2 1.56 4.1 7.2 1 5.3 2.24 238.3 172 90 124 34 CYC.REG
4 22 UM 12 160 58.3 22.8 110/70 84 66 94 0.70 9.8 0.15 8.2 4.2 1.95 2.3 7.4 1.18 6.3 3.6 320 184 84.2 118 42
5 26 UM 12 148 50 22.8 90/70 84 90 110 0.82 7.6 0.08 7.3 4 1.83 2.4 7.4 0.5 8.6 2.9 290 220 134 156 38 CYC.REG
6 22 UM 12 165 45 16.5 100/70 72 90 84 1.07 9.8 0.11 6.2 6.8 0.91 3.07 10.02 0.8 7.3 0.4 264 175 89 110 36
7 23 UM 12 168 70 24.8 100/70 87 94 112 0.84 8.6 0.09 8.1 4.3 1.88 3.6 10.2 4.3 7.1 2.26 272 176 96 132 36
8 22 UM 12 170 66 22.8 110/70 84 80 104 0.77 8.6 0.11 7.2 5.2 1.38 2.2 11.4 0.9 6.2 3.2 206 168 98 102 38
9 20 UM 12 159 62 24.5 110/70 87 90 110 0.82 8.3 0.09 6.2 5 1.24 3.1 11.2 0.8 16 3.2 258 166 136 140 35
10 22 UM 12 154 63 26.6 110/70 92 90 112 0.80 10.6 0.12 10 4 2.50 2.3 7.3 0.7 6 3.1 263 220 84 88 34
11 24 UM 12 165 48 17.6 120/70 74 76 110 0.69 8 0.11 8.4 4 2.10 2.3 11.2 0.7 7 3 257 216 86 98 36
12 24 M 12 165 69 25.3 110/70 87 98 84 1.17 10.2 0.10 9.2 4.8 1.92 4.1 8.4 1.1 10.2 1.8 240 228.4 100 169 38 PCO+
13 26 M 12 152 60 26 140/90 90 96 110 0.87 9.8 0.10 7.2 3.8 1.89 3.6 10.6 0.5 6.1 2.1 262 241 151 132 36 PCO+
14 28 M 12 164 50.3 18.7 130/70 76 84 93 0.90 6.8 0.08 8.6 4 2.15 3.2 13.2 1.04 3.8 3.8 280 156.2 74 84.3 62 PCO+
15 30 M 12 151 38 16.7 130/80 72 82 96 0.85 7 0.09 8.4 3.6 2.33 2.8 9.2 0.9 5.3 3 243 166 147 140 34 PCO+
16 28 M 12 162 72 27.4 120/80 92 94 114 0.82 10.6 0.11 8.2 4 2.05 4 9.8 0.9 7.3 4.3 600 228 118 150 44 PCO+
17 26 M 12 164 60 22.3 130/80 82 69 84 0.82 5.3 0.08 7.3 4 1.83 2.1 10.2 0.6 10.3 1.53 183 176 96 136 36 PCO+
18 24 M 12 158 56 22.4 130/80 82 84 96 0.88 12.1 0.14 6.2 4.2 1.48 1.8 4.7 0.6 4.3 1.7 150 210 86 96 38 GES.SAC
19 24 M 12 172 62 21 126/82 80 76 84 0.90 5.4 0.07 7.1 4 1.78 2.6 14.2 0.1 6.2 2.1 186 166 98 102 38 GES.SAC
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20 28 M 12 156 48 19.7 130/80 78 76 94 0.81 8.6 0.11 6.1 4.8 1.27 2.7 10 0.16 4.3 2.24 201 164 134 136 34.3 GES.SAC
21 24 M 12 154 58 24.5 120/80 87 96 88 1.09 6.3 0.07 7 4 1.75 4 7.6 0.9 6 2.26 259 183 80 100 34.2 GES.SAC
22 22 M 12 158 66 26.4 122/82 90 96 88 1.09 7.6 0.08 5.8 4.6 1.26 3.4 10.3 1.04 6 2.24 248 170 94 136 38 GES.SAC
23 26 M 12 148 52 23.7 110/70 86 92 123 0.75 8.4 0.09 6.1 5.2 1.17 3.2 6.1 0.6 4 2.8 210 222 132 158 45 GES.SAC
24 28 M 12 170 66 22.8 120/80 84 90 106 0.85 8 0.09 6 3.9 1.54 2.4 7.6 1.04 3.8 2.24 200 170 90 134 38 GES.SAC
25 30 M 12 160 64 25 120/80 87 80 92 0.87 9.4 0.12 8.4 5.2 1.62 3.2 15.2 1.5 10.2 2.26 264 186 96 116 37 PCO+
26 30 M 12 168 70 24.8 140/90 87 90 110 0.82 8.8 0.10 10.2 3.8 2.68 2.24 9.8 1.4 12.2 2.26 276 174 94 136 36 PCO+
27 20 UM 12 170 63 21.8 140/90 82 90 124 0.73 17 0.19 11.6 4.2 2.76 3.5 7.4 0.8 10.2 2.26 274 178 96 136 32 PCO+
28 22 UM 12 158 73 29.2 120/80 96 84 110 0.76 8.6 0.10 9.4 5 1.88 3.4 4.3 4.9 8.4 2.4 280 164 102 136 34 PCO+
29 26 M 12 154 66 27.8 120/80 94 90 110 0.82 8.8 0.10 12 5.8 2.07 2.7 12 0.7 5.6 2.4 259 176 98 136 32 PCO+
30 28 M 12 165 52 19.1 120/70 76 96 80 1.20 9.1 0.09 10.8 4 2.70 3.7 12 0.8 17.6 0.7 280 176 84 116 38 PCO+
1 12 UM 16
2 24 UM 16 164 64 23.8 110/70 86 102 110 0.93 3.5 0.03 6.2 5.4 1.15 3.2 11.2 1 5.2 1.3 200 164 110 120 34 CYC.REG
3 22 UM 16
4 22 UM 16 160 58.3 22.8 110/80 84 64 90 0.71 9.1 0.14 7.6 5 1.52 2.3 7 1.18 6.3 3.6 270 184 82.6 178 42 CYC.REG
5 26 UM 16 148 49 22.4 90/70 82 92 124 0.74 7.5 0.08 6.4 4.20 1.52 2.50 7.20 0.60 5.4 2.9 270 220 134 154 38
6 22 UM 16 165 45 16.5 100/70 72 94 84 1.12 9 0.10 5.4 6 0.90 3.05 8.25 0.8 5.8 0.4 252 170 86 100 36 CYC.REG
7 23 UM 16 168 68 24.1 120/80 86 92 120 0.77 8.2 0.09 6.2 4.6 1.35 3.6 9.6 4.3 6.2 2.26 251 176 96 132 36 CYC.REG
8 22 UM 16 170 65 22.5 110/70 84 90 106 0.85 8 0.09 6.6 7 0.94 2.2 10.2 0.9 5.4 3.2 206 168 98 104 38 CYC.REG
9 20 UM 16 159 60 23.7 120/80 86 80 120 0.67 6.4 0.08 5.2 6.2 0.84 3.2 10 0.8 10.2 3.2 250 166 136 140 46 CYC.REG
10 22 UM 16 154 62 26.1 100/70 90 90 118 0.76 10 0.11 9.2 5.6 1.64 2.3 7 0.7 6 3.1 263 220 84 88 34
11 24 UM 16 165 48 17.6 110/70 74 76 110 0.69 8 0.11 7.6 4.2 1.81 2.4 10.6 0.7 7 3 257 216 86 100 36
12 24 M 16 165 66 24.2 110/70 86 90 73 1.23 8 0.09 7.2 4.4 1.64 4.1 6.2 1 7.1 1.8 232 220 100 162 38 GES.SAC
13 26 M 16 152 58 25.1 130/80 87 88 112 0.79 7.4 0.08 6.6 4.1 1.61 3.6 9.9 0.5 4.2 2 241 232 147 112 36 GES.SAC
14 28 M 16 164 51.2 19 130/70 76 82 96 0.85 6.8 0.08 7 3.9 1.79 3.2 12.3 1 3.05 3.8 266 156.2 72.6 84.2 62.3 GES.SAC
15 30 M 16 151 40 17.5 130/80 74 82 96 0.85 6.8 0.08 7.2 3.8 1.89 2.8 8.2 0.9 5.2 3 220 166 147 138 34 GES.SAC
16 28 M 16 162 70 26.7 120/80 92 96 114 0.84 8.2 0.09 7 4.4 1.59 4 6.2 0.9 6.2 4.3 584 228 118 150 44 GES.SAC
17 26 M 16 164 60 22.3 130/90 82 70 84 0.83 5.3 0.08 6.2 4.2 1.48 2.1 9.2 0.6 6.2 1.5 162 176 96 136 36 GES.SAC
18 24 M 16
19 24 M 16
20 28 M 16
21 24 M 16
22 22 M 16
23 26 M 16
24 28 M 16
25 30 M 16 160 62 24.2 120/70 86 84 100 0.84 9.4 0.11 7.1 5.1 1.39 3.4 15 1.5 10.2 2.26 264 184 94 116 38 PCO+
26 30 M 16 168 70 24.8 140/92 87 92 110 0.84 8.6 0.09 9.6 4.2 2.29 2.24 8.4 1.4 12 2.26 276 174 94 136 38 PCO+
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27 20 UM 16 170 64 21.8 130/80 82 88 110 0.80 17 0.19 10.2 4.9 2.08 3.6 7 0.8 10.4 2.26 274 180 96 136 32 PCO+
28 22 UM 16 158 72 28.8 120/70 96 92 112 0.82 8.6 0.09 9 4.2 2.14 3.4 12 4.9 8.4 2.4 280 164 98 136 34 PCO+
29 26 M 16 154 65 27.4 120/70 94 94 112 0.84 8.8 0.09 10.6 5.2 2.04 2.7 12 0.7 5 2.4 259 176 98 136 32 PCO+
30 28 M 16 165 52 19.1 110/70 76 90 110 0.82 9 0.10 10.6 4.8 2.21 3.8 10.9 0.8 17 0.7 280 176 84 118 38 PCO+
1 12 UM 20
2 24 UM 20
3 22 UM 20
4 22 UM 20
5 26 UM 20
6 22 UM 20
7 23 UM 20
8 22 UM 20
9 20 UM 20
10 22 UM 20 154 60 25.3 110/70 87 90 112 0.82 8.2 0.09 8.2 4 2.05 2.3 5.2 0.7 5.2 3.1 263 220 84 88 34 CYC.REG
11 24 UM 20 165 48 17.6 110/80 74 82 110 0.68 7.6 0.09 7 5.2 1.35 2.4 9.6 0.7 6.1 3 242 216 88 98 36 CYC.REG
12 24 M 20
13 26 M 20
14 28 M 20
15 30 M 20
16 28 M 20
17 26 M 20
18 24 M 20
19 24 M 20
20 28 M 20
21 24 M 20
22 22 M 20
23 26 M 20
24 28 M 20
25 30 M 20 160 62 24.2 120/70 86 82 114 1.08 8.6 0.10 6.2 4.8 1.29 3.4 13.2 1.3 7.2 2.2 240 184 94 116 38 GES.SAC
26 30 M 20 168 68 24.1 130/80 86 92 120 0.77 8.2 0.09 7.1 4 1.78 2.2 8.2 1.3 8.4 2.26 248 174 94 136 38 GES.SAC
27 20 UM 20 170 60 20.8 130/80 80 88 114 0.80 17 0.19 10.3 4.6 2.24 3.6 7 0.8 10.4 2.26 274 180 98 134 32 PCO+
28 22 UM 20 158 70 28 124/82 94 96 126 1.14 8.6 0.09 9 4.8 1.88 3.3 11.6 4.9 8.4 2.3 280 164 98 134 34 PCO+
29 26 M 20 154 65 27.4 120/70 94 90 118 1.10 8.6 0.10 10.8 5 2.16 2.7 11.8 0.7 4.8 2.4 259 176 98 136 32 PCO+
30 28 M 20 165 52 19.1 110/70 76 60 110 0.60 9 0.15 10.9 5.2 2.10 3.8 10.9 0.8 17 0.8 280 176 84 116 40 PCO+
1 12 UM 24
2 24 UM 24
3 22 UM 24
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4 22 UM 24
5 26 UM 24
6 22 UM 24
7 23 UM 24
8 22 UM 24
9 20 UM 24
10 22 UM 24
11 24 UM 24
12 24 M 24
13 26 M 24
14 28 M 24
15 30 M 24
16 28 M 24
17 26 M 24
18 24 M 24
19 24 M 24
20 28 M 24
21 24 M 24
22 22 M 24
23 26 M 24
24 28 M 24
25 30 M 24
26 30 M 24
27 20 UM 24 170 60 20.8 130/80 80 92 124 0.74 16 0.17 10.2 4.2 2.43 3.6 7 0.8 9.6 2.26 274 180 98 134 32 PCO+
28 22 UM 24 158 70 28 120/80 94 96 126 0.76 8 0.08 9.6 4.2 2.29 3.3 11.2 4.8 8 2.3 274 164 98 134 34 PCO+
29 26 M 24 154 65 27.4 120/70 94 90 118 0.76 8 0.09 10.2 5.9 1.73 2.7 11.8 0.7 4.2 2.4 248 176 98 136 32 PCO+
30 28 M 24 165 50 18.4 110/70 74 96 86 1.12 8.6 0.09 10 5.9 1.69 3.8 10.9 0.8 12.3 0.8 273 174 84 116 40 PCO+
CASE SHEET 
Registration no:        Date:  
 
Name:      Age:    Sex: 
 
Address:                                                  Phone no: 
 
Occupation:           Marital Status:   Weight (Kg):     
  
 
Height (Cm):                                 BMI:                 
 
Abdominal circumference:                    Waist hip ratio: 
 
Complaints: 
 
 
H/o Present illness: 
 
 
Past History 
 
 
Personal History: 
 
 
Family History: 
 
Menstrual  History: 
 
 
Obstetric History: 
 
 
General Examination: 
           Patients     conscious   oriented      pallor      cyanosis      clubbing       pedal    edema   
            generalised  lymphadenopathy         Hirsutism        Virilism 
            Breast Examination     
           Thyroid Examination 
             BP:                                      PR:                       RR: 
 
Systemic examination:  
 
Investigation: 
COMPLETE 
HAEMOGRAM: 
BASELINE 4
th
 
week 
8
th
 
week 
12
th
 
week 
16
th
 
week 
20
th
 
week 
24
th
 
week 
Fasting Glucose                               
Fasting Insulin        
Insulin to Glucose 
Ratio 
       
HORMONAL 
PROFILE: 
       
LH        
FSH        
LH/FSH Ratio        
TSH        
               
USG Findings: 
 
 
 
Treatment: 
 
 
                                                                                                                 
 
 
 
Signature of Investigator 
Prolactin        
Serum  Total  
Testosterone 
              Free 
Testosterone 
       
Serum 
Androstenedione 
       
Serum DHEA-S        
LIPID PROFILE        
Total Cholesterol        
TGL                              
LDL        
HDL        
LDL/HDL Ratio        
VLDL        
CONSENT FORM 
 
(To be obtained from subject) 
 
Introduction: 
 
I,………………………… is willing to participate in a study conducted in 
department of Pharmacology, Chennai Medical College Hospital & Research Centre, 
Irungalur, Tiruchirapalli, Tamil Nadu entitled. 
 
“EVALUATION OF EFFICACY AND SAFETY OF MYOINOSITOL IN 
WOMEN WITH POLYCYSTIC OVARIAN SYNDROME TREATED AT A 
TERTIARY CARE HOSPITAL” 
 
My participation in this study is Voluntary. I am at liberty to participate/ withdraw 
from the study. I have read this consent form carefully and ask the Consultant,  questions 
I may have about the study before signing. 
 
Explanation of Procedure: 
 
By agreeing to participate in this study, I know that the investigator  will ask some 
question to me and collect relevant information/ Blood sample/Body fluids and perform 
Ultra sound abdomen scan. I may be examined by the investigator and I am willing to 
take the tablets given by the investigator. Data from the study will be used for research 
purposes only. The results of the study will not to be given to me directly. There will be 
no cost to me participating in this study. 
 
Potential benefits: 
 
My participation will help the investigator  to know the risk factor of this problem 
and results of this study will be beneficial for future generations. 
 
Assurance of Confidentiality: 
 
The information concerning my participation in the study will be kept confidential 
to the full extent permitted by law and used only for scientific purposes. No one except 
members of the research team will have access the results. My name will not be disclosed 
in any report or released in any way. 
 
Patient Consent: 
 
I have read the explanation about this study and have been given an opportunity to 
discuss it and to ask questions. I have not received any money for participating in this 
study. 
 
 
 
 
Signature of Subject Signature of Witness Date 
 
 
 
 
Signature of Researcher  
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